Psychosocial factors and type 1 diabetes by Fickley, Catherine
 PSYCHOSOCIAL FACTORS AND TYPE 1 DIABETES 
 
 
 
 
by 
Catherine E. Fickley 
B. A. in Liberal Arts, Saint Vincent College, 2009 
M. P. H. in Epidemiology, University of Pittsburgh, 2010 
 
 
 
 
Submitted to the Graduate Faculty of 
the Department of Epidemiology 
Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
University of Pittsburgh 
2014 
 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
This dissertation was presented 
by 
Catherine E. Fickley 
It was defended on 
July 16, 2014 
and approved by 
 
Cathy E. Lloyd, PhD, Senior Lecturer, Open University, Faculty of Health and Social Care, 
United Kingdom 
 
Tina Costacou, PhD, Assistant Professor, Epidemiology, Graduate School of Public Health, 
University of Pittsburgh 
 
Thomas Songer, PhD, Assistant Professor, Epidemiology, Graduate School of Public Health, 
University of Pittsburgh 
 
Vincent Arena, PhD, Associate Professor, Biostatistics, Graduate School of Public Health, 
University of Pittsburgh 
 
Dissertation Director: Trevor J. Orchard, MD, M.Med.Sci., FAHA, FACE, Professor, 
Epidemiology, Graduate School of Public Health, University of Pittsburgh 
 
 
 
  ii 
Copyright © by Catherine E. Fickley  
2014 
 
  iii 
 ABSTRACT 
Introduction:  Psychosocial factors have been associated with outcomes in the general population 
and type 2 diabetes, yet rarely in those with type 1 diabetes.  We previously demonstrated that 
type A behavior is associated with lower mortality risk, while higher depression symptoms are 
associated with an increased risk.  In addition, stressful life events have been previously 
demonstrated to lead to increased depression and poor glycemic control in those with type 1 
diabetes. 
Methods: We aimed to further understand the type A behavior and mortality relationship through 
assessment of potential mediators, moderators, and confounders, and well as by examining the 
different Bortner Rating Scale scoring methods using Cox proportional hazards modeling.  We 
also investigated which psychosocial factors, including trait-anger, interacted with depressive 
symptoms to predict mortality, again utilizing Cox proportional hazards modeling.  Lastly, we 
investigated whether increased life events scores were associated with high depression symptoms 
or a change in glycemic control using logistic and linear regression. 
Results:  We found that type A behavior was no longer significantly predictive of mortality after 
the additions of age, inflammatory markers/stress reactants, and waist-to-hip ratio, and that the 
item “fast eater, walker, etc.” was the best type A predictor of mortality, but also lost 
significance in multivariable modeling.  Next, we found that increased depressive symptoms, 
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independent of anxiety and stress, were associated with increased mortality risk only in those 
with low anger scores.  Lastly, we found that increased life events scores were predictive of high 
depressive symptomatology, but not with change in glycemic control. 
Discussion:  Along with the well established, physiological and diabetes care risk factors, 
psychosocial factors also play an important role in outcome development.  These factors in type 
1 diabetes were very understudied, thus this work has a large public health impact.  In line with 
earlier theories of health locus of control, psychosocial factors may impact on mortality risk 
through a variety of pathways following a diabetes diagnosis.  Future research should focus on 
further exploring these psychosocial factors as individual predictors of mortality, and examining 
them in a clinical trial setting to potentially improve outcomes. 
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PREFACE 
 
Dr. Trevor Orchard’s Epidemiology of Diabetes Complications-Pittsburgh (EDC) Study 
has been vital to understanding many components of type 1 diabetes previously understudied, 
and thus has had substantial public health impact.  We, as the longest type 1 diabetes prospective 
cohort study, have demonstrated the importance of considering diabetes care and biological risk 
factors, genetic risk factors, through Dr. Tina Costacou’s work, and now psychosocial factors as 
well.  Dr. Cathy Lloyd created a foundation for this psychosocial research by studying these 
factors in the first few years of the study, and I have now been able to expand her research up to 
25 years later. I am extremely thankful for the EDC participants and their dedication, the 
invaluable education, guidance, and collaboration efforts I received from Dr. Trevor Orchard, my 
academic advisor and Graduate Student Researcher supervisor; the expertise and prompt 
assistance on many matters offered by Dr. Cathy Lloyd; the constant advice, support, and 
friendship offered by Dr. Tina Costacou, and the direction offered by my other dissertation 
committee members, Drs. Thomas Songer and Vincent Arena.  I would also like to thank my 
family, Mark, Cindy, Matt, and Abbey Fickley, Grandma Dorothy Fickley and Grandpap Bob 
Baker, and Dylan Holt, my dearest companion and biggest enthusiast, for all of their love and 
support throughout my years in graduate school. 
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1.0  INTRODUCTION 
Type 1 diabetes (T1D) is a significant health issue in the United States.  The incidence of 
T1D has risen by approximately 3% per year [1], and accounts for 5% of all diagnosed cases of 
diabetes in the United States [2]. T1D occurs when the immune system destroys pancreatic beta 
cells, which are the only cells in the body producing the hormone insulin which, in turn, 
regulates blood glucose in the body [2].  Unfortunately, prevention of T1D is not yet feasible.   
T1D is associated with short and long-term health problems.  Insulin deficiency in those 
with T1D can lead to abnormal fuel utilization and acute complications such as ketoacidosis or 
weight loss [3].  Although survival in those with T1D has improved [4]–[12], the T1D 
population continues to be at an increased risk of several long-term complications (i.e. coronary 
artery disease (CAD), retinopathy, nephropathy, neuropathy, and cerebrovascular disease), and 
in particular, renal and cardiovascular disease [13].  Several studies have found an excess 
mortality in those with T1D (compared to populations without diabetes), even before the onset of 
complications [14]. However, a more recent study has demonstrated T1D life expectancy is now 
within four years of community-based life expectancy [15].   
Several modifiable risk factors are now recognized for the development of T1D 
complications and mortality.  While physiological risk factors are important, psychosocial 
factors may also affect T1D outcomes and care.  Important psychosocial factors to consider in 
complication development and thus early mortality and for which we have data include 
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personality type, depressive symptomatology, hostility, anger, anxiety, stressful life events, and 
interpersonal support.  The 2013 Executive Summary: Standards of Medical Care in Diabetes: 
2013 stresses the importance of the psychosocial aspects of diabetes care and notes that 
screenings for problems such as depression, stress, and anxiety are currently poor and 
insufficient [16].  This further emphasizes the need for such research and screenings in the total 
care of T1D. 
1.1 EPIDEMIOLOGY 
Although T1D has been shown to be on the rise, worldwide variation exists in incidence. 
The best data available suggests that T1D demonstrated a stable and somewhat low incidence 
over the first half of the 20th century, followed by an increase that began roughly in the middle 
of the century [17].  This increase in incidence of T1D continues, with the majority of the rise 
occurring in those under 15 years of age [18].  
T1D is diagnosed mostly in children and young adults, although it can occur at any age 
[2].  The IDF Diabetes Atlas reports that in 2010, 7.0% of people worldwide were living with 
diabetes, and 7.9% were living with impaired glucose tolerance (IGT) [18]. Approximately 
76,000 children under the age of 15 develop T1D annually throughout the world [18].  An 
estimated 480,000 children globally are currently living with T1D, with 24% of these children 
coming from the South-East Asia region, however, European regions are at a close second, 
making up 23% [18]. 
Among those 10 years old and younger in the United States, the incidence of new T1D 
cases is approximately 19.7 per 100,000 per year and for those 10 years and older, there are 18.6 
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per 100,000 new cases per year [2]. Non-Hispanic whites have the highest rate of new cases 
(24.8 per 100,000 per year in those ≤10 years of age and 22.6 per 100,000 per year for ages 10–
19) [2].  Among other racial groups (e.g. blacks, Native Americans, and Asians) T1D is less 
common (Figure 1) [19].   
 
Figure 1: Rate of new cases of type 1 and type 2 diabetes among youth aged <20 years, by race/ethnicity, 
2002-2005 
Finland has the highest incidence rates of T1D in the world.  In Finland, a child is almost 
40 times more likely to develop T1D than in Japan and almost 100 times more likely to develop 
the disease than in certain regions of China [20]. The EURODIAB study, which involves a 
registry including 44 countries in Europe, suggests an annual rate of increase of 3-4% in 
incidence of T1D.  A greater increase was seen in some central and eastern European countries 
[21].  The EURODIAB Study also noted that the largest rate of increase takes place in children 
0-4 years of age. A systematic review of trends from 1960–1996 was conducted.  The 
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investigators noted a significant rise in incidence for 24 of 37 longitudinal studies from 27 
different countries (with a similar trend in another 12 studies), and only 1 study reported a small 
decline. The average annual increase was 3.0% [20].  A global survey suggests that no 
population is exempt from childhood T1D, but pointed out, importantly, a >350-fold difference 
in incidence rates depending on the country and region [17]. 
Risk factors for T1D can be autoimmune related, genetic, and/or environmental [22]. A 
common assumption for the development of T1D is that something novel has come in to the 
childhood environment to initiate T1D, such as a change in early nutrition or an infection. An 
alternative view is that protective factors have been lost over time [1], [23].   
A nutritional aspect that has received a lot of attention is that of early introduction to 
cow’s milk and formula based on cow’s milk [24].  One study found an increased risk of T1D 
with early exposure to a cow's milk-based formula, as well as a short duration of breastfeeding 
only, and a high dietary intake of cow's milk protein [25].  Another study found similar results, 
demonstrating that the introduction to formula or cow’s milk before five months of age resulted 
in an increased risk of developing T1D [26].  However, a more recent cohort study demonstrated 
an increased risk for T1D among those fed with cow’s milk after the age of 3.8 months compared 
to those who were introduced to it before 3.8 months, demonstrating no increased risk of T1D by 
consumption of cow’s milk in early infancy [27].  The Trial to Reduce Insulin-dependent 
diabetes mellitus in the Genetically at Risk (TRIGR), which is currently ongoing, found during 
their pilot study that weaning the infants from breast milk to a highly hydrolyzed formula 
decreased the cumulative incidence of one or more diabetes-associated autoantibodies by 
approximately 50% by a mean age of 4.7 years [28].  Extensively hydrolyzed formula is a 
formula made from casein with the proteins broken down into their basic, amino acid parts, 
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compared to normal formula, which contains complete proteins.  The extensively hydrolyzed 
formula is mainly used for infants with cow’s milk allergies.  The possible mechanisms for this 
detrimental association between cow’s milk and T1D are thought to involve an increase in 
intestinal permeability [29], inflammation in the intestines [30], and a deregulation of the 
immune system’s response to the proteins in cow’s milk [31]. 
In addition to the risk of T1D due to cow’s milk consumption, many studies have found 
that breastfeeding is protective against the development of T1D, with Mayer et al. finding that 
children with T1D were breastfed for a shorter duration compared with healthy subjects [32].  
The investigators also found that breastfeeding for 12 months or longer was protective against 
T1D, and another study found a marginal increased risk among children not breastfed [33].  
Children, in a separate study who were younger than seven years of age, were at an increased 
risk of T1D when breastfed for shorter than three months as babies [34].  It is thought that the 
protective nature of breast milk is due to its several antimicrobial substances (e.g. lactoferrin, 
lysozome, and secretory immunoglobin A), which may offer protection against infections and 
viruses [35]–[37]. 
Viruses are another environmental exposure thought to put individuals at risk for T1D 
[21], [38].  A case-control study in the United Kingdom found that illness, including infections 
and respiratory difficulties, increased the risk for T1D in the neonatal period [39]. Several 
viruses, including enteroviruses [40], have been considered possible causal agents for the 
development of T1D [41].   New technologies have allowed for the study of enteroviruses, 
especially through the use of polymerase chain reaction methods to identify these viruses in the 
blood [41]–[45]. Studies in different countries have demonstrated that enterovirus infection 
accompanies or precedes the T1D onset in many children [41].  It remains unclear, however, if 
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this same relationship is seen in older people who develop T1D. Enterovirus infection not only in 
infancy, but in pregnancy, as well, has also been thought to lead to T1D [38], [41]. Prospective 
studies in Finland examined this relationship through studying siblings of children with T1D 
who were free from T1D at enrollment. Blood samples were taken every 6 months and the 
investigators found that enterovirus infections were found more frequently in those siblings who 
progressed to T1D compared to the siblings who did not.  They also found that infections were 
clustered to the time period immediately before the detection of autoantibodies [41], [46], [47]. 
The mechanism behind this association is due to the initiation of islet-cell autoantibodies as well 
as the expression of interferon-alpha [41]. Islet-cell destruction can occur as a result of these. It 
seems plausible that a number of other viruses may be involved, although these associations are 
not yet understood. 
In addition to the findings described above, the Diabetes Autoimmunity Study in the 
Young (DAISY), involving a genetically susceptible population versus a general population, 
found that the number of illnesses occurring during the first 9 months did not vary between those 
children with no islet autoimmunity versus those who developed islet autoimmunity for 
gastrointestinal illnesses, respiratory diseases, fevers, or upper respiratory symptoms [48].  They 
did find, however, that gastrointestinal illnesses were associated with an increased risk of islet 
autoimmunity among babies exposed to barley or wheat either early or late in their infancy [48].  
Therefore, it appears that viruses early in life combined with the presence of inflammation 
caused by the diet may increase the risk of developing T1D.  These findings are very interesting 
because they involve a combination of potential risk factors for the development of T1D, 
including diet, infections, and genetics. 
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Another important aspect of T1D development, as mentioned above, deals with genetics 
[21], [49]–[51]. A positive family history of T1D has been linked to a profound increased risk for 
the development of the disease [52], [53].  A study conducted in the United States determined 
that the concordance for T1D is approximately 50% for monozygotic twins, and a first degree 
relative has an approximate risk of 5% [54]. The occurrence of T1D among the parents of 
children diagnosed with T1D in the Pittsburgh study was found to be 2.6% [55]. These 
investigators found an increased risk to siblings of someone with T1D who experienced onset at 
an early age, with siblings having a cumulative risk of 0.80% by age 10, 3.3% by age 20, and 
4.4% by age 30 [55]. Additional increased risk of 10.5% occurred in siblings of someone with 
T1D in families with at least one parent with T1D, as well [55]. 
The main gene associated with an increased risk for T1D is “the major histocompatibility 
complex (MHC) on chromosome 6, in the region associated with the genes for the highly 
polymorphic immune-system-recognition molecules known as HLA” [51]. HLA class I 
molecules present antigenic peptides to CD8 T lymphocytes, and HLA class II molecules present 
antigenic peptides to CD4 (helper or inducer) T lymphocytes [51]. Genetic risk further increases 
with the specific involvement of the DR3, DQ2, DR4, or DQ8 haplotypes, which occur in 90% 
of patients who develop T1D, whereas fewer than 40% of controls have these haplotypes.  It was 
also found that DR3-DR4 heterozygosity is highest in those younger than five years of age 
(50%) who develop T1D and lowest in adults with T1D (20-30%). Thus, it appears that the 
higher the heterozygosity the earlier the onset of T1D.  In addition, because those with low 
heterozygosity are still at risk, environmental factors must play a role in onset.  The US 
population prevalence of this heterozygosity is only 2.4% [51]. A patient’s specific HLA 
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genotype can affect their ability to respond to an antigen. Therefore, the genes encoding antigen-
presenting molecules are often correlated with the occurrence of autoimmune diseases [56].  
There are two explanations for how the detrimental HLA genes influence the increase in 
risk for T1D. One theory is that these genes may affect the degree of immune responsiveness to a 
pancreatic beta-cell autoantigen.  This would result in an overly forceful immune response which 
may in turn instigate damage to the pancreatic beta cells [57]. Another theory is that certain HLA 
genes may present the beta-cell autoantigen in a way that does not encourage normal 
immunologic tolerance to one’s self [58].  T1D, with its complex genetic, environmental, and 
immunologic links, remains a challenge to explain for epidemiologists.  Once the onset of T1D 
has occurred, individuals are at an increased risk of not only acute complications, but also major-
organ complications, and ultimately mortality 
 
1.2 RISK OF EARLY MORTALITY 
People with T1D experience high mortality rates due to vascular diseases [59]–[61].  A 
study utilizing data from the Allegheny County childhood-onset T1D registry demonstrated that 
within the first 10 years following diagnosis of T1D, the leading cause of death was acute 
diabetes complications (73.6%) [62]. During the next 10 years, deaths were attributed to acute 
(15%), cardiovascular (22%), renal (20%), or infectious (18%) causes of mortality. After living 
with T1D for 20 years, chronic diabetes complications were responsible for >70% of all deaths. 
Cardiovascular disease (CVD) was found to be the leading cause of death (40%) in this 
population [62], as well as in others [63],  and worldwide it was found that CVD causes 50% of 
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the deaths in T1D [64]. This is particularly seen in young adults with T1D, who may experience 
a 10-fold increased risk of CAD compared to the general population [65].  
Glycemic control is a significant predictor of a number of acute and chronic 
complications, and therefore early mortality [66].  A measure of glycemic control is HbA1c 
which reflects average glycemia over several months [67]. The Diabetes Control and 
Complications Trial (DCCT) demonstrated that improved glycemic control was associated with 
lower rates of microvascular and neuropathic complications [68]. The Epidemiology of Diabetes 
Interventions and Complications (EDIC) study, a follow-up study of the DCCT cohort, 
demonstrated a continuation of this effect in the previously intensively treated group, even 
though their glycemic control became the same as that of the standard care group during follow-
up [68]. This demonstrated that the effects of tight control earlier on might offer protection in the 
long term.  In addition, cardiovascular outcomes were also reduced in the intensively treated arm 
[69].  The physiological risk factors for early mortality in people with T1D have been well 
established; however, how psychosocial factors contribute to this increased early mortality risk is 
understudied. 
1.3 TYPE A BEHAVIOR 
Type A behavior has been described as an action-emotion complex, such that the 
behavior is a response to the outside environment [70].  People characterized as having type A 
behavior tend to focus toward achieving and accomplishing more in less time than others.  
Because of these tendencies, these people are inclined to be competitive, aggressive, time urgent, 
work-oriented, and can become annoyed if things are not achieved in a time frame they find 
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sufficient [70]. Therefore, it seems that type A behavior is a result of predispositions within a 
person that are exhibited due to specific environmental cues [70]. 
In an earlier review regarding type A behavior and coronary heart disease (CHD), 
Matthews et al. noted that although type A behavior was directly associated with CHD in the 
general population, the findings were consistently inverse in chronic disease populations, 
suggesting a protective effect [70]. A review of the literature examining psychosocial variables 
and CHD suggested that type A behavior and hostility were only associated with CHD in less 
than half of the studies using healthy populations at baseline, and were associated with CHD in 
13% of prognostic studies leading them to conclude that there was no consistent evidence linking 
type A behavior and CHD [71].  In terms of the literature specific to non-diabetes populations, it 
appears that type A behavior may have different effects on health depending on underlying 
chronic disease status and the definition of type A behavior.   
Type A behavior has been demonstrated to be protective against a number of 
complications present in those with T1D [72].  In addition, type A behavior has been linked both 
positively and negatively to glycemic control, and this is most likely due to differences in study 
design and measurements of type A behavior and glycemic control [73].  Furthermore, these 
early studies lack the covariates necessary to identify the population differences.  Whether T1D 
is an additional high risk group in which the inverse association between type A behavior and 
health outcomes, i.e. complications and mortality, remains conflicting in the literature [73]–[79].  
Furthermore, one of the main objectives in the management of T1D is the achievement of 
adequate glycemic control [80], and whether type A behavior plays a role in this relationship is 
inconclusive.  One explanation of the inverse relationship may be that higher type A behavior is 
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related to better glycemic control and lower complication rates due to the high-achieving, more 
meticulous nature of those with type A behavior. 
A study performed by Lloyd et al. in the EDC study investigated whether psychosocial 
factors were cross-sectionally associated with diabetes related complications [81].  Investigators 
found that the number of complications was significantly related to participants’ type A behavior 
score, with lower type A behavior being related to more complications.  Additionally, those with 
the lowest type A behavior scores had higher rates of retinopathy and macrovascular disease.  
The study authors concluded that type A behavior demonstrated a protective effect against the 
number of prevalent complications and note that this association needs to be re-examined in a 
prospective study.  A limitation of this study was the cross-sectional design, and therefore 
temporality could not be established.  
A more recent study prospectively examined the relationship between psychosocial 
variables and diabetes related outcomes in those with T1D [82].  This was the first study to 
utilize a prospective design in investigating personality type in T1D.  Among the questionnaires 
distributed to study participants was the Eysenck Personality Questionnaire (EPQ-R).  The EPQ-
R consists of 48 items and measures three dimensions of personality, including extraversion 
(such as sociability and optimism), neuroticism (such as negative emotions, anxiety, and 
moodiness), and psychoticism (such as acting hostile and lacking empathy).   
The study investigators found a marginal inverse correlation between neuroticism at 
diagnosis of T1D and glycemic control 12 months later.  The authors suggested that higher 
neuroticism is related to better glycemic control. The study authors hypothesize that this effect 
may be due to neuroticism being associated with participants having a “greater tendency to 
worry about the future effects and consequences of diabetes” [82]. Utilizing correlations for this 
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portion of the analysis is a limitation, as this method does not take into account possible 
confounders; however, the directionality of the relationship between neuroticism and glycemic 
control proves to be the same as in the study by Lloyd et al discussed above. 
The most recent work regarding type A behavior in a T1D population, also performed in 
the EDC Study, was able to investigate type A behavior prospectively [83].  The objective of the 
study was to determine whether type A behavior predicted all cause mortality and incident CAD, 
as well as CAD-related mortality among those with prevalent CAD.   Twenty-two year follow-up 
data from the EDC study were analyzed for the participants who completed the Bortner Rating 
Scale (measuring type A behavior) and Beck’s Depression Inventory (BDI) at baseline (1986-
1988).  We demonstrated an inverse univariate relationship between Bortner scores and all cause 
mortality, however, the addition of BDI scores attenuated the relationship and a significant 
interaction was observed, such, that any protective effect against mortality was limited among 
individuals with lower BDI scores (bottom 3 quintiles), while no effect was seen in those with 
higher BDI.   Strengths of this study were that it was the first to investigate the relationship 
between type A behavior and all-cause mortality in a T1D population, as well as the long length 
of follow-up time, large sample size, and complete data obtained for the population.  One 
limitation was the minimal covariate list.  Future research should focus on understanding this 
relationship through an evaluation of potential mediators, covering a wide range of diabetes-
related risk factors for early mortality.  In addition, because there is some evidence that resulting 
health outcomes varied according to which measurement of type A behavior was utilized, the 
different scoring methods of type A behavior should be examined, as well. 
In conclusion of the overall T1D literature regarding type A behavior and health 
outcomes, only the last three papers published were completed with adequate sample sizes, and 
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therefore hold more weight in terms of their validity compared to the previous literature.  
However, the older papers found either null or detrimental affects of type A behavior and 
glycemic control, which differs from the conclusions drawn from the more recent studies.  Based 
on this information, increased type A behavior may be protective against poor glycemic control 
and complications in people with T1D, and perhaps it has no association with health outcomes in 
the general population, but further research is needed to confirm or deny these inferences. 
Whether or not type A behavior predicts mortality in people with T1D requires further, more in-
depth investigation. In particular, studies with large sample sizes investigated prospectively with 
a complete list of potential mediators and multivariable analyses will be important in deciding 
whether an effect of type A behavior on health outcomes truly exists.  In addition, investigating 
how the different type A behavior scoring methods relate to mortality would make an important 
contribution to the literature.  
1.4 DEPRESSIVE SYMPTOMATOLOGY 
Depression affects a large portion of the population, with a lifetime risk of major 
depressive disorder of approximately 16.2% [84].  Discouragingly, in a survey of the 48 
continental U.S. states, only 51.6% of 12-month depression cases (that is, long lasting depression 
for at least 12 months) were found to be receiving health care treatment, and out of these people, 
treatment was adequate in just 41.9%.  This results in only 21.7% of 12-month depression cases 
having adequate treatment [84].  Being female, a homemaker, classified as "other" for 
employment status (most were unemployed or disabled), never married, previously married, 
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having less than 12 years of education, and living in or around poverty were all associated with 
an increased risk of either 12-month depression or lifetime depression [84].   
Prevalent depression puts individuals at a higher risk of comorbid physical conditions, as 
well.  A recent meta-analysis found that depression was significantly associated with increased 
stroke morbidity and mortality [85].  A separate study prospectively studied whether depression 
was associated with the risk of developing type 2 diabetes (T2D), and vice versa, and 
investigators found that during 10 years of follow-up, both depressed mood and use of 
antidepressants increased the risk of developing T2D [86].  In addition, those with T2D were at a 
significantly increased risk of developing clinical depression, regardless of treatment via oral 
hypoglycemic agents or insulin.[86] Major depression has also been shown to cause a 60% 
increased risk of hypertension [87], and a review of the literature demonstrated an increased risk 
of CVD morbidity and mortality in those with depressive symptomatology or major depression, 
as well [88]. 
High prevalence of depression and the comorbidities that occur along with it result in 
detrimental economic effects not only due to the health care necessary for treatment, but due to 
the loss of work performance, as well [89].  A nationally representative U.S. sample of workers 
found that major depressive disorder resulted in 27.2 lost workdays per year for each worker 
with depression [90].  This study also found that there were approximately 225.0 million 
workdays and $36.6 billion in productivity lost per year due to major depressive disorder [90]. 
  The importance of depressive symptomatology in T1D has been demonstrated: those 
with high depressive symptomatology are at an increased mortality [91] and morbidity risk 
(including diabetes complications) [92]. Co-morbid depression and T1D is also associated with 
poorer diabetes self-management and metabolic control, decreased quality of life, and higher 
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healthcare usage [91].  In addition, one study found that those with T1D were over three and a 
half times more likely to have depression, were over two and a half times more likely to have a 
history of depression, and were two times more likely to be on an antidepressant than their 
controls free from T1D [93].  A U.K. study found that the prevalence of depression was three-
times higher in those with T1D compared to those free of diabetes [94].     
It has been demonstrated that depressive symptomatology plays an important role in the 
incidence and progression of diabetes associated acute and chronic complications.  In addition, 
diabetes itself appears to play an important role in the development and progression of 
depression. The EDC study’s previous research has demonstrated that duration, hypertension, 
waist-to-hip ratio (WHR), physical activity, and depressive symptomatology were all significant 
independent predictors of CAD in women [95].  Depressive symptomatology was not a risk 
factor for CAD in men initially [95], but this relationship was demonstrated in both sexes in a 
more recent EDC study [96].  This more recent EDC study showed that increased BDI 
significantly predicted CHD even after controlling for hypertension, WHR, white blood cell 
count, fibrinogen, smoking status, distal symmetric polyneuropathy, and overt nephropathy.  
However, this relationship became attenuated after the addition of all possible variables in the 
mediation analysis [96].  Depressive symptomatology has also been found to be associated with 
increased WHR in both genders [97] as well as with macrovascular disease and a higher number 
of complications [98]. Based on these study results, depressive symptomatology is a 
demonstrated risk factor for poor outcomes in those with T1D.  It seems that elevated depressive 
symptomatology can be an immediate risk factor for markers of illness, such as WHR, and in 
addition, affect long-term health as well.  Perhaps in some instances, elevated depressive 
symptomatology does not demonstrate detrimental effects until a longer period of time has 
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passed, like with CAD in men.  It may be important to identify increased depressive 
symptomatology early, especially when in combination with other risk factors, such as an 
increased WHR, to intervene before the onset of serious complications. 
Regarding the existing research on depressive symptomatology and subsequent risk of 
mortality in T1D, only two studies has been performed thus far.  The FinnDiane Study Group 
concluded that in women, prior antidepressant agent purchase (their surrogate marker for 
depression) was associated with an increased mortality risk [99].  In the EDC study, we were 
recently able to replicate these results; however we found the association between self-reported 
depressive symptomatology and mortality in both men and women, with an almost three-fold 
increased risk of mortality with clinically important depressive symptomatology (BDI≥16) [100].  
Whether other relevant psychosocial variables interact with depressive symptomatology to 
predict mortality, however, is unexplored. 
Depression and diabetes have an interwoven relationship.  Perhaps the mechanisms 
underlying depression and T2D have reciprocal effects, through which each can affect the other 
[101].  In addition, there may be other risk factors that put an individual at risk for both diabetes 
and depression [86]. 
It has been difficult to disentangle the role depression plays in T2D due to the bi-
directionality, but this has been thoroughly demonstrated to cause an increased risk of morbidity 
and less so, mortality, in T1D.   Because T2D can be managed with lifestyle changes or oral 
agents, and most often the body continues to produce some insulin, the demands of care may not 
be equal to those of T1D, especially at diagnosis.  Those with T1D have the difficult task of 
caring for a chronic disease, which requires maintenance multiple times a day, as well as living 
with the stress and fear of T1D complications due to the disease often being diagnosed in 
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childhood or adolescence.  Unfortunately, these fears regarding future complications can lead to 
depression, with depression itself increasing the risk of complication development and 
progression.  As discussed below, in combination with depression and type A behavior, hostility, 
anger, anxiety, life events stress, and interpersonal support may play important psychosocial 
roles in predicting health outcomes, as well. 
1.5 ADDITIONAL PSYCHOSOCIAL MEASURES 
While type A behavior and depression are the most commonly studied psychosocial 
factors in T1D, there are other potentially important psychosocial factors to consider, as well, 
which have shown health effects in other populations.  Hostility is usually explained as “a 
negative attitude or cognitive trait directed toward others” [102].  Hostility does, however, differ 
from anger, which is described as “an emotional state that consists of feelings that vary in 
intensity from mild irritation or annoyance to intense fury or rage, and aggressiveness as a verbal 
or physical behavioral pattern manifest in yelling, intimidation, or physical assaults” [102].  
Hostility has also been defined as “a multidimensional personality trait, the most common 
components of which are (1) cynicism, or the belief that others are motivated primarily by selfish 
concerns, and (2) mistrust, or the expectation that people are likely to be hurtful and sources of 
mistreatment” [103].  Hostility and anger are oftentimes combined or used interchangeably when 
in fact they are separate constructs and should be examined as such.  It has been explained that 
“hostility is distinct in that it refers to a cognitive trait, in contrast to anger, which is an emotion” 
[103]. 
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Since the 1980s, hostility has been linked to an increased risk of CHD [104];  however, 
only recently was a systematic review/meta-analysis conducted examining this relationship in 
prospective cohort studies.  The investigators found, via their subgroup analyses, that the 
Minnesota Multiphasic Personality Inventory (MMPI) and its derivative, the Cook-Medley 
hostility scale (CMHS) were significantly associated with CHD  in healthy and existing CHD 
studies, with increased hostility resulting in an approximate 20% increase in CHD risk in both 
populations [102].  Investigators also found that this relationship was more prominent in men.   
Possible mechanisms that may explain this relationship are 1) behavioral pathways, such 
that hostility causes individuals to partake in detrimental health behaviors such as poor diet, less 
physical activity, smoking, inadequate sleep, or poorer self care 2) direct physiological pathways, 
via autonomic nervous dysregulation, increases in inflammatory and coagulation factors, and 
higher cortisol circulation [102]. 
Because hostility is such an important predictor of health outcomes, specifically 
cardiovascular disease (CVD), it may play a role in complication development in people with 
T1D.  The existing literature investigating the effects of hostility within T1D is extremely 
limited.  One study conducted in a population of African-Americans with T1D found that the 
development of hypertension over a 6-year follow-up period was independently predicted by 
hostility and overt proteinuria [105].  These findings highlight the importance of combining 
physical and psychosocial factors in the prediction of disease development.  An additional study 
done in this same African-American population found that female gender, childhood trauma, and 
hostility were significantly associated with having attempted suicide (as was depression in a 
separate model) [106].  Additionally, those with T1D were more likely to attempt suicide than 
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the controls.  Whether depression and hostility interacted to predict suicide attempts was not 
studied.  
Investigators in the Netherlands demonstrated that those T1D participants with a high 
hostility score exhibited an increase in anger during hypoglycemic episodes compared to those 
with low hostility scores [107].  However, this study was performed with a very small sample 
size of 10 and therefore it is difficult to draw conclusive results.  This very limited literature 
suggests a trend similar to that seen in the general population; that is, hostility is detrimental 
regarding health outcomes in T1D.  Thus, studying our main predictors (those we have previous 
evidence in our population are associated with mortality), type A behavior and depressive 
symptomatology, in combination with hostility in those with T1D would fill a significant gap in 
the literature. 
Anger, which is often examined with hostility but exists, as explained above, as its own 
construct, is an additional psychosocial area of focus in the literature.  Most commonly, anger is 
broken down into two constructs: trait-anger and state-anger using Spielberger’s validated and 
popular questionnaire [108].  Trait-anger refers to anger that comprises part of one’s personality 
[108], whereas state-anger is anger experienced as a reaction to the surrounding environment.  
Other common characteristics involve keeping anger to oneself (“anger-in”), taking anger out on 
others (“anger-out”), or discussing anger with a friend or family member (“anger-discuss”). The 
physical manifestations of anger can involve, for example, developing a headache or feeling 
weak, and these are known as “anger-symptoms” [109]. 
Similar to hostility, anger has been linked to CVD events, as well.  The Framingham 
Study used the anger-in, anger-out, anger-discuss, anger-symptoms, and state-anger constructs to 
investigate the association with CHD, atrial fibrillation (AF), and total mortality.  In age-adjusted 
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analyses, they found no association of anger with the development of CHD; however, increased 
trait-anger and anger-symptoms in men predicted AF at the 10-year follow-up [110].  Anger was 
measured using both the original Framingham scale [109] and with the Spielberger scale. 
Increased trait-anger was also associated with AF and total mortality in men in multivariable 
analyses [110].  No associations between any of the anger variables with CHD, atrial fibrillation 
(AF), or total mortality were seen in women. Whether anger is associated with mortality in 
people with T1D has not been studied.  In addition, whether anger interacts with type A behavior 
and depressive symptomatology in predicting mortality has not been studied, either. A meta-
analysis investigating psychosocial variables and their association with CHD found that anger 
was associated with increased CHD events in healthy population studies as well as in those with 
existing CHD [102].  This association was more common in men compared to women, which has 
also been demonstrated previously with hostility.  Furthermore regarding this sex difference, a 
recent meta-analysis demonstrated that anger and hostility were associated with cardiovascular 
responses to psychological stressors more strongly in men compared to women [111].  This 
suggests that the additive effect of daily, increased stress responses might have 
pathophysiological significance for CHD in men only. 
As discussed previously, it is essential to investigate psychosocial factors in combination 
with one another, and importantly a Canadian study examined the role anger played in 
generalized anxiety disorder.  Anxiety is another important aspect of psychosocial factors and 
their involvement with disease progression and development [112].  Investigators used the 
Generalized Anxiety Disorder Questionnaire, the State-Trait Anger Expression Inventory, and 
the Aggression Questionnaire, and found that generalized anxiety disorder significantly differed 
from participants free of anxiety regarding higher levels of trait-anger and internalized anger 
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expression.  Participants with generalized anxiety disorder also significantly differed from those 
free from anxiety on the combined aggression subscales [112].  These results further emphasize 
the importance of examining psychosocial factors together.  Furthermore, this work was 
performed in non-T1D populations, additionally emphasizing the need for psychosocial factors 
to be examined together in a T1D population, where such literature is severely lacking.  The 
psychosocial risk factors may predict outcomes differently in a T1D population, thus it is 
difficult to determine that the same effects demonstrated in the general population would be 
demonstrated in T1D.  For example, people with T1D may not be anxious by nature, but are 
anxious due to a fear of complications, thus perhaps their anxiety would interact with anger 
differently than in the general population. 
Generalized anxiety disorder is defined as the presence of continuous and excessive 
worry, differing from the diagnosis of major depressive disorder which results in depressed 
mood or loss of interest [113]. The DSM-IV criteria for generalized anxiety disorder involves 
restlessness/agitation, fatigue, concentration difficulties, sleep problems, and irritability [113].  
One study found that generalized anxiety disorder was prevalent in 5.3% of their stable CAD 
population [113];  investigators also found that within their participants with stable CAD, anxiety 
and depression resulted in increased odds of having a cardiac event over two years of follow-up, 
even after multivariable adjustments [113]. 
As expected, anxiety is more prevalent in the diabetes population than in the general 
population [114].  A study in the U.K. examined the relationship between generic and diabetes 
specific psychological factors and their impact on glycemic control in participants with T1D. 
Investigators found that anxiety was predictive of HbA1c, even after controlling for relevant 
demographic and medical covariates [115].  They also found that diabetes related distress was a 
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significant predictor of HbA1c.  Because they initially found that anxiety was correlated with 
diabetes specific distress, mediation analysis was performed [115]. Diabetes related distress 
attenuated the relationship between anxiety and HbA1c.  Authors stress that “[t]he experience of 
anxiety is likely to be linked both to the cognitions initiated by the awareness of the adverse 
long-term health consequences of sub optimal metabolic control and the experience of 
hypoglycemic episodes” [115].  Whether anxiety interacts with type A behavior and depressive 
symptomatology to predict health consequences, specifically mortality, in T1D has yet to be 
determined.   
An additional psychosocial factor that has been demonstrated to impact health in the 
general population as well as in people with T1D is life events stress.  Previous literature has 
established a strong association between stressful life events and major depressive episodes in 
short term [116] as well as long term follow-up [117].  In addition, stressful life events have been 
associated with poor health outcomes, including cancer [118] and mortality [119].   
Because we have previously demonstrated a relationship between depressive 
symptomatology and mortality, we were interested in whether stressful life events increased 
depressive symptomatology in T1D populations, however this literature is extremely limited.  
Specific to T1D, a cohort of African American participants found that those reporting greater 
incidences of childhood trauma were more likely to experience depressive symptomatology 
[120]. In addition to the potential impact of stressful live events on depressive symptomatology 
in diabetes, there is concern for whether stressful life events impact change in glycemic control, 
as well.  HbA1c is an important risk factor for complications and early mortality in those with 
T1D, as discussed above.  Elevated HbA1c levels predict an increase, sometimes drastically, of 
chronic T1D complications [121].  Previous research has also shown that stressful life 
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experiences were associated with maintained poor control or deterioration of control in those 
with T1D [122].  The authors note, however, that these results require replication in a larger 
study population and in those with diabetes-related complications, as well. 
Stressful life events involve stressors in the environment, and in addition, social support 
is another psychosocial construct in the external environment.  Social support refers to the 
network of family and friends surrounding a person.  Not unlike the other psychosocial variables 
discussed previously, social support has been shown to be associated with health outcomes, as 
well.  A review and meta-analysis investigating social support and the prognosis of CHD found 
that after controlling for relevant covariates, increased social support remained significantly 
predictive of lower all-cause mortality in those with prevalent CHD [123].   
A separate study (WISE) which combined several psychosocial variables in order to 
assess whether they were associated with CVD risk factors, found that depression, social 
network index, and the hostility component were significant independent variables [124].  
Another trial studied the effects of treating depression and low perceived social support on the 
clinical outcomes after participants suffered an MI (Enhancing Recovery in Coronary Heart 
Disease Patients (ENRICHD) Randomized Trial) [125].   Investigators found that those who 
received the cognitive behavioral therapy, and SSRIs when needed, had improvements in 
depression and perceived social support compared to those in the usual care group change.  
However, they did not find a significant difference in those surviving event free between the two 
groups.  The literature regarding social support in those with T1D is currently limited.  Social 
support may prove to be important in those with T1D, as it has shown to be beneficial in chronic 
disease populations [123].  Because of the daily maintenance required to care for T1D, perhaps 
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increased social support, whether from peers with T1D or from family members, assists those 
with T1D in coping with their disease.    
A review study on social support and its effects on different health risks in those with 
diabetes was performed; however, a limitation of the study is that it does not distinguish between 
T1D and T2D [126].  The investigators concluded that peer support demonstrated some potential 
to improve diabetes related outcomes; however, the existing evidence is too inconsistent and 
sparse to maintain an overall consensus [126].   
A pilot study investigated social support in those with T1D, implemented in a 
professionally-run (via a clinical psychologist) support group for youth with T1D making the 
transition to care [127].  Investigators found that participants mainly wanted to converse about 
how others manage their T1D in day-to-day life, the interactions experienced with those who do 
not have T1D, and the emotions one experiences related to their T1D [127].  This pilot study 
offered important feedback about the importance of social support for people with T1D and 
future psychosocial research should focus on including social support as a predictor in this 
population.  Because social support has been demonstrated to have potential importance for 
people with T1D, support should be taken into account when behavior type and depressive 
symptomatology are investigated as perhaps depressive symptomatology operates differently in 
the presence of high social support compared to low support.  Furthermore, high type A behavior 
combined with high social support may potentially be more protective than type A behavior 
alone. 
In conclusion, hostility, anger, anxiety, life events stress, and social support all have been 
associated with health outcomes in the general population and within those with T1D; however 
this literature investigating psychosocial factors in T1D is very limited.  CVD outcomes appear 
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to be the most prevalently studied, while mortality is rarely studied.  A reoccurring theme within 
the literature is the web these factors form with one another and how different combinations can 
affect health outcomes uniquely.  Thus, our research focused on studying type A behavior and 
depressive symptomatology in depth, and in the context of other psychosocial factors in terms of 
mortality prediction in those with T1D (Table 17). 
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2.0  TYPE A BEHAVIOR AND MORTALITY IN T1D: MEDIATORS, 
MODERATORS, AND CONFOUNDERS 
As discussed above, we have previously demonstrated that those with T1D and a higher 
type A behavior score had a lower all-cause mortality rate compared to those with a lower type A 
score.  Thus, our first aim is to further understand this relationship by examining the extent to 
which the type A behavior and mortality relationship is mediated, moderated, or confounded by 
diabetes related and general health risk factors. 
2.1 INTRODUCTION 
T1D continues to be a significant public health and clinical issue, with the incidence of 
T1D rising by approximately 3% per year [1]. Excess mortality has been documented in children 
with T1D, even before the onset of late, chronic complications [14], although more recent 
research has demonstrated that T1D life expectancy is now within four years of community-
based life expectancy [15]. Despite the improved survival [4]–[12], those with T1D continue to 
be at an increased risk of developing several long-term complications (i.e. CAD, retinopathy, 
nephropathy, neuropathy, and cerebrovascular disease (CBVD)), as well, as renal and CVD) 
[128], [129]. Thus, the search for modifiable risk factors for T1D mortality and complications 
remains important. 
  
26 
Type A behavior is a trait that has not been extensively examined as a risk factor in T1D 
mortality and complications.  People characterized as having type A behavior tend to exhibit 
behaviors such as focusing on achieving and accomplishing more in less time than others.  
Because of these tendencies, these individuals are often competitive, aggressive, time urgent, and 
work-oriented [70]. These type A behaviors are thought to be inherent within a person and not 
solely due to environmental triggers [70]. It has been previously demonstrated that in those with 
T1D, glycemic control differs by behavior type (A/B), and this has been reported in both 
directions, with type A behavior predicting both poor control and good control [75], [130], [131].  
In contrast to type A behavior discussed above, those with type B behavior are thought to 
generally live with lower stress and tend to work more steadily, enjoying achievement but not 
becoming stressed over it. 
We have previously reported a relationship between type A behavior and mortality in a 
T1D population. Participants in a study population of individuals with T1D with higher type A 
behavior had a lower all-cause mortality rate compared to those with a lower type A score, an 
effect that interacted with depressive symptomatology such that type A behavior was only 
protective in those with low depressive symptomatology [83].  We proposed that this may be due 
to individuals with type A behavior being better able to cope with the intense regimented control 
needed in T1D (perhaps due to being able to do many things at once, such as thinking ahead 
regarding doctor visits, and feeling ambitious or motivated regarding the care and treatment of 
their T1D (e.g. testing blood sugar, adjusting diet and insulin dose)) [132].  This conclusion, that 
type A behaviors may increase the efficiency with which an individual cares for their T1D, 
therefore reducing the risk of early mortality, however, has not yet been confirmed from research 
evidence. 
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The goal of this paper is to further our understanding of how type A behavior protects 
against mortality with the following objective:  to examine the extent to which the type A- 
mortality relationship is mediated, moderated, or confounded by other factors both diabetes and 
non-diabetes related (i.e.: demographic, behavioral, diabetes care, physiological measures, and 
depressive symptomatology). 
2.2 METHODS 
This evaluation is focused on participants in the EDC study, comprising individuals 
diagnosed with T1D between 1950 and 1980 at age <17 years, and seen within one year of 
diagnosis at Children’s Hospital of Pittsburgh.  Biennial follow-up of the EDC study cohort has 
occurred since baseline in 1986-1988, and included questionnaires with physician examinations 
and laboratory analyses of urine and blood for the first 10 years and again at 18 years and 25 
years.  Data up to 22-years of follow-up are now available.  Participants ≥18 years of age at 
study baseline who completed the Bortner Type A Rating Scale (1986-1988) [132] were eligible 
for the study. 
Overall total mortality, including complication status, was determined as of February 25, 
2011 through contact of next of kin and searches in both the Social Security Death Index and the 
National Death Index.   Death certificates were obtained to confirm each death, as well as: 1) 
hospital records; 2) autopsy/coroner’s reports; and 3) interview with next of kin regarding the 
death.  
The following baseline covariates were examined in detail based on prior evidence from 
the EDC study of their relationship with diabetes complications and mortality [83], [133]:  age, 
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sex, duration, education, calories consumed, physical activity, smoking status, insulin dose, 
frequency of blood glucose testing per week, hypertension, high-density lipoprotein (HDL) 
cholesterol, non-HDL cholesterol, lipid medication use, white blood cell count (WBC), 
fibrinogen, WHR, HbA1c, and depressive symptomatology. Education was assessed using a 5-
point scale, i.e.: some high school, high school graduate, some college, bachelor’s degree, 
graduate education beyond bachelor’s. Daily calories consumed were obtained through use of the 
Willett Food Frequency Questionnaire averaged over a week [134]. Physical activity was 
assessed using questions about current levels of leisure activities and was expressed as total 
kilocalories expended [135].  Smoking status was defined as having smoked more than 100 
cigarettes over their lifetime.  Insulin dosage was expressed as the number of units of insulin 
used per day divided by the participants’ weight in kilograms.   
Testing per week was reported as the number of times blood glucose levels were tested 
each week. Hypertension was defined as systolic blood pressure (SBP) greater than or equal to 
130 or diastolic blood pressure (DBP) greater than or equal to 80 or on blood pressure 
medication.  Fasting blood samples were assayed for lipids, WBC count, and fibrinogen as 
previously described [136].  Fasting blood samples were also analyzed for HbA1 (microcolumn 
cation exchange; Isolab, Akron, OH, USA), and these original HbA1 values were converted to 
Diabetes Complications and Control Trial (DCCT)-aligned HbA1c for all analyses using a 
regression equation derived from duplicate assays (DCCT HbA1c=0.14+0.83[EDC HbA1]).  
WHR was calculated by measuring at the smallest circumference of the natural waist and by 
measuring the hip circumference at the widest part of the buttocks or hip. Finally, depressive 
symptomatology was measured using the Beck Depression Inventory (BDI), also collected at 
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baseline [137]. BDI scores have been shown to approximate clinically significant symptoms of 
depression [137]. 
The Bortner Type A Rating Scale (1986-1988) [132] is comprised of 14 items that are 
each composed of two phrases between 1 and 24 equally set apart scale points on a horizontal 
line, ranging from less type A to more type A, and respondents were asked to mark on  the line 
where they believed they fell in terms of their own behavior (ex: always rushed vs. never rushed, 
even under pressure).  The score obtained from each of the 14 items was added up and type A 
behavior was assessed as a continuous variable with the higher the score representing higher type 
A behavior. 
Cox proportional hazards models were utilized to examine the univariate relationship 
between baseline Bortner Score and overall mortality and to examine the prospective 
associations between the baseline covariates (potential mediators, moderators, or confounders) 
and mortality.  Next, Student’s t-tests or Wilcoxon rank-sign tests were used as appropriate to 
assess the univariate associations between Bortner score and these potential covariates.  
Significant covariates were then grouped into five main risk factor categories to investigate 
which pathways may explain the relationship between Bortner Score and mortality: 
demographic, behavioral, diabetes care, physiological measures, and depressive 
symptomatology. Those covariates that maintained significance in the five separate multivariable 
models were then entered into a final, composite model of Bortner score and covariates 
predicting mortality, and this model is the one reported.  Influential covariates were also 
examined to assess if they were mediating, moderating, or confounding the previously reported 
Bortner score relationship based on the following approach.  
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We determined confounding to be present if the covariate was a known risk factor for 
mortality and was associated with Bortner score, but was not thought to result from Bortner score 
[138].  If the covariate was intermediate in a causal sequence such that Bortner score influenced 
the covariate and the covariate affected mortality risk, then we concluded that the covariate was a 
mediating variable [139]. If the relationship between Bortner score and mortality differed at 
different values of the covariate, then we determined that the covariate was a moderating 
variable. Furthermore, we assessed whether the moderator was directly affecting the pathway 
between Bortner score and mortality, or if it was an antecedent moderator, meaning that it 
contributed to both Bortner score and mortality. The main difference between mediating and 
moderating variables is that the mediating variable specifies a causal relationship between 
Bortner score and mortality while the moderating variable affects the relationship between 
Bortner score and mortality across different levels of the covariate [139]. To determine if formal 
modifying was present we tested for a significant interaction between Bortner score and a 
covariate in predicting mortality. If a covariate significantly predicted mortality and was 
significantly associated with Bortner score, but was not thought to be biologically plausible as a 
mediator, we designated it as a confounder.  The same approach was used to assess type A 
behavior and mortality by sex. 
2.3 RESULTS 
At the EDC baseline exam, of the 595 participants aged 18 years or older, and thus 
eligible for the BDI and Bortner questionnaires, 100 were excluded due to missing covariate 
measures: predominantly the Bortner and BDI questionnaires and physical activity measures.  
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Those excluded from analyses had a higher WBC count (p<0.01); were younger (p=0.03); had a 
larger WHR (p=0.03); were less likely to have an education greater than high school (p<0.01); 
were more likely to have ever smoked (p=0.01) and were more likely to be male (p=0.04), but 
did not differ for age, duration, insulin dose, testing per week, physical activity, hypertension, 
fibrinogen, HbA1c, non-HDL, HDL, calorie intake, Bortner score, or BDI score. 
Out of these 495 remaining participants, there were 125 deaths (25.2%).  These 125 
participants differed from the survivors for most covariates (Table 1).  Those who died were 
older, had a longer duration, higher HbA1c, higher WBC count, were less physically active, had 
a greater WHR, higher fibrinogen level, lower HDL, higher non-HDL, were more often smokers, 
had higher depressive symptomatology, were more likely to be hypertensive, and had lower type 
A behavior scores (Table 1). 
Table 1: Baseline Characteristics by Mortality Status (N=495) 
Covariate Deceased (n=125) Alive (n=370) p-value 
Age (years) 33.4 (6.3) 27.7 (6.4) <0.0001 
Duration 24.4 (6.5) 18.8 (6.8) <0.0001 
Percent Males (n) 53.6 (67) 47.0 (174) 0.19 
Education 
%(n), Above High 
School 
60.0 (75)  65.9 (244) 0.22 
HbA1c (%) 9.1 (1.6) 8.6 (1.4) <0.01 
Insulin Dose (Total 
units/kg body weight) 
0.73 (0.29) 0.76 (0.21) 0.25 
Glucose Testing at 
Least Once per Week, 
%(n), Yes 
64.0 (80) 63.7 (236) 0.96 
WBC 7.4 (2.0) 6.2 (1.7) <0.0001 
Total caloric 
expenditure in sports 
/week (kilocalories) 
0 (0.0, 525.0) 387.5 (0.0, 1440.0) <0.0001 
WHR 0.86 (0.80, 0.92) 0.82 (0.76, 0.86) <0.0001 
Fibrinogen (mg/dL) 310.0 (270.0, 390.0) 265.0 (210.0, 310.0) <0.0001 
HDL (mg/dL) 49.1 (42.5, 57.9) 53.4 (45.7, 61.8) <0.01 
non-HDL (mg/dL) 163.6 (46.7) 132.4 (38.2) <0.0001 
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Table 1 Continued 
Daily Calories 
Consumed 
1895.2 (1501.5, 
2441.8) 
1960.5 (1528.2, 
2424.2) 
0.47 
Ever Smoker 
% (n), Yes 
56.8 (71) 33.7 (125) <0.0001 
Pack years of 
smoking (n=192) 
36.5 (24.8, 48.6) 52.1 (30.4, 91.2) <0.01 
Depressive 
Symptomatology 
8.0 (4.0, 14.0) 5.0 (2.0, 10.0) <0.0001 
Hypertension 
% (n), Yes 
53.6 (67) 25.1 (93) <0.0001 
Lipid Medication 
% (n), Yes 
0.80 (1) 0.54 (2) 0.74 
Type A Behavior 187.2 (26.9) 194.4 (25.1) <0.01 
 
 
 In combined analyses of men and women, age, sex, and education (all p<0.10) were 
included from the demographic model between Bortner score and mortality; total sports energy 
expenditure and ever smoked (both p≤0.05) were included from the behavioral model; none were 
included from the diabetes care model (both p>0.10); hypertension, non-HDL, WBC, fibrinogen, 
WHR, and HbA1c (all p<0.05) were included from the physiological risk factor model; and BDI 
(p<0.001) from the depressive symptomatology model.  Type A behavior (Figure 2), was 
univariately significant in predicting mortality [HR=0.76 (0.63-0.91); p<0.01].   
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Figure 2: Type A Behavior Quintiles and Mortality; p-trend=0.01 
 
In the final multivariable model to assess mediation, which was comprised of Bortner score and 
all significant covariates described above (Table 1), the association between Bortner score and 
mortality was no longer significant [HR= 0.94 (0.78, 1.15); p=0.58].  The individual effects of 
these influential covariates from each of the five risk factor models on the type A behavior and 
mortality relationship can be seen in Table 2. 
 
 
 
 
 
   
  
34 
 Table 2: Individual Relationship between Type A Behavior, Influential Covariates, and Mortality (N=495) 
Main Predictor Model Hazard Ratio Confidence 
Interval 
p-value 
Type A Behavior†  0.85 (0.70-1.02) 0.08 
 + Age 1.10 (1.07-1.13) <0.001 
Type A Behavior†  0.81 (0.68-0.97) 0.02 
 + Fibrinogen† 1.55 (1.35-1.78) <0.001 
Type A Behavior†  0.80 (0.67-0.96) 0.01 
 + WBC 1.24 (1.16-1.34) <0.001 
Type A Behavior†  0.76 (0.64-0.92) <0.01 
 + Non-HDL 1.01 (1.01-1.01) <0.001 
Type A Behavior†  0.77 (0.64-0.92) <0.01 
 +Beck 1.05 (1.03-1.08) <0.001 
† per 1 SD 
 
The significant risk factors that appeared to explain most of the relationship between Bortner 
score and mortality was younger age, which increased the HR from 0.76 to 0.85 (p=0.08); non-
HDL, fibrinogen, and WBC had further but less striking effects on the HR (Table 2). 
 Further analyses were carried out in order to examine the role of age, non-HDL, 
fibrinogen, and WBC and to determine if they were mediating, moderating, or confounding the 
relationship.  Because all four (age, non-HDL, fibrinogen, and WBC) significantly predicted 
mortality and were also significantly associated with Bortner score (Table 3-4) we determined 
that, based on these two criteria and the assessment of biological plausibility, mediation may be 
present.  
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Table 3: Association between type A behavior and all-cause mortality in T1D- Stepwise Cox regression (n=495; 125 events) 
aFinal Model= allowed for age, sex, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, hypertension, HDL, non-
HDL, lipid medication, WBC, fibrinogen, WHR, HbA1c, and depressive symptomatology
Model 1 2 3 4 5 6 7 8 9 10 11 
Type A 
Behavior 
0.76 (0.63-
0.91); p<0.01 
0.85 (0.70-
1.02); p=0.08 
0.84 (0.70-
1.01); 
p=0.07 
0.87 (0.72-
1.05); p=0.15 
0.90 (0.74-
1.09); p=0.29 
0.94 (0.78-
1.14); p=0.57 
0.92 (0.76-
1.12); 
p=0.44 
0.91 
(0.75-
1.11); 
p=0.38 
0.92 
(0.76-
1.12); 
p=0.45 
0.92 (0.76-
1.12); 
p=0.43 
0.94 (0.78-
1.15); p=0.58 
Age  1.10 (1.07-
1.13); p<0.001 
1.10 (1.07-
1.13); 
p<0.001 
1.09 (1.07-
1.12); 
p<0.001 
1.09 (1.06-
1.12); 
p<0.001 
1.09 (1.06-
1.11); 
p<0.001 
1.08 (1.06-
1.11); 
p<0.001 
1.09 
(1.06-
1.11); 
p<0.001 
1.09 
(1.06-
1.11); 
p<0.001 
1.08 (1.05-
1.11); 
p<0.001 
1.08 (1.05-
1.11); p<0.001 
Sex   0.73 (0.51-
1.03); 
p=0.08 
0.85 (0.60-
1.22); p=0.39 
0.77 (0.54-
1.11); p=0.17 
1.47 (0.91-
2.38); p=0.10 
1.30 (0.81-
2.10); 
p=0.27 
1.38 
(0.85-
2.25); 
p=0.18 
1.49 
(0.91-
2.46); 
p=0.11 
1.75 (1.05-
2.92); 
p=0.03 
1.59 (0.95-
2.68); p=0.07 
non-HDL    1.01 (1.00-
1.01); 
p<0.001 
1.01 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 
(1.00-
1.01); 
p<0.001 
1.00 
(1.00-
1.01); 
p<0.01 
1.00 (1.00-
1.00); 
p=0.01 
1.00 (1.00-
1.01); p=0.07 
Fibrinogen*     1.41 (1.20-
1.66); 
p<0.001 
1.38 (1.18-
1.61); 
p<0.001 
1.34 (1.15-
1.57); 
p<0.001 
1.26 
(1.08-
1.48); 
p<0.01 
1.23 
(1.05-
1.44); 
p<0.01 
1.20 (1.02-
1.41); 
p=0.02 
1.20 (1.01-
1.42); p=0.02 
WHR*      1.62 (1.27-
2.03); 
p<0.001 
1.55 (1.22-
1.96); 
p<0.001 
1.58 
(1.23-
2.02); 
p<0.001 
1.61 
(1.25-
2.08); 
p<0.001 
1.62 (1.26-
2.09); 
p<0.001 
1.54 (1.19-
2.00); p<0.001 
Depressive 
Symptomatology 
      1.03 (1.01-
1.06); 
p<0.01 
1.04 
(1.01-
1.06); 
p<0.01 
1.03 
(1.01-
1.06); 
p<0.01 
1.04 (1.01-
1.06); 
p<0.01 
1.04 (1.01-
1.06); p<0.01 
HbA1c        1.20 
(1.06-
1.36); 
p<0.01 
1.23 
(1.08-
1.39); 
p<0.01 
1.26 (1.11-
1.42); 
p<0.001 
1.26 (1.11-
1.44); p<0.001 
Ever smoker         1.62 
(1.12-
2.35); 
p<0.01 
1.83 (1.25-
2.66); 
p<0.01 
1.66 (1.12-
2.45); p=0.01 
Hypertension          1.85 (1.25-
2.74); 
p<0.01 
1.92 (1.30-
2.84); p<0.01 
WBC           1.10 (1.00-
1.20); p=0.03 
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Table 4: Correlations between Type A Behavior and the Covariates 
Covariate Type A Behavior Mean Bortner by Categorical 
Covariates 
Age (years) -0.197*** -- -- 
Duration -0.149*** -- -- 
HbA1c (%) 0.043 -- -- 
Insulin Dose (Total units/kg 
body weight) 
0.023 -- -- 
WBC -0.116** -- -- 
Total caloric expenditure in 
sports /week (kilocalories) 
0.149*** -- -- 
WHR -0.096* -- -- 
Fibrinogen (mg/dL) -0.120* -- -- 
HDL (mg/dL) 0.077 -- -- 
non-HDL (mg/dL) -0.091* -- -- 
Daily Calories Consumed 0.103* -- -- 
Depressive Symptomatology -0.040 -- -- 
Ever Smoker -- No 
195.4 (25.9)** 
Yes 
188.1 (24.9)** 
Hypertension -- No 
193.6 (25.4) 
Yes 
190.2 (26.4) 
Lipid Medication -- No 
192.6 (25.8) 
Yes 
183.3 (13.2) 
Sex -- Male 
193.7 (26.6) 
Female 
191.4 (24.9) 
Education -- Above High 
School 
195.8 (25.3)*** 
Below High 
School 
186.6 (25.6)*** 
Glucose Testing at Least Once 
per Week 
-- No 
194.3 (26.3) 
Yes 
191.6 (25.4) 
*p<0.05 
**p<0.01 
***p<0.001 
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To assess whether they were full or partial mediators, each was placed separately in a Cox 
proportional hazards model along with Bortner score to determine if age, non-HDL, fibrinogen, 
or WBC would cause the HR between Bortner score and mortality to reach HR=1.0.  Because 
none of the three totally eliminated the relationship between Bortner score and mortality, we 
determined that while none of these variables were full mediators, some might be partial 
mediators.   
Before concluding these were mediators, we tested for an interaction between each of the 
three variables and Bortner score in predicting mortality to determine if moderation was present.  
Fibrinogen had a borderline significant (p=0.06) interaction while non-HDL and WBC did not, 
though this may be due to our sample size. Age did not significantly interact with Bortner score 
in the prediction of mortality, and because it is not plausible for age to be a mediator, it is most 
likely operating as an antecedent modifier.  Therefore, we concluded that fibrinogen was a 
moderator while non-HDL and WBC had the potential to be mediators.  Lastly, we tested for an 
interaction between Bortner score and BDI and found a p-value=0.18.  Because depressive 
symptomatology is also predictive of mortality but is unlikely to be directly caused by type A 
behavior, it is possible that depressive symptomatology is a confounder in this relationship.  
Based on the analyses, the definitions used to define mediators, moderators, and confounders, 
and biological plausibility, we determined that depressive symptomatology was a confounder, 
non-HDL and WBC were mediators, fibrinogen was a moderator, and age was an antecedent 
modifier (Figure 3). 
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 Figure 3: Mediators, Moderators, and Confounders for Combined Men and Women (n=495) 
 
 Because of prior sex variations in the role of psychosocial factors, similar sex specific 
analyses were conducted although the Bortner-gender interaction was non-significant (p=0.28) 
[140].  There was a significant univariate association between Bortner score and mortality found 
in men [HR=0.68 (0.53, 0.87); p<0.01] but not in women [HR=0.84 (0.65-1.09); p=0.20]. The 
association between Bortner score and mortality in men was lost in the multivariable analysis 
[HR=0.87 (0.65-1.16); p=0.36] (Table 5).  Most of the factors that appeared to explain the 
relationship between Bortner score and mortality in men were the same as in the combined 
analyses, with the addition of WHR (HR increased from 0.81 to 0.84; p=0.22) and calories 
consumed (HR increased from 0.81 to 0.86; p=0.30) (Table 5) (Figure 4).  
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Table 5: Association between type A behavior and all-cause mortality in T1D in men- Stepwise Cox regression (n=241; 67 events) 
Model 1 2 3 4 5 6 7 8 9 10 11 
Type A 
Behavior 
0.68 (0.53-
0.87); p<0.01 
0.78 (0.61-
0.99); p=0.04 
0.81 (0.63-
1.05); 
p=0.12 
0.84 (0.65-
1.10); p=0.22 
0.82 (0.63-
1.08); p=0.17 
0.81 (0.62-
1.07); p=0.14 
0.86 (0.65-
1.14); 
p=0.30 
0.86 
(0.65-
1.15); 
p=0.32 
0.91 
(0.68-
1.21); 
p=0.52 
0.88 (0.66-
1.17); 
p=0.40 
0.87 (0.65-
1.16); p=0.36 
Age  1.10 (1.06-
1.14); p<0.001 
1.09 (1.05-
1.13); 
p<0.001 
1.06 (1.01-
1.10); p<0.01 
1.06 (1.01-
1.10); p<0.01 
1.06 (1.01-
1.10); p<0.01 
1.06 (1.02-
1.10); 
p<0.001 
1.06 
(1.02-
1.10); 
p<0.001 
1.06 
(1.02-
1.10); 
p<0.001 
1.05 (1.02-
1.09); 
p<0.01 
1.05 (1.01-
1.09); p=0.01 
non-HDL   1.01 (1.00-
1.01); 
p<0.001 
1.01 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); p=0.01 
1.00 (1.00-
1.01); 
p=0.01 
1.00 
(1.00-
1.01); 
p=0.01 
1.01 
(1.00-
1.01); 
p=0.02 
1.01 (1.00-
1.01); 
p=0.08 
1.01 (1.00-
1.01); p=0.08 
WHR*    1.97 (1.41-
2.74); 
p<0.001 
1.85 (1.34-
2.55); 
p<0.001 
1.92 (1.37-
2.71); 
p<0.001 
2.00 (1.42-
2.82); 
p<0.001 
2.03 
(1.43-
2.88); 
p<0.001 
1.96 
(1.38-
2.77); 
p<0.001 
1.89 (1.34-
2.68); 
p<0.001 
2.02 (1.40-
2.92); p<0.001 
Fibrinogen*     1.36 (1.10-
1.68); 
p<0.001 
1.27 (1.01-
1.58); p=0.03 
1.22 (0.97-
1.52); 
p=0.08 
1.11 
(0.87-
1.41); 
p=0.37 
1.08 
(0.84-
1.38); 
p=0.53 
1.09 (0.85-
1.40); 
p=0.45 
1.05 (0.82-
1.35); p=0.66 
HbA1c      1.21 (1.00-
1.46); p=0.04 
1.21 (1.01-
1.46); 
p=0.03 
1.23 
(1.02-
1.49); 
p=0.02 
1.27 
(1.05-
1.54); 
p=0.01 
1.28 (1.06-
1.55); 
p<0.01 
1.31 (1.08-
1.59); p<0.001 
Calories 
Consumed 
      1.00 (0.99-
1.00); 
p=0.04 
1.00 
(0.99-
1.00); 
p=0.02 
0.99 
(0.99-
1.00); 
p=0.01 
1.00 (0.99-
1.00); 
p=0.01 
0.99 (0.99-
1.00); p<0.01 
Depressive 
Symptomatology 
       1.03 
(1.00-
1.07); 
p=0.03 
1.03 
(1.00-
1.07); 
p=0.03 
1.04 (1.00-
1.08); 
p=0.01 
1.04 (1.00-
1.08); p=0.02 
WBC         1.14 
(1.00-
1.30); 
p=0.04 
1.16 (1.01-
1.32); 
p=0.02 
1.12 (0.97-
1.28); p=0.09 
Hypertension          1.74 (1.00-
3.04); 
p=0.04 
2.01 (1.14-
3.57); p=0.01 
Ever Smoker           1.69 (0.97-
2.96); p=0.06 
aFinal Model= allowed for age, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, hypertension, HDL, non-HDL, 
lipid medication, WBC, fibrinogen, WHR, HbA1c, and depressive symptomatology
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 Figure 4: Mediators, Moderators, and Confounders for Men Only (n=241) 
 
Next, to better understand the role of these additional influential covariates, we investigated 
whether these variables were mediators, moderators, or confounders in the Bortner score and 
mortality relationship.  We found that WHR did not significantly interact with Bortner score 
(p=0.22) while calories consumed did (p=0.05).  Thus, we concluded that WHR was a likely 
mediator and calories consumed were a moderator in the relationship between Bortner score and 
mortality. 
Based on our previously published work where we found a significant interaction 
between Bortner score and BDI so that Bortner score was only operative in those with a low BDI 
[83], we tested for an interaction between Bortner score and BDI in men and now found the 
interaction term to be non-significant in predicting mortality (p=0.17).  Because in our 
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previously published work the Bortner score and depressive symptomatology interaction was 
more significant in men, we repeated these findings in our current population and found that in 
those with a BDI<7 (prior median cut-point used), total Bortner score was more protective 
against mortality (p=0.16) compared to in those with a BDI score of ≥7, where Bortner score lost 
most of its protective effect (p=0.47).   
2.4 DISCUSSION 
In this current analysis, we have built on our previous research, which demonstrated a 
protective effect of type A behavior on mortality in those with T1D through further investigation 
of how the covariates influence the relationships between the other risk factors and mortality 
(confounders vs. moderators vs. mediators).  Overall, we found that in men and women 
combined, type A behavior (as indicated by the Bortner score) was univariately protective 
against mortality, however this relationship was no longer significant after other risk factors were 
considered, due, most prominently, to the additions of age (antecedent moderator), non-HDL and 
WBC (mediators), and fibrinogen (moderator) (Figure 3). When these analyses were performed 
separately by sex, type A behavior was univariately protective against mortality in men but not in 
women.  However, in men this relationship was lost in the multivariable modeling, most 
predominately after WHR (mediator) and age (antecedent moderator) were taken in to account in 
the type A behavior and mortality relationship (Figure 4).  
It is an interesting finding that age moderates the relationship between type A behavior 
and mortality because it seems that behavior type may differ across the lifespan.  Our findings fit 
in with much of the literature that suggests that personality changes with age [141]–[145].  In our 
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population, age (a known risk factor for mortality) was negatively correlated with type A 
behavior, but is not caused by type A behavior, thus leading to our conclusion that age is an 
antecedent moderator in the relationship between type A behavior and mortality.  In other words, 
younger participants scored themselves higher on the Bortner scale compared to older 
participants.  This may be due to several factors, including younger people having more energy 
for time urgency or they may be new in their careers and extremely motivated and energetic. 
Type A behavior may be linked to mortality through a relationship with inflammation in 
the body.  Previous investigators have found that several markers of inflammation were 
significantly increased in subjects with T1D compared with controls [146]. In addition, 
inflammation increases vascular disease, which is turn increases the risk of mortality [59]–[61], 
[147]–[150].  Because of this pathway, it is plausible that low type A behavior scores may lead 
to increased inflammation levels/stress reactants (marked by increased WBC and non-HDL) and, 
further moderated by fibrinogen, may increase the risk for mortality in those with T1D through 
complications. Furthermore, according to our results, the protection offered through type A 
behavior on mortality operates best among those with low levels of fibrinogen. Our analyses 
suggested that two markers of inflammation, WBC and non-HDL, operated as mediators while 
the other fibrinogen, operated as a moderator.  Biological plausibility wise, this difference is 
difficult to explain. Fibrinogen had only a borderline significant interaction with type A behavior 
in mortality prediction, so perhaps it is actually working as a mediator, or we did not have 
enough statistical power to detect interactions with the other two and type A behavior. 
It is also difficult to tease out whether those who had high type A behavior scores had a 
reduced risk of inflammation or if those who scored themselves low on the Bortner Scale had 
high levels of inflammation and possible subclinical disease leading to mortality.  While the 
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Bortner Score most likely indicates a combination of a health status and genuine behavior, type 
A behavior’s relationship with mortality was not completely eliminated after non-HDL and 
WBC mediated the relationship, after fibrinogen modified the relationship, or with age 
functioning as an antecedent moderator.  Therefore, it seems likely that type A behavior was not 
simply a marker of health since the inflammatory markers did not fully explain its relationship 
with mortality (Table 3) and thus did represent some benefit of the behavior type, as well. 
Because we found non-HDL to be a mediator between type A behavior and mortality, we 
looked into the literature to investigate whether other studies support this finding.  A separate 
study comprised of older participants free from diabetes found that those with type A behavior 
compared to type B behavior had higher serum total cholesterol [151]  After analyses, the 
authors concluded that there might be an association between type A behavior and lipid 
metabolism, however they did not take gender and age into account while investigating this 
relationship which may not have properly accounted for confounding [151].  Another study 
found similar results in a general Cretan population: that total serum cholesterol level was 
positively associated with type A behavior score [152].  In our population of people T1D, non-
HDL had a significant, negative correlation with type A behavior score, which is opposite of 
what was observed in these other populations.   This is consistent with type A behavior having a 
protective effect in high risk populations compared to a potential detrimental effect in the general 
population, most likely due to people living with a chronic disease benefiting from a more 
regimented behavior type [70], [153], [154]. Because non-HDL was determined to be a mediator, 
it appears that higher type A behavior leads to a person’s lower non-HDL cholesterol level and 
therefore reduced mortality risk. 
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In our sex-specific analyses, men were protected against mortality by high type A 
behavior before considering other variables, with lower WHR and age subsequently having the 
largest effect on this relationship. However, in women, type A behavior provided no protection 
against mortality. WHR was found to be a partial mediator, age an antecedent moderator, and 
depressive symptomatology appeared to confound but not moderate the relationship between 
type A behavior and mortality in men.   
A relationship between type A behavior and WHR has previously been demonstrated in 
our population, particularly in men, with a higher WHR associated with lower type A behavior 
score [97]. Our current data fit in with this, as WHR was an important risk factor in the 
relationship between type A behavior and mortality, greatly reducing the protective effect of type 
A behavior on mortality.  Again, this mediating relationship is difficult to understand.  Because 
WHR is a mediator, it is in the causal pathway between type A behavior and mortality, therefore, 
it seems that those who rated themselves higher on the type A behavior questionnaire had lower 
WHR and therefore a reduced risk of mortality.  However, having a lower WHR mediated the 
effect high type A behavior had on mortality risk but did not completely eliminate the 
demonstrated relationship. While WHR did not affect the hazard ratio as drastically in men and 
women combined, this is most likely due to it having a close relationship with the inflammatory 
markers in the combined population and thus its contribution to the mediation was diluted by the 
inclusion of the inflammatory markers.  Based on WHR not completely eliminating the 
relationship in men, it seems that a combination of behavior type and traditional health markers 
for mortality are occurring together and Björntorp’s theory regarding stress and comorbidities 
becomes important [155].   
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Björntorp theorizes that elevated cortisol may cause the accumulation of fat in visceral 
adipose tissues as well as cause the metabolic syndrome [155]. He further describes these 
relationships by noting that depression in men is followed with time by similar abnormalities. 
Several factors, including psychosocial and socioeconomic disadvantages and depressive 
symptomatology and anxiety may increase stress. It is possible that 'stress-eating' may result, 
increasing abdominal adiposity (measured in our cohort by WHR) [155].  This theorizing, 
combined with our demonstrated effect of WHR’s importance in men along with depressive 
symptomatology as a confounder, may explain the biological plausibility of WHR mediating the 
relationship between type A behavior and mortality. 
In related work, the Japanese Collaborative Cohort Study investigated whether 
psychological factors had an influence on disease processes [156]. One of their included factors 
was “sense of hurry,” which is seemingly similar to “always rushed,” a component of the type A 
behavior questionnaire used in our study.  Researchers found that participants who scored 
themselves “yes” on the “sense of hurry” question had a decreased risk of mortality from all 
causes compared to “maybe yes” while those rating themselves as “no” had an increased risk for 
mortality in both sexes. They hypothesized that this relationship may be due to these participants 
rating themselves as “yes” and above on “sense of hurry” having a generally more positive 
attitude regarding their lives [156].   
To expand on this idea regarding type A behavior and increased positivity, a separate, 
small, United States study researched whether stress-induced declines in positivity increased 
inflammation, and in turn, whether this increase was associated with increased depressive 
symptomatology in women [157].  Authors found that a decreased positive outlook during stress 
was associated with high pro-inflammatory reactivity and that there was a borderline trend 
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towards higher depressive symptomatology.  Through a mediation model, they determined a 
significant mediation effect such that decreased positive outlook during stress lead to increased 
inflammation, which lead to increased depressive symptomatology.  Authors conclude that these 
results demonstrate potential that those who maintain hope and confidence during stress may be 
at a reduced risk of depressive symptomatology.  It seems that something similar is happening in 
our population.  A low type A behavior score, and thus potential low positivity, may work with 
increased inflammation and depressive symptomatology to increase the risk for mortality. 
 In our study, we considered a large number of covariates as possible explanatory factors 
between type A behavior and mortality.  Although the Japanese study saw a protective effect in 
both men and women, we only saw this effect in men.  Their hypothesis about these participants 
having a positive life outlook may be applicable to our T1D population.  Living with T1D poses 
many stresses and worries that the general population, free from a chronic disease, may not 
experience.  Perhaps rating oneself very high on the type A behavior scale is indicative of having 
the enthusiasm to rush to complete daily tasks and create busy schedules for themselves despite 
challenges stemming from their chronic disease.  This enthusiasm seems like it would be a 
marker of an overall positive attitude.  The second study described above demonstrated that an 
increased positive outlook during a stressor may protect against inflammation in the body, as 
well as against depressive symptomatology which we have demonstrated to be an increased risk 
factor for mortality [100].  Those with type A behavior in our study may have a more positive 
outlook in general, offering protective benefits against mortality. 
 A limitation of our study was the number of participants excluded from the analyses as 
well as the excluded participants being sicker than those included.  However, we described the 
differences in populations and confirmed that those excluded were not significantly different 
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regarding their type A behavior scores.  In our current study, age influenced the relationship 
between type A behavior and mortality to a larger degree than our previous work.  This 
difference is most likely due to the difference in populations (20 discordant participants) 
resulting from the use of different covariates.  The purpose of the current study was to 
understand the type A behavior and mortality relationship in greater detail, thus a more extensive 
list of covariates was utilized. 
 Future research should focus on continuing to understand the benefit type A behavior has 
on delaying mortality and how it interacts with other potentially important psychosocial factors 
(e.g. social support, hostility, stress, anger, and anxiety mechanisms). In conclusion, we were 
able to derive a better understanding of the type A behavior association with mortality using 
these select components as well as analyses to determine whether mediation, moderation, or 
confounding was present using several levels of risk factors. We conclude that there may be 
protective aspects of high type A behavior that play an important role in mortality prevention, 
but that age, WHR, non-HDL, and inflammatory markers can largely explain this protection.  We 
hope future research will be able to use these psychosocial findings to delay mortality in people 
with T1D. 
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3.0  PSYCHOSOCIAL FACTORS AND THEIR INTERACTIONS IN THE 
PREDICTION OF MORTALITY 
We expanded on our previous research by examining a complete list of covariates in the 
type A behavior and mortality relationship.  In addition, we have also previously demonstrated a 
relationship between depressive symptomatology and mortality.  As discussed above, there is a 
substantial gap in the literature in terms of studying how psychosocial factors interact with one 
another to predict mortality. Thus, we examined whether psychosocial risk factors interact with 
type A behavior and depressive symptomatology to predict mortality up to 22-years later in our 
T1D population. 
3.1 INTRODUCTION 
Psychosocial factors, including depressive symptomatology, type A behavior, hostility, 
trait-anger, anxiety, and social support, have all been associated with health outcomes in the 
general population and somewhat within those with T1D.  T1D is mostly diagnosed in children 
and young adults, although it can occur at any age [2].  The EURODIAB study, which involves a 
registry of 44 countries in Europe, suggests an annual rate of increase of 3-4% in incidence of 
T1D. Although survival in those with T1D has improved [4]–[12], [15], the population continues 
to be at an increased risk of several long-term complications [129]. While several modifiable risk 
  
49 
factors are recognized for the development of these complications, how psychosocial factors may 
interact to contribute to early mortality in people with T1D is understudied. 
It has been previously demonstrated that higher depressive symptomatology is associated 
with increased mortality [91] and morbidity risk (including diabetes complications) [92]. Co-
morbid depression and T1D is also associated with poorer diabetes self-management and 
metabolic control, decreased quality of life, and higher healthcare usage [91]. In addition, one 
study found that those with T1D were over three and a half times more likely to have depression, 
over two and a half times more likely to have a history of depression, and were twice as likely to 
be on an antidepressant than people free from T1D [93].  Through a meta-analysis, investigators 
found a prevalence of depression between 12.0% and 13.4% in T1D [158]. 
Personality type and behavioral factors have also been found to be associated with health 
outcomes.  People characterized as having type A behavior tend to focus on accomplishing more 
in less time than others, and are often more competitive, time urgent, and work-oriented [70].  
We have previously demonstrated that those with T1D and higher type A behavior scores 
interact with depressive symptomatology such that those with high type A behavior have lower 
all-cause mortality in the absence of high depressive symptomatology [83].  In addition, cross-
sectional analysis has shown type A behavior to be negatively associated with the number of 
complications present in those with T1D [72]. The authors hypothesized that this may be due to a 
protective effect of some aspect of behavior regarding self-management of diabetes leading to a 
reduced risk of complication development [72].  A combination of depressive symptomatology, 
type A behavior, and other psychosocial factors may improve the prediction of mortality 
compared to studying them separately. 
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A potentially detrimental psychosocial factor is hostility, and a recent meta-analysis 
found, via their subgroup analyses, that the Minnesota Multiphasic Personality Inventory 
(MMPI) and its derivative, the Cook-Medley hostility scale (CMHS) were significantly 
associated with CHD events in healthy and existing CHD study cohorts, with increased hostility 
resulting in an approximate 20% increase in CHD event risk in both populations [102]. Another 
study conducted in a population of African-Americans with T1D found that the development of 
hypertension over a 6-year follow-up period was independently predicted by hostility and overt 
proteinuria [105]. 
Anger, which is usually examined in combination with hostility but exists as its own 
construct, is an additional psychosocial area of focus in the literature. Anger can be described as 
“an emotional state that consists of feelings that vary in intensity from mild irritation or 
annoyance to intense fury or rage, and aggressiveness as a verbal or physical behavioral pattern 
manifest in yelling, intimidation, or physical assaults [102].” The limited literature that exists 
suggests that anger is associated with increased CHD events in healthy population studies as well 
as in those with existing CHD [102]. The literature surrounding T1D and hostility and trait-anger 
is, however, extremely limited. 
An additional important psychosocial factor in chronic disease progression is anxiety, 
with anxiety-related personality traits found to be associated with increased risk for the 
development of depression and anxiety-related disorders [159]. As expected, anxiety is more 
prevalent in the diabetes population than in the general population partially due to the burden of 
living with a chronic disease [114].   A study found that generalized anxiety disorder was 
prevalent in about 5% of their population [113]; investigators also found that within their 
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participants with stable CAD, anxiety and depression resulted in increased odds of having a 
cardiac event over two years of follow-up, even after multivariable adjustments [113]. 
An additional psychosocial factor, social support, has also been found to influence health 
[125], [126], [160], [161]. Social support refers to the network of family and friends surrounding 
a person in their external environment. A review concluded that peer support demonstrated some 
potential to improve diabetes related outcomes; however, the existing evidence is too 
inconsistent and sparse to maintain an overall consensus [126]. A separate clinical trial of people 
with diabetes, through the Veteran’s Affairs Organization, [161] demonstrated  that reciprocal 
peer support resulted in a significant decrease in HbA1c level six months later compared to the 
usual care group, where HbA1c levels actually increased. They also found that the reciprocal 
peer support group reported greater increases in social support at six months compared to the 
usual care group, thus demonstrating a change in perceived social support, as well [161]. 
In summary, depressive symptomatology, type A behavior, hostility, trait-anger, anxiety, 
and social support have all been associated with health outcomes in the general population and in 
those with diabetes.  In T1D, we have previously demonstrated that depressive symptomatology 
is an independent predictor of mortality in both men and women [100], as is type A behavior 
[83].  A recurring theme within the literature is the potential web these factors form with one 
another and how different combinations and interactions may affect health outcomes [132], 
[137]. We thus examined whether the psychosocial risk factors discussed above (hostility, trait-
anger, anxiety, stress, and social support) interacted with type A behavior and depressive 
symptomatology to predict mortality in our T1D population over a 22-year follow-up period. 
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3.2 METHODS 
The EDC Study is comprised of T1D participants diagnosed between 1950 and 1980 at 
age <17 years.  These participants were seen within one year of diagnosis at the Children’s 
Hospital of Pittsburgh.  Biennial follow-up has occurred since baseline (1986-1988) with surveys 
and, for the first 10 years and again at 18 years, with examinations.  These follow-ups included 
questionnaires, physician examinations, and laboratory analyses of urine and blood.  Data up to 
the 22-year follow-up are now available.  
Participants ≥18 years of age at study entry completed a series of forms including the 
Bortner Rating Scale, the Interpersonal Support Evaluation List, the Spielberger Anger/Anxiety 
Scale, the Cook-Medley Hostility Scale, Cohen’s Perceived Stress Scale, and the BDI, which 
were examined in the analyses. The BDI is a 21-item self-report scale that is widely used in both 
healthy and ill populations to measure depressive symptomatology [137]. The Bortner Rating 
Scale measures aspects of type A behavior, and participants circled where they fell on the dotted 
line between items like “always rushed” and “never rushed, even under pressure” (Appendix A) 
[132]. A slightly modified (with wording changed on item 2) version of the 10 statement 
Appraisal Scale component of The Interpersonal Support Evaluation List [162] was used and 
measures the perceived accessibility of someone with which to talk about one’s problems. The 
Spielberger Trait Anger-Anxiety Scale [163] was used to measure trait (how people generally 
feel during typical situations experienced on a regular basis) anger and anxiety. The Cook-
Medley Hostility Scale was utilized [164], which measures various cognitive, emotional, and 
behavioral characteristics of someone’s negative orientation towards interactions with others 
[164]. Lastly, Cohen’s 5 item Perceived Stress Scale [165] was used to measure perceived level 
of stress during the past month.  
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Overall mortality and complication status was determined as of February 25, 2011. The 
underlying causes of death, and the hierarchal order for all contributing causes of death, were 
determined by a Mortality Classification Committee consisting of two or more physician 
epidemiologists [166].  Covariates were chosen based on prior evidence for our final mortality 
prediction models [83], [133]. Education was assessed using a 5-point scale, and then 
dichotomized to above or below a high school education. Daily calories consumed were 
measured through use of the Willett Food Frequency Questionnaire averaged over a week [167]. 
Physical activity was assessed using questions about current levels of leisure activities [168].  
Smoking status was defined by whether or not more than 100 cigarettes had been smoked over 
their lifetime.  Insulin dosage was expressed as the number of units of insulin used per day 
divided by the participants’ weight in kilograms.  Frequency of blood glucose testing per week 
was reported as the number of times blood glucose levels were tested each week.  
Hypertension was defined as systolic blood pressure SBP≥130 or DBP≥80 or on blood 
pressure medication.  Fasting blood samples were assayed for lipids, WBC count, and fibrinogen 
as previously described [136], [169]. Fasting blood samples were also analyzed for HbA1 
(microcolumn cation exchange; Isolab, Akron, OH, USA), and these original HbA1 values were 
converted to DCCT-aligned HbA1c for all analyses using a regression equation derived from 
duplicate assays (DCCT HbA1c=0.14+0.83[EDC HbA1]).  WHR ratio was calculated by 
measuring at the smallest circumference of the natural waist and then measuring the hip 
circumference at the widest part of the buttocks or hip.  
Cox proportional hazards models were utilized to examine the univariate relationship 
between baseline type A behavior (Bortner Score) and mortality, depressive symptomatology 
(BDI score) and mortality, and other baseline covariates and mortality. Student’s t-tests or 
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Wilcoxon rank-sign tests were used to assess the univariate associations between the primary 
predictors of interest, Bortner Score and BDI, and other covariates, including trait-anger. Cox 
proportional hazards modeling was then used to examine the multivariable relationship between 
Bortner Score, controlling for significant baseline covariates, and overall mortality over 22 years 
of follow-up.  The same was repeated with BDI as the main predictor.  
A correlation matrix of the psychosocial variables (main predictors: type A behavior and 
depressive symptomatology; covariates: trait-anger, anxiety, hostility, support, and stress) was 
completed, and when significant correlations between the psychosocial variables ≥0.65, residual 
values were calculated by regressing the correlated psychosocial variables on one another. These 
calculated residual values were then used in the multivariable models in place of the original 
psychosocial variables.  This allowed us to assess the impact of each psychosocial variable 
independent of the other, correlated variables. BDI was highly correlated with anxiety and stress, 
so we regressed anxiety and stress on to BDI to calculate a residual value and used that value in 
the model in place of the original BDI value for each observation.  We regressed BDI and stress 
on to anxiety to calculate a residual value for anxiety, and used it as described for BDI.  Lastly, 
we regressed BDI and anxiety on to stress to calculate a residual value for stress, and again, used 
it the same way in our modelling.  Interactions between Bortner Score and BDI and the other 
psychosocial variables were evaluated and used in multivariable modeling as appropriate. All 
statistics were performed using SAS 9.3 (SAS Institute, Cary, NC). 
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3.3 RESULTS 
At the baseline visit, 592 participants were 18 years and older and eligible to complete 
the psychosocial questionnaires. One hundred participants were excluded from this analysis for 
having missing covariate measures, primarily the psychosocial questionnaires and physical 
activity measures.  Out of those who were age eligible, those who were excluded had a higher 
WBC count, a higher WHR, were more likely to be male, ever smokers, and were less likely to 
have higher than a high school education.  
Out of the remaining 492 participants, there were 125 deaths (25.4%).  As expected, 
differences existed by subsequent mortality for most baseline covariates. Deceased participants 
tended to be older, with longer diabetes duration, higher HbA1c, higher insulin dose, higher 
WBC, lower physical activity levels, higher WHR, fibrinogen, non-HDL, lower HDL, were more 
likely to be smokers, have hypertension, higher BDI scores, lower interpersonal support, and 
lower Bortner Scale scores (Table 6). 
 
Table 6: Baseline Characteristics by Mortality Status (N= 492) 
Covariate Deceased (n=125) Alive (n=370) p-value 
Age (years) 33.4 (6.3) 27.6 (6.5) <0.0001 
Duration 24.4 (6.5) 18.7 (6.8) <0.0001 
Percent Males %(n) 53.8 (63) 46.8 (177) 0.18 
Education 
%(n), Above High 
School 
58.9(69) 65.6 (248) 0.19 
HbA1c (%) 9.1 (1.6) 8.6 (1.4) <0.01 
Insulin Dose (Total 
units/kg body weight) 
0.65 (0.53, 0.85) 0.75 (0.62, 0.88) <0.01 
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Table 6 Continued 
Glucose Testing at Least 
Once per Week, %(n), 
Yes 
64.0 (80) 63.7 (234) 
 
0.96 
WBC 7.0 (6.0, 8.8) 6.0 (5.1, 7.2)) <0.0001 
Total caloric 
expenditure in sports 
/week (kilocalories) 
0 (0.0, 525.0) 387.5 (0.0, 1425.0) <0.0001 
WHR 0.86 (0.80, 0.92) 0.82 (0.76, 0.86) <0.0001 
Fibrinogen (mg/dL) 310.0 (270.0, 390.0) 270.0 (210.0, 310.0) <0.0001 
HDL (mg/dL) 49.1 (42.5, 57.9) 53.4 (45.8, 61.4) <0.01 
non-HDL (mg/dL) 159.2 (133.0, 187.6) 125.2 (104.4, 150.8) <0.0001 
Daily Calories 
Consumed 
1895.2 (1501.5, 2441.8) 1958.2 (1528.2, 2419.9) 0.50 
Ever Smoker 
% (n), Yes 
56.4 (66) 34.1 (129) <0.0001 
Hypertension 
% (n), Yes 
55.5 (65) 24.8 (94) <0.0001 
Lipid Medication 
% (n), Yes 
0.85 (1) 0.53 (2) 0.69 
Hostility 98.0 (12.6) 98.1 (11.9) 0.96 
Anger 20.0 (16.0, 23.0) 19.0 (16.0, 23.0) 0.29 
Anxiety 19.0 (15.0, 24.0) 19.0 (15.0, 24.0) 0.88 
Depressive 
Symptomatology 
8.0 (4.0, 14.0) 5.0 (2.0, 10.0) <0.0001 
Stress 12.0 (11.0, 16.0) 13.0 (11.0, 16.0) 0.59 
Interpersonal Support- 
Appraisal Scale 
7.0 (5.0, 9.0) 8.0 (6.0, 9.0) 0.05 
Type A Behavior 187.2 (26.9) 194.4 (25.2) <0.01 
 
 Residual values for BDI scores, anxiety, and stress (as described above) were used in 
modeling and in interaction assessment as these three variables were highly correlated.  Residual 
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BDI scores [HR=1.65 (1.41-1.934); p<0.0001] and Bortner Scale scores [HR=0.76 (0.63-0.91); 
p<0.01] were univariately associated with mortality.  We tested for interactions between residual 
BDI scores and Bortner Scale scores and the other psychosocial covariates, and found that 
residual BDI scores had a borderline interaction only with trait-anger (p=0.08) while Bortner 
Score did not significantly interact with any of the psychosocial variables. Interaction terms were 
used as predictors where appropriate (p<0.10) in the two separate multivariable models: one for 
residual BDI scores and mortality and one for Bortner scores and mortality.   We used a step-
wise approach offering age or duration, and sex first, then additional behavioral and biological 
risk factors, followed by psychosocial variables, and finally interactions between the 
psychosocial variables if applicable (Tables 7-8).  
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Table 7: Final Multivariable Models of depressive symptomatology and all-cause mortality in T1D- Stepwise Cox regression (n=492; 125 events) 
 1 2 3 4 5 6 7 8 9 10 11 
Depressive 
Symptomatology 
1.65 (1.41-
1.93); 
p<0.001 
1.55 (1.31-
1.84); 
p<0.001 
1.58 (1.33-
1.88); 
p<0.001 
1.49 (1.26-
1.76); 
p<0.001 
1.46 (1.23-
1.72); 
p<0.001 
1.40 (1.18-
1.66); 
p<0.001 
1.43 (1.21-
1.70); 
p<0.001 
1.36 (1.15-
1.62); 
p<0.001 
1.35 
(1.13-
1.61); 
p<0.001 
1.37 
(1.15-
1.63); 
p<0.001 
------- 
Agea  1.09 (1.07-
1.12); 
p<0.001 
1.09 (1.07-
1.12); 
p<0.001 
1.09 (1.07-
1.12); 
p<0.001 
1.08 (1.05-
1.11); 
p<0.001 
1.08 (1.06-
1.11); 
p<0.001 
1.08 (1.05-
1.11); 
p<0.001 
1.08 (1.05-
1.10); 
p<0.001 
1.08 
(1.05-
1.11); 
p<0.001 
1.08 
(1.05-
1.10); 
p<0.001 
1.08 (1.05-
1.10); 
p<0.001 
Sex (Females)   0.66 (0.46-
0.95); 
p=0.02 
0.81 (0.56-
0.95); 
p=0.25 
1.55 (0.97-
2.47); 
p=0.06 
1.64 (1.01-
2.64); 
p=0.04 
1.90 (1.16-
2.59); 
p<0.01 
2.10 (1.27-
3.47); 
p<0.01 
1.90 
(1.14-
3.17); 
p=0.01 
1.53 
(0.88-
2.65); 
p=0.12 
1.37 (0.79-
2.39); 
p=0.25 
non-HDLb    1.01 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.01 
1.00 
(1.00-
1.01); 
p=0.05 
1.00 
(1.00-
1.01); 
p=0.06 
1.00 (1.00-
1.01); 
p=0.04 
WHR†     1.66 (1.30-
2.12); 
p<0.001 
1.71 (1.33-
2.20); 
p<0.001 
1.70 (1.33-
2.19); 
p<0.001 
1.74 (1.35-
2.26); 
p<0.001 
1.66 
(1.28-
2.16); 
p<0.001 
1.66 
(1.28-
2.16); 
p<0.001 
1.64 (1.26-
2.13); 
p<0.001 
HbA1c      1.21 (1.07-
1.36); 
p<0.01 
1.22 (1.08-
1.38); 
p<0.01 
1.27 (1.12-
1.44); 
p<0.001 
1.27 
(1.13-
1.44); 
p<0.001 
1.28 
(1.13-
1.45); 
p<0.001 
1.28 (1.13-
1.45); 
p<0.001 
Hypertension       1.75 (1.19-
2.59); 
p<0.01 
1.94 (1.31-
2.87); 
p<0.001 
2.03 
(1.37-
3.00); 
p<0.001 
2.03 
(1.37-
3.00); 
p<0.001 
1.93 (1.30-
2.86); 
p<0.01 
Ever smoker        1.81(1.24-
2.64); 
p<0.01 
1.66 
(1.12-
2.45); 
p=0.01 
1.69 
(1.15-
2.49); 
p<0.01 
1.72 (1.16-
2.55); 
p<0.01 
WBC         1.09 
(1.00-
1.19); 
p=0.03 
1.10 
(1.01-
1.20); 
p=0.02 
1.10 (1.01-
1.21); 
p=0.02 
Calories Consumed          1.00 
(0.99-
1.00); 
p=0.04 
1.00 (0.99-
1.00); 
p=0.04 
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Table 7 Continued 
 
Depressive 
SymptomatologyxAngerd 
          p=0.09 
AIC: 1462.2 1411.6 1408.7 1377.8 1364.0 1356.2 1350.6 1342.9 1340.6 1338.5 1336.8 
*Residual Value 
†Accompanying HR (95% CI) per 1 SD change in item score 
Modela allowed for: age, sex 
Modelb allowed for: age, sex, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, hypertension, 
HDL, non-HDL, lipid medication, WBC, fibrinogen, WHR, and HbA1c 
Modelc-d allowed for: age, sex, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, hypertension, 
HDL, non-HDL, lipid medication, WBC, fibrinogen, WHR, HbA1c, anxiety, hostility, stress, and interpersonal support 
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Table 8: Final Multivariable Model of type A behavior and all-cause mortality in T1D- Stepwise Cox regression (n=492; 125 events) 
 1 2 3 4 5 6 7 8 9 10 11 
Type A Behavior 0.76 
(0.63-
0.91); 
p<0.01 
0.85 (0.70-
1.02); p=0.08 
0.84 
(0.70-
1.01); 
p=0.07 
0.87 (0.72-
1.05); 
p=0.15 
0.90 (0.74-
1.09); 
p=0.29 
0.94 (0.78-
1.14); 
p=0.07 
0.94 (0.78-
1.13); 
p=0.54 
0.95 (0.79-
1.15); 
p=0.64 
0.95 
(0.79-
1.15); 
p=0.65 
0.97 
(0.80-
1.17); 
p=0.78 
0.93 (0.77-
1.12); 
p=0.47 
Agea  1.10 (1.07-
1.13); 
p<0.001 
1.10 
(1.07-
1.13); 
p<0.001 
1.09 (1.07-
1.12); 
p<0.001 
1.09 (1.06-
1.12); 
p<0.001 
1.08 (1.06-
1.11); 
p<0.001 
1.09 (1.06-
1.11); 
p<0.001 
1.08 (1.06-
1.11); 
p<0.001 
1.08 
(1.06-
1.11); 
p<0.001 
1.08 
(1.05-
1.11); 
p<0.001 
1.08 (1.05-
1.10); 
p<0.001 
Sex (Females)   0.73 
(0.51-
1.04); 
p=0.08 
0.85 (0.59-
1.22); 
p=0.39 
0.77 (0.53-
1.11); 
p=0.17 
1.41 (0.88-
2.28); 
p=0.14 
1.51 (0.93-
2.47); 
p=0.09 
1.63 (0.99-
2.67); 
p=0.05 
1.86 
(1.12-
3.10); 
p=0.01 
1.72 
(1.03-
2.89); 
p=0.03 
1.71 (1.02-
2.89); 
p=0.04 
non-HDLb    1.01 (1.00-
1.01); 
p<0.001 
1.01 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 
(1.00-
1.01); 
p=0.01 
1.00 
(1.00-
1.00); 
p=0.07 
1.00 (1.00-
1.00); 
p=0.08 
Fibrinogen†     1.40 (1.19-
1.64); 
p<0.001 
1.37 (1.17-
1.60); 
p<0.001 
1.28 (1.08-
1.50); 
p<0.01 
1.24 (1.05-
1.45); 
p<0.01 
1.20 
(1.01-
1.41); 
p=0.03 
1.19 
(1.00-
1.42); 
p=0.04 
1.14 (0.96-
1.36); 
p=0.11 
WHR†      1.58 (1.25-
2.00); 
p<0.001 
1.62 (1.27-
2.07); 
p<0.001 
1.68 (1.30-
2.15); 
p<0.001 
1.66 
(1.28-
2.14); 
p<0.001 
1.58 
(1.22-
2.05); 
p<0.001 
1.56 (1.20-
2.03); 
p<0.001 
HbA1c       1.20 (1.06-
1.36); 
p<0.01 
1.23 (1.08-
1.40); 
p<0.01 
1.26 
(1.11-
1.44); 
p<0.001 
1.27 
(1.11-
1.44); 
p<0.001 
1.23 (1.08-
1.41); 
p<0.01 
Ever smoker        1.67 (1.17-
2.43); 
p<0.01 
1.90 
(1.30-
2.76); 
p<0.001 
1.73 
(1.17-
2.55); 
p<0.01 
1.60 (1.08-
2.38); 
p=0.01 
Hypertension         1.75 
(1.19-
2.59); 
p<0.01 
1.85 
(1.25-
2.75); 
p<0.01 
1.96 (1.32-
2.91); 
p<0.001 
WBC          1.09 
(1.00-
1.19); 
p=0.04 
1.08 (0.99-
1.17); 
p=0.07 
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Table 8 Continued 
Depressive 
Symptomatologyc* 
          1.36 (1.13-
1.62); 
p<0.001 
AIC: 1488.3 1432.6 1397.1 1383.0 1369.7 1364.1 1358.1 1352.3 1349.6 1349.6 1339.8 
 
*Residual Value 
†Accompanying HR (95% CI) per 1 SD change in item score 
Modela allowed for: age, sex 
Modelb allowed for: age, sex, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, 
hypertension, HDL, non-HDL, lipid medication, WBC, fibrinogen, WHR, and HbA1c 
Modelc allowed for: age, sex, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, 
hypertension, HDL, non-HDL, lipid medication, WBC, fibrinogen, WHR, HbA1c , anxiety, hostility, stress, depressive 
symptomatology, and interpersonal support 
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After multivariable modeling, the residual BDI scores and trait-anger interaction term remained 
borderline predictive of mortality (p=0.09), along with age, sex, non-HDL, WHR, HbA1c, 
hypertension, ever smoker, WBC, and calories consumed (Table 7).  To examine this further, we 
repeated the analysis of the multivariable model stratifying by trait-anger above and below the 
median of 19.  BDI residual scores were only predictive of mortality in those with a trait-anger 
score <19 [HR=2.09 (1.46-2.97); p<0.001], but not in those with a trait-anger score ≥19 
[HR=1.18 (0.96-1.45); p=0.11] (Table 9). 
 
Table 9: Depressive Symptomatology by Anger Predicting Mortality 
Category Covariate Hazard Ratio 95% Confidence 
Interval 
p-value 
Anger <19 Depressive Symptomatology* 2.09 (1.46-2.97) <0.001 
 Age 1.09 (1.04-1.14) <0.001 
 Sex (Females) 1.68 (0.73-3.85) 0.22 
 Calories Consumed 1.00 (0.99-1.00) 0.18 
 Ever Smoker 1.76 (0.94-3.30) 0.07 
 Hypertension 1.54 (0.78-3.07) 0.21 
 Non-HDL 1.00 (1.00-1.01) 0.02 
 WBC 1.09 (0.95-1.24) 0.19 
 WHR† 1.82 (1.21-2.74) <0.01 
 HbA1c 1.19 (0.97-1.46) 0.09 
Anger≥19 Depressive Symptomatology* 1.18 (0.96-1.45) 0.11 
 Age 1.07 (1.03-1.11) <0.001 
 Sex (Females) 1.42 (0.67-0.98) 0.35 
 Calories Consumed 1.00 (0.99-1.00) 0.22 
 Ever Smoker 1.85 (1.10-3.10) 0.02 
 Hypertension 1.99 (1.21-3.28) <0.01 
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Table 9 Continued 
 Non-HDL 1.00 (0.99-1.00) 0.28 
 WBC 1.10 (0.97-1.25) 0.11 
 WHR† 1.55 (1.07-2.26) 0.02 
 HbA1c 1.35 (1.15-1.58) <0.001 
*Residual Value 
†Accompanying HR (95% CI) per 1 SD change in item score 
 
The same stepwise modeling approach described above was used to investigate Bortner 
Score and mortality (Table 8).  Because an interaction term was not appropriate (none reached a 
significance level of p<0.10), we used the original Bortner Score as the main predictor and found 
that it lost significance in multivariable modeling [HR=0.93 (0.77-1.12); p=0.47] and that age, 
sex, non-HDL, fibrinogen, WHR, HbA1c, smoking status, hypertension, WBC, and residual BDI 
scores remained important predictors of mortality in this model.   
3.4 DISCUSSION 
Our study has found that depressive symptomatology (residual) is significant in 
predicting mortality regardless of which covariates were included in the model. In addition, 
depressive symptomatology (residual) only increased the risk for mortality in those with low 
trait-anger scores.  Type A behavior did not significantly interact with any psychosocial 
variables, and lost significance in mortality prediction in multivariable modeling. 
 The importance of depressive symptomatology in those with T1D has been previously 
demonstrated [170]. The co-existence of depression and T1D is associated with poorer diabetes 
self-management and metabolic control, decreased quality of life, and higher healthcare usage 
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[91].  A United Kingdom study found that the prevalence of depression was three-times higher in 
those with T1D and almost twice as high in those with T2D compared to those free of diabetes 
[94].  In the EDC study we have previously demonstrated that depressive symptomatology is 
associated with increased WHR in both genders [97], macrovascular disease and a higher 
number of complications [171], including incidence of coronary artery disease [96].   
 Our finding that depressive symptomatology was only detrimental in those who scored 
low on the trait-anger scale is of particular interest.  Trait-anger has been previously 
demonstrated to be detrimental to health.  For example, the Framingham study found that 
increased trait-anger was associated with total mortality in men in multivariable analyses [110].  
However, investigators from the Religious Order Study have reported findings somewhat 
consistent with ours, although their population greatly differs as the mean age of their sample 
was 75.4 years and was not diabetes-specific.  They found that internally experienced distress 
(i.e. depressive symptomatology and suppressed anger) was associated with an increased risk of 
mortality while externally experienced anger, including trait-anger and anger-out, was not [172].  
Our data could be similarly interpreted: perhaps participants with higher depressive 
symptomatology who rated themselves low on the trait-anger scale were not externalizing their 
distress and were therefore at an increased risk for mortality compared to those participants with 
higher depressive symptomatology who were externalizing their experiences of distress.  In 
addition, a Japanese study found that while depression was associated with increased risk of 
cardiovascular disease (CVD) hospitalization or death in those with prevalent CVD, anger was 
associated with lower risk [173]. 
 As discussed above, the depressive symptomatology and trait-anger interaction we 
observed may be due to some benefit offered by externalizing distress, in this case in the form of 
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anger.  For example, The Health Professionals Follow-up Study found that moderate levels of 
anger expression were protective against both stroke and nonfatal myocardial infarction among 
older males [174].  In addition, the Nova Scotia Health Survey found that decreased constructive 
anger in men increased the risk of incident CHD [175].  While we did not differentiate between 
constructive versus deconstructive anger, this may additionally explain our results, as our 
participants reporting higher trait-anger scores may be constructively dealing with their 
depressive symptomatology, offering them protection. 
 We have previously demonstrated an interaction between type A behavior and depressive 
symptomatology, however this was not found in the current analysis.  It appears that this is due 
to using depressive symptomatology as a residual value (adjusted for anxiety and stress) rather 
than as an independent variable to assess the interaction.  Thus it appears that a portion of 
depressive symptomatology that interacts with type A behavior is due to anxiety and stress, as 
well, since the residual values do not interact as the original BDI scores did. 
 While we saw an interaction between depressive symptomatology and trait-anger in 
predicting mortality, there were no interactions with hostility, anxiety, stress, or social support.  
Regarding social support, we only had one scale, the Appraisal Scale, thus perhaps other aspects 
of social support interact with either type A behavior or depressive symptomatology when 
predicting mortality in T1D.  Interestingly, trait-anger appeared to be important in protecting 
against mortality in those with high depressive symptomatology, while hostility was not.  This 
may be due to the differences between hostility and anger described above.  Future research 
should focus on studying these psychosocial variables as independent predictors, as they may 
prove to be independently predictive of mortality, separate from depressive symptomatology and 
type A behavior.   
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 There were several strengths and limitations regarding our study.  Our long-term follow-
up allowed us to utilize mortality as an outcome when looking at psychosocial covariates in T1D, 
which has rarely been examined.  In addition, we used numerous psychosocial factors and their 
interactions to predict mortality, responding to a documented gap in the literature.  The 
limitations of our study include the number of participants excluded due to missing psychosocial 
data, and the large interval between when our psychosocial factors were measured and mortality; 
however, we attempted to account for this using Cox proportional hazards modeling.  Another 
limitation was the use of the slightly modified interpersonal support questionnaire; however, we 
did not find significant associations with this measure (perhaps because the validity had been 
compromised) in multivariable analyses and thus if interpersonal support did bias our results it 
was towards the null. Lastly, the lack of follow-up regarding psychosocial data is limiting in that 
we cannot analyze these variables over time and are confined to baseline data for prediction only. 
 In conclusion, we demonstrated the importance of assessing the interactions of 
psychosocial factors when predicting mortality as effects may vary across risk factor categories 
(e.g. high trait-anger versus low trait-anger).  We found that for people with T1D and higher 
depressive symptomatology, having a high trait-anger score eliminates the increased mortality 
risk due to this depressive symptomatology.  Our findings have potential significant implications 
for practice; encouraging individuals to externalize their distress may promote emotional well-
being and potentially improve diabetes self-management and outcomes.  Future research should 
focus on understanding this depressive symptomatology and trait-anger interaction to potentially 
improve the lives of those suffering from T1D. 
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4.0  STRESSFUL LIFE EVENTS PREDICT ELEVATED DEPRESSIVE 
SYMPTOMATOLOGY, BUT NOT WORSENING OF GLYCEMIC CONTROL 
As demonstrated in our previous work as well as in chapter 3.0, depressive 
symptomatology is an important risk factor for mortality in people with T1D.  Described above, 
previous literature has established a strong association between stressful life events and major 
depressive episodes in non-T1D populations, but research is lacking in regards to T1D 
populations.  In addition, little is also known about stressful life events and glycemic control in 
T1D.  We thus aimed to investigate the relationship between stressful life events and subsequent 
depressive symptomatology and change in glycemic control/other diabetes care measures in our 
T1D population. 
4.1 INTRODUCTION 
Depression appears to be more prevalent in T1D, with a recent meta-analysis suggesting 
that people with T1D had nearly four times the prevalence of clinical depression compared to 
non-diabetic controls [158]. People with T1D and depression are at increased risk of several 
diabetes-related complications, including coronary artery disease and nephropathy [176].  We 
previously demonstrated that increased depressive symptomatology over 20 years of follow up 
increased the risk for mortality in our T1D population [100], and thus  investigated potential 
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factors which may help to contribute to these increased depressive symptomatology.  The 2013 
ADA Executive Summary for standards of care for people with diabetes stresses the importance 
of psychosocial aspects of care and notes that screening for problems such as depression, stress, 
and anxiety are currently poor and insufficient [177].  This emphasizes the need for such 
screenings in the total care of people with T1D.   T1D remains incurable, thus it is important to 
explore new avenues on which to intervene to improve the elevated mental health burden 
demonstrated in this population. 
Previous literature has established a strong association between stressful life events and 
major depressive episodes [116].  A study investigating youth with T1D found that stressful life 
events were associated with greater psychological distress, poorer self-care behavior, and worse 
control in both cross-sectional and longitudinal analyses [178].  Furthermore, a cohort of African 
American participants with T1D found that individuals reporting greater incidences of childhood 
trauma were more likely to experience depressive symptomatology at the time the surveys were 
completed [120].  Similar findings have been observed in people with T2D [179]. 
In addition to the potential impact of stressful live events on depressive symptomatology, 
there is concern for whether stressful life events impact on changes in glycemic control.  Poor 
glycemic control is an important risk factor for the development of diabetes complications and 
early mortality in those with both T1D and T2D [121].  Key clinical trials have demonstrated the 
importance of tight regulation of HbA1c in the reduction of these complications [68].  Previous 
research has also shown that stressful life experiences were associated with continuously poor 
control or deterioration of glycemic control in those with T1D [122].  The latter study was 
conducted in a relatively small sample and these findings require replication in a larger study 
population and in those with diabetes-related complications. 
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Due to the size of the EDC population it is possible to examine these issues in a larger 
sample. We thus aimed to investigate the relationship between stressful life events and 
subsequent depressive symptomatology and change in glycemic control, while assessing other 
diabetes care measures as potential mediators, in a T1D population.  
4.2 METHODS 
The EDC study recruited participants diagnosed with T1D between 1950 and 1980 at age 
<17 years and seen by Children’s Hospital of Pittsburgh within one year of diagnosis.  Biennial 
follow-up has occurred since baseline in 1986-1988.  Between 1992 and 1994, participants 
completed a 50-item Life Events Checklist along with other questionnaires and underwent a 
clinical exam.  In order to record significant life events, participants were asked to place a check 
next to each event that occurred during the previous year (e.g. “Engaged or married,” “Birth of a 
child,” “Death of an immediate family member,” “Declared bankruptcy or got into debt,” etc.).  
Each question was assigned a weighted score according to the weighting system designed by 
Holmes and Rahe for their Social Readjustment Rating Scale [180].  Each participant’s score for 
each life event was then added up to a total, composite Life Events score.  One question 
(“convicted of any crime”) was omitted because there was no comparable weighted score 
according to the Social Readjustment Rating Scale.  Depressive symptomatology was measured 
using the BDI, a measure where scores of 16 or higher have been shown to approximate 
clinically significant symptoms of depression [137], [181].  BDI scores recorded at the same time 
point as the Life Events Checklist were used in the analysis as these represented the presence of 
depressive symptomatology after one year’s worth of life events.   
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Fasting blood samples were analyzed for HbA1 (microcolumn cation exchange; Isolab, 
Akron, OH, USA), and these original HbA1 values were converted to DCCT-aligned HbA1c for 
all analyses using a regression equation derived from duplicate assays (DCCT 
HbA1c=0.14+0.83[EDC HbA1]).  HbA1c is reported in the baseline characteristics table as both 
% and mmol/mol.  Change in HbA1c was calculated as the positive change between HbA1c at 
the time point prior to completion of the Life Events Checklist and the HbA1c measured at the 
concurrent time point (1992-1994).  Because participants were reporting life events over the past 
year, this measure represented the change in HbA1c that occurred after one year’s worth of life 
events. 
 The following covariates were chosen based on our previously reported evidence of an 
association with depressive symptomatology and/or glycemic control and/or diabetes self-care 
care [83], [122]:  age, sex, duration, education, having ever smoked, insulin dose, number of 
times testing blood glucose levels per week, prevalent major outcomes of diabetes (including 
coronary artery disease, proliferative retinopathy, amputation, blindness, and nephropathy), body 
mass index (BMI), and any leisure time activity.  Student’s t-tests or Wilcoxon rank-sum tests 
were used to assess the univariate relationship between Life Events score (per 1 standard 
deviation) and high depressive symptomatology (BDI≥16) and to examine the associations 
between the baseline covariates and depressive symptomatology.  Next, to assess the univariate 
associations between Life Events and these potential covariates, Student’s t-tests or Wilcoxon 
rank-sum tests were again used as appropriate.  In addition, correlations were performed between 
all of the covariates.   Those covariates that maintained significance in univariate analyses were 
then entered into the multivariable logistic regression model as covariates with life events 
predicting high depressive symptomatology.   
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 Correlations and Wilcoxon rank-sum tests were used as appropriate between baseline 
covariates and positive change in glycemic control from the past visit to the current visit.  
Change in HbA1c (as described above) was used as the outcome in a linear regression model 
with life events predicting change in glycemic control as represented by HbA1c.  Assessment of 
the other diabetes care covariates for potential mediation between stressful life events and 
positive change in HbA1c was done in the multivariable modeling.  All statistics were performed 
using SAS 9.3 (SAS Institute, Cary, NC). 
4.3 RESULTS 
Out of 579 living participants, there were 395 participants who were in the Pittsburgh 
area or able to travel in for the exam and thus completed the Life Events Checklist between 
1992-1994; 314 thereof had complete covariate data.  Those that were excluded from the 
analysis were most commonly missing the Life Events Checklist (n=184), Beck Depressive 
Inventory (n=54), and HbA1c measures (1990-1992) (n=25).  These 265 excluded participants 
differed from the remaining 314 for the following covariates: they were younger, tested their 
blood sugar more often per week, had higher depressive symptomatology, and were less likely to 
have an education beyond high school (all p<0.05). 
Out of the included 314 participants (mean age=27.9 and diabetes duration=18.8), 31 
(9.8%) had a BDI score≥16.  Life event scores ranged from 0 to 443, with a median of 84 points.  
Participants with high depressive symptomatology (BDI score≥16) had a higher Life Events 
score, higher prior cycle BDI score, and were more likely to be female, but did not differ for age, 
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diabetes duration, HbA1c, insulin dose, testing per week, ever smoked, education, or prevalent 
major outcomes of diabetes (Table 10). 
 
Table 10: Baseline Characteristics for Life Events and High Depressive Symptomatology, 1992-1994 (N=314) 
Covariate Low Depressive 
Symptomatology (n=283) 
High Depressive 
Symptomatology (n=31) 
p-value 
Age 34.2 (7.1) 35.9 (7.3) 0.21 
Sex; Females %(n) 48.0 (136) 67.7 (21) 0.03 
Duration 25.7 (7.3) 27.1 (8.1) 0.32 
Insulin Dose 0.69 (0.21) 0.64 (0.19) 0.20 
Glucose Testing at Least 
Once per Week, %(n), 
Yes 
71.3 (202) 74.2 (23) 0.74 
HbA1c, % 9.1 (1.4); [76 mmol/mol] 8.9 (1.5); [74 mmol/mol] 0.38 
Depressive 
Symptomatology (1990-
1992) 
4.0 (1.0-8.0) 14.0 (9.0-18.0) <0.001 
Life Events Score* 78.0 (35.0-139.0) 125.0 (85.0-232.0) <0.001 
Ever Smoked; Yes %(n) 37.4 (106) 45.1 (14) 0.40 
Education Above High 
School; %(n) 
71.0 (201) 77.4 (24) 0.45 
Prevalent Major 
Outcomes of Diabetes; 
Yes %(n) 
72.0 (204) 74.1 (23) 0.80 
*per 1 SD 
 
We found a significant univariate relationship between Life Event scores and high depressive 
symptomatology with an odds ratio (OR)=[1.84 (1.34-2.53); p<0.001] (Figure 5); (when 
continuous BDI scores were examined there was a significant association between higher BDI 
scores and higher life event scores (p<0.001)).   
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 Figure 5: Prevalence (%) of Elevated (≥16) BDI Scores by Quintiles of Life Events Scores Over the Prior 12 
Months 
 
The relationship was maintained in multivariable modeling adjusting for the covariates described 
above OR=[1.56 (1.06-2.31); p=0.02] (Table 11). 
 
Table 11: Logistic Regression Results: Life Events and High Depressive Symptomatology (N=314) 
Variable Odds 
Ratio 
95% 
Confidence 
Interval 
p-value 
Life Events* 1.56 1.06-2.31 p=0.02 
Insulin Dose 1.37 0.16-11.59 p=0.76 
Frequency of 
Testing per Week 
0.80 0.43-1.49 p=0.49 
Education 0.77 0.28-2.11 p=0.61 
Duration 1.01 0.95-1.07 p=0.71 
Sex (Females) 0.58 0.23-1.43 p=0.24 
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Table 11 Continued 
Ever Smoked 1.17 0.47-2.91 p=0.72 
Prevalent Major 
Outcomes 
1.29 0.45-3.69 p=0.63 
HbA1c 0.82 0.58-1.15 p=0.26 
Depressive 
Symptomatology 
(1990-1992) 
1.18 1.10-1.26 p<0.001 
  *per 1 SD 
For the second outcome of interest, change in HbA1c, the mean change between the two 
time points was 0.17±1.29% (N=311), i.e. there was an overall increase in HbA1c levels over 
time.  Correlational analyses (Table 12) demonstrated that the increase in HbA1c over time was 
significantly associated with lower initial levels of HbA1c, BDI score and BMI.  
Table 12: Correlations and between Change in HbA1c and Continuous Covariates (N=311) 
                                                                                                  
                                                                                             Increase in HbA1c 
Risk Factors Correlation p-value 
Life Events Score -0.03 0.55 
Duration -0.02 0.69 
Age 0.04 0.39 
HbA1c (1990-1992) -0.39 <0.001 
Insulin Dose -0.05 0.35 
Testing per Week -0.01 0.76 
Depressive Symptomatology -0.10 0.05 
BMI -0.16 <0.01 
   
                              Mean Change in HbA1c, % 
Ever Smoked* Never Smoker: 
0.03 (1.05) 
Ever Smoker: 
0.41 (1.58) 
Education Below High School: 
0.20 (1.44) 
High School or Above: 
0.17 (1.23) 
Sex Male: 
0.16 (1.18) 
Female: 
0.19 (1.39) 
Prevalent Major Outcomes No: 
0.30 (1.46) 
Yes: 
0.13 (1.22) 
Any Leisure Time Activity No: 
0.21 (1.34) 
Yes: 
0.14 (1.25) 
Pump No: 
0.19 (1.30) 
Yes: 
-0.33 (1.04) 
*p<0.05 
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 Those who had ever smoked had a greater increase in change in HbA1c.  After univariate linear 
regression, there was no relationship between Life Event scores and increased HbA1c (p=0.67).  
After multivariable modeling, there was not much difference in the p-value (p=0.71). Previous 
HbA1c measures, ever smoked status, and prevalent major outcomes of diabetes were the only 
significant risk factors for an increase in HbA1c.  Severity of life events (i.e. life events with 
weighted scores in the top vs. bottom quintile) was not significantly associated with poorer 
HbA1c (p=0.71). 
An investigation of whether diabetes self-care measures (i.e.: frequency of testing, insulin 
dose, insulin pump, BMI, and leisure time activity) mediated the relationship between stressful 
life events and change in HbA1c, demonstrated that the relationship between life events and 
increases in HbA1c did not change (p=0.70).  Testing at least once per week and BMI were 
significant covariates for directly predicting positive change in HbA1c (p<0.05).  The results did 
not differ when only assessing severe stressful life events.  
4.4 DISCUSSION 
We demonstrated that higher life events scores predicted clinically meaningful depressive 
symptomatology (BDI score≥16) up to one year later, even with a small proportion (9.8%) of 
participants having high BDI scores.  We did not, however, find a relationship with change in 
HbA1c after the occurrence of the life events, nor did we find that any of our other diabetes care 
covariates notably impacted the relationship. 
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For our adjusted model, an OR=1.56 can be interpreted such that 1 standard deviation 
increase in life event score results in a 56% increased odds of having clinically relevant 
depressive symptomatology. These findings regarding life events and increased odds of 
depression confirm previous research performed in general populations where investigators 
found that life events were an independent risk factor for depressive symptomatology or a 
depressive episode [182], [183].  In regards to the plausibility of this relationship, it has been 
hypothesized that certain components of clinical disease may be critically affected by the 
environmental context (e.g. life events) [184].  The results of another previous study [185] as 
well as our current research suggest that depression is, in fact, responsive to the environment.  
We did not, however, find that change in HbA1c resulted from life events. These results 
differ from much of the previous research in diabetes populations.  Investigators studying 
adolescents with diabetes found that stressful life events were associated with poor glycemic 
control and also with deteriorating control [186].  This population greatly differed from ours, 
though, in terms of age.  These participants were approximately 10-14 years old at baseline with 
a mean diabetes duration of 5 years, compared to our population with a mean age of 28 years and 
diabetes duration close to 19 years at study entry.  It has been demonstrated that adolescents with 
diabetes tend to be in poor control [187],  in contrast to adult populations who tend to have better 
control and may be less likely to have their blood sugar levels affected by stressful life events. 
We did not find that age or duration were significantly correlated with change in HbA1c in our 
population, however our participants were mostly middle-aged adults at the time the life events 
checklist was completed.   
Another study in T1D participants free from severe diabetes complications with a mean 
age of 27 years and 12 years of duration found that those who were in poor or deteriorating 
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glycemic control were more likely to report severe personal stressors compared to remaining in 
fair or improving their glycemic control [122].  This finding differed from our results, even when 
we investigated only the most severe life events scores (top quintile). This difference may be, in 
part, due to the different methods used to measure stressful life-events (in-depth interviews 
compared to a self-complete checklist) as well as differences in weighting and classification. We 
also did not find that other diabetes care measures influenced the relationship between life events 
and positive change in HbA1c (using all life events scores or the most severe scores).  This may 
be due to people with T1D already experiencing high levels of stress due to the nature of the 
disease, and thus the additional stresses of life events do not change their diabetes care 
behaviors. 
While we did not find that stressful life events predicted change in HbA1c, we did find a 
significant relationship between stressful life events and high depressive symptomatology.  There 
were several limitations to our study.  First, we had a large number of excluded participants due 
to a lack of completion of the Life Events Checklist and Beck Depression Inventory; however we 
did our best to report the differences in populations to assist in interpretation of our findings.  
Another limitation is that our life events were reported retrospectively, with participants recalling 
events over the past year. This may have been influenced by the presence of depressive 
symptomatology at the time of reporting, with those feeling depressed perhaps more likely to 
report negative events.  We attempted to control for this statistically however, by adjusting for 
the previous time point’s depressive symptomatology in multivariable modeling and found that 
the association was not lost after this adjustment.  
In conclusion, we found that increased life events scores predicted increased risk of 
clinically significant depression, but did not impact any change glycemic control.  Future 
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research should be conducted to assess whether interventions following stressful life events can 
improve depression outcomes.  We hope the findings from our study will continue to improve 
the mental health, and thus physical health outcomes and mortality risk, in those with T1D. 
  
79 
5.0  INVESTIGATING THE SCORING METHODS AND INDIVIDUAL 
COMPONENTS OF THE BORTNER TYPE A SCALE IN PREDICTING MORTALITY 
Type A behavior has been inversely related to mortality in those with T1D using a 
modified version of the Bortner Scale. In this current report we explored whether all scoring 
methods of the Bortner Rating Scale demonstrated a similar association. 
5.1 INTRODUCTION 
Despite improved survival, people with T1D [8], [11] continue to be at an increased risk 
of several, often devastating, long-term complications including coronary artery disease and 
nephropathy [188]. Thus the search for modifiable risk factors, both physiological and 
psychosocial (such as behavior type), remains important.  Studies have shown that people rating 
themselves as having high type A behaviors tend to focus on achieving and accomplishing more 
in less time than others and describe themselves as hard-driving [70].  It has been previously 
shown that in those with T1D, glycemic control differs by behavior type, and this has been 
reported in both directions, with type A behavior being associated with both poor and good 
control [75], [130], [131].  This is most likely due to different measures of type A behavior 
and/or glycemic control and the different types of studies utilized. 
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We have previously reported a relationship between type A behavior and mortality in 
those with T1D [83]. Participants with higher type A behavior scores had lower all-cause 
mortality. However this association was only found in those individuals with low BDI scores 
[83].   Our finding that type A behavior is protective in T1D is consistent with the literature in 
the general population which has demonstrated that type A behavior may have different effects 
on health depending on underlying chronic disease status (for example, it is a benefit in those 
with prevalent CAD) [71], [189]–[192].  However, whether different Bortner Type A Behavior 
Scale scoring methods or individual components of type A behavior may serve as better 
predictors for mortality in T1D is unclear.   
By improving our understanding of how type A behavior might protect against mortality 
it may be possible to develop improved interventions for people with T1D and thus reduce the 
risk of premature death. In our previously published research [83], we examined a limited 
number of important and relevant covariates (age, sex, duration, education, physical activity, 
smoking, BMI, HbA1c, insulin dosage, and depressive symptomatology) along with the Bortner 
Score to measure type A behavior. We found that type A behavior was predictive of mortality, 
and that this relationship interacted with depressive symptomatology such that any protection 
offered was lost in those with higher depressive symptomatology. In this previous analysis we 
used the original Bortner scale (BO) – the 14 item – to measure type A behavior with reverse 
coding for five items (#4, 7, 8, 11, and 13(Appendix A)) [132] as recommended by the 
originators following behavioral interviews. However, there are a number of other scoring 
methods available. The Bortner Scale can be scored without those five items reversed (BR); as a 
7-item scale with the same items reversed (B7R); a 7-item scale with original scoring (B7O); and 
as separate items (14 individual items (BI)).   
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In this current report we explore these different scoring methods in order to examine the 
relationship between type A behavior and mortality in greater detail with the following 
objectives: 1) to evaluate the different scoring methodologies of the Bortner Type A Behavior 
Rating Scale, as well as its individual components, in terms of prediction of mortality in our T1D 
population.  2) to perform multivariable analyses with the strongest predictor from the Bortner 
scale predicting mortality, 3) to re-evaluate the previously demonstrated interaction of type A 
behavior and depressive symptomatology in the prediction of mortality using the most predictive 
Bortner scoring method.  
5.2 METHODS 
The EDC study recruited participants diagnosed with T1D between 1950 and 1980 at age 
<17 years and seen by Children’s Hospital of Pittsburgh within one year of diagnosis.  Biennial 
follow-up has occurred since baseline in 1986-1988 and data up to the 22-year follow-up are 
now available. Participants ≥18 years of age at study entry completed the Bortner Type A Scale 
[132] and were instructed to mark on the line where they fell between two different items (more 
type A versus less type A).  Examples of the sentences included “never late” versus “casual 
about appointments;” “always rushed” versus “never rushed, even under pressure;” and “take 
things one at a time” versus “try to do many things at once, thinking about what I am going to do 
next.”  The five possible Bortner scoring methods were defined as the following: 1) the BO 
[132]; 2) the BR with items 4, 7, 8, 11, and 13 with scoring reversed [132]; 3) the B7O 
(Appendix B) [193]; 4) the B7R rescored as above where applicable (i.e. with the relevant items 
reverse scored); 5) the BI with the original scoring. 
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Overall mortality was determined as of February 25, 2011 and searches were completed 
in the Social Security Death Index and the National Death Index. To classify cause(s) of death, 
death certificates were obtained, plus as appropriate: 1) hospital records; 2) autopsy/coroner’s 
reports; and 3) interview with next of kin regarding the death. The covariates were chosen based 
on prior evidence for our final mortality prediction model [83], [133]. Depressive 
symptomatology was measured using the BDI, a measure shown to approximate clinically 
significant symptoms of depression [137]. The assessment of the other variables is described 
elsewhere [Chapter 2.0].   
In accordance with the specific aims, Cox proportional hazards models were utilized to 
examine the univariate relationship between baseline Bortner score and overall mortality and to 
examine the prospective associations between the baseline covariates and mortality.  Next, to 
assess the univariate associations between the different Bortner scoring methods and these 
potential covariates, Student’s t-tests or Wilcoxon rank-sign tests were used as appropriate.  In 
addition, correlations were performed between all of the covariates.   Those covariates that 
maintained significance in univariate analyses were then entered into a final multivariable model 
as covariates with the Bortner scale predicting mortality.  This was repeated for each of the five 
separate Bortner scoring methods.  The final scoring method using the best univariate predictor 
representing type A behavior was determined and used in mortality prediction.  The best 
univariate predictor was defined as the predictor with the most univariately protective hazard 
ratio.  Lastly, this best scoring method was used to investigate the interaction with depressive 
symptomatology in predicting mortality.  All statistics were performed using SAS 9.3 (SAS 
Institute, Cary, NC). 
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5.3 RESULTS 
At the EDC baseline exam, of the 592 participants aged 18 years or older, and thus 
eligible for the BDI and Bortner questionnaires, 97 were excluded due to missing covariate 
measures: predominantly the Bortner and BDI questionnaires and physical activity measures 
resulting in 495 eligible participants.  Those excluded differed from our included population in 
the following regards: they were older (p=0.03); had a higher WBC count (p<0.01); higher WHR 
(p=0.03); were more likely to have ever smoked (p=0.01); be male (p=0.04); and were less likely 
to have education beyond high school (p<0.01).  There were no other significant differences 
observed, including type A behavior score.  Out of these 495 remaining participants, there were 
125 deaths (25.2%).  These 125 deceased participants differed from the remaining 370 for most 
of the covariates (Table 13).   
 
Table 13: Baseline Characteristics by Mortality Status (N= 495) 
Covariate Deceased (n=125) Alive (n=370) p-value 
Age (years) 33.4 (6.3) 27.7 (6.4) <0.0001 
Duration 24.4 (6.5) 18.8 (6.8) <0.0001 
Percent Males (n) 53.6 (67) 47.0 (174) 0.19 
Education 
%(n), Above High 
School 
60.0 (75)  65.9 (244) 0.22 
HbA1c (%) 9.1 (1.6) 8.6 (1.4) <0.01 
Insulin Dose 0.73 (0.29) 0.76 (0.21) 0.25 
Glucose Testing at 
Least Once per Week, 
%(n), Yes 
64.0 (80) 63.7 (236) 0.96 
WBC 7.4 (2.0) 6.2 (1.7) <0.0001 
Total caloric 
expenditure in leisure 
time activity /week 
0 (0.0, 525.0) 387.5 (0.0, 1440.0) <0.0001 
WHR† 0.86 (0.80, 0.92) 0.82 (0.76, 0.86) <0.0001 
Fibrinogen (mg/dL) † 310.0 (270.0, 390.0) 265.0 (210.0, 310.0) <0.0001 
HDL (mg/dL) 49.1 (42.5, 57.9) 53.4 (45.7, 61.8) <0.01 
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Table 13 Continued 
non-HDL (mg/dL) 163.6 (46.7) 132.4 (38.2) <0.0001 
Daily Calories 
Consumed 
1895.2 (1501.5, 
2441.8) 
1960.5 (1528.2, 
2424.2) 
0.47 
Ever Smoker 
% (n), Yes 
56.8 (71) 33.7 (125) <0.0001 
Pack years of 
smoking (n=192) 
36.5 (24.8, 48.6) 52.1 (30.4, 91.2) <0.01 
Depressive 
Symptomatology 
8.0 (4.0, 14.0) 5.0 (2.0, 10.0) <0.0001 
Hypertension 
% (n), Yes 
53.6 (67) 25.1 (93) <0.0001 
Lipid Medication 
% (n), Yes 
0.80 (1) 0.54 (2) 0.74 
† per 1 SD 
 
Those who died were older, had a longer duration of diabetes, higher HbA1c, higher WBC 
count, were less physically active, had a greater WHR, higher fibrinogen level, lower HDL, 
higher non-HDL, were more often smokers, had a higher depressive symptomatology score, 
were more likely to be hypertensive.  Those who died also had lower type A behavior scores for 
most scoring methods with the exception of individual items #1, 3, 5, 6, 7, 8, 9, and 12 (Table 
14). 
 
Table 14: Bortner Scoring Methods by Mortality Status (N=495)† 
Covariate Deceased (n=125) Alive (n=370) p-value 
BO 169.3 (31.6) 180.0 (29.7) <0.001 
BR 187.2 (26.9) 194.4 (25.1) <0.01 
B7O 88.0 (16.4) 92.0 (15.2) 0.01 
B7R 96.3 (18.7) 100.4 (17.7) 0.03 
1. Never Late 18.0 (6.5) 17.4 (6.1) 0.36 
2. Very Competitive 13.2  (7.0) 14.8 (6.4) 0.01 
3. Anticipate what 
others are going to say 
9.0 (6.6) 9.0 (5.9) 0.97 
4. Always Rushed 13.0 (5.9) 14.8 (5.4) <0.01 
5. Impatient when 
waiting 
12.2 (7.6) 13.0 (7.1) 0.31 
6. Go “all out” 13.7 (6.9) 14.5 (6.2) 0.20 
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7. Try to do many 
things at once 
10.3 (6.5) 10.1 (5.9) 0.79 
8. Emphatic speech 10.8 (6.1) 11.4 (5.4) 0.34 
9. Want a good job to 
be recognized by 
others 
14.6 (6.6) 15.6 (5.8) 0.11 
10. Fast eater, walker 12.0 (7.2) 15.4 (6.0) <0.0001 
11. Hard driving 9.2 (5.9) 10.5 (5.7) 0.04 
12. Express my 
feelings 
11.8 (7.0) 11.2 (6.6) 0.39 
13. Few interests 10.2 (7.0) 8.5 (6.2) 0.01 
14. Ambitious 11.9 (6.2) 13.9 (5.5) <0.01 
† per 1 SD 
 
 Analyses demonstrated that the individual components, specifically, “fast eater, walker, 
etc.,” was the most informative in terms of mortality prediction based on its significance (Table 
1B), such that lower scores were associated with higher risk of mortality. The “fast eater, walker, 
etc.” rating was also the most important significant Bortner item after adjustment for age 
[HR=0.72 (0.60-0.86); p<0.001] (Table 15).   
 
Table 15: Univariate Associations between Type A Behavior Scoring Methods and Mortality (N=495)*† 
Covariate Hazard Ratio Confidence Interval p-value 
BO 0.75 (0.63-0.88) <0.001 
BR 0.85 (0.70-1.02) 0.08 
B7O 0.77 (0.65-0.92) <0.01 
B7R 0.91 (0.75-1.09) 0.31 
1. Never Late 0.97 (0.81-1.17) 0.80 
2. Very Competitive 0.90 (0.75-1.08) 0.29 
3. Anticipate what 
others are going to say 
1.00 (0.83-1.20) 0.98 
4. Always Rushed 0.73 (0.62-0.87) <0.001 
5. Impatient when 
waiting 
0.94 (0.78-1.12) 0.51 
6. Go “all out” 0.88 (0.74-1.04) 0.15 
7. Try to do many 
things at once 
1.01 (0.84-1.20) 0.91 
8. Emphatic speech 0.93 (0.77-1.11) 0.43 
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9. Want a good job to 
be recognized by 
others 
0.79 (0.66-0.95) 0.01 
10. Fast eater, walker 0.72 (0.60-0.86) <0.0001 
11. Hard driving 0.80 (0.66-0.97) 0.02 
12. Express my 
feelings 
1.03 (0.87-1.23) 0.67 
13. Few interests 1.07 (0.90-1.27) 0.41 
14. Ambitious 0.83 (0.69-0.99) 0.04 
*Adjusted for age 
† per 1 SD 
 
Using the “fast eater, walker, etc.” item as the main predictor for mortality, we analyzed the final 
model comprised of all significant covariates to predict mortality (Table 16).   
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Table 16: Association between “fast eater, walker, etc.” and all-cause mortality in T1D- Stepwise Cox regression (n=495; 125 events) 
 1 2 3 4 5 6 7 8 9 10 11 
Fast eater, 
walker, etc. † 
0.62 
(0.52-
0.74); 
p<0.0001 
0.72 (0.60-
0.86); 
p<0.001 
0.71 
(0.60-
0.85); 
p<0.001 
0.76 
(0.60-
0.85); 
p<0.001 
0.77 (0.68-
0.97); 
p<0.01 
0.81 (0.65-
0.97); 
p=0.02 
0.82 (0.68-
0.98); 
p=0.02 
0.82 
(0.68-
0.98); 
p=0.03 
0.80 
(0.67-
0.96); 
p=0.01 
0.83 (0.70-
1.00); 
p=0.05 
0.85 (0.71-
1.02); 
p=0.09 
Age  1.09 (1.06-
1.12); 
p<0.0001 
1.09 
(1.06-
1.12); 
p<0.0001 
1.09 
(1.06-
1.11); 
p<0.0001 
1.08 (1.05-
1.11); 
p<0.0001 
1.08 (1.05-
1.11); 
p<0.0001 
1.08 (1.05-
1.11); 
p<0.0001 
1.08 
(1.05-
1.11); 
p<0.0001 
1.08 
(1.05-
1.10); 
p<0.0001 
1.07 (1.05-
1.10); 
p<0.0001 
1.08 (1.05-
1.11); 
p<0.0001 
Sex   0.70 
(0.49-
1.00); 
p=0.05 
0.84 
(0.59-
1.21); 
p=0.36 
1.67 (1.05-
1.11); 
p=0.03 
1.48 (0.92-
2.38); 
p=0.10 
1.30 (0.81-
2.10); 
p=0.27 
1.38 
(0.85-
2.25); 
p=0.18 
1.53 
(0.93-
2.50); 
p=0.08 
1.73 (1.04-
2.88); 
p=0.03 
1.59 (0.95-
2.67); 
p=0.07 
Non-HDL    1.01 
(1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 (1.00-
1.01); 
p<0.001 
1.00 
(1.00-
1.01); 
p<0.01 
1.00 
(1.00-
1.00); 
p<0.01 
1.00 (1.00-
1.00); 
p=0.02 
1.00 (0.99-
1.00); 
p=0.09 
WHR†     1.66 (1.32-
2.09); 
p<0.001 
1.60 (1.27-
2.01); 
p<0.001 
1.53 (1.21-
1.93); 
p<0.001 
1.57 
(1.23-
2.00); 
p<0.001 
1.54 
(1.21-
1.96); 
p<0.001 
1.61 (1.25-
2.06); 
p<0.001 
1.54 (1.19-
1.98); 
p<0.001 
Fibrinogen†      1.34 (1.14-
1.57); 
p<0.001 
1.30 (1.11-
1.52); 
p<0.001 
1.23 
(1.05-
1.44); 
p=0.02 
1.20 
(1.02-
1.42); 
p=0.01 
1.17 (0.99-
1.38); 
p=0.05 
1.18 (0.99-
1.39); 
p=0.05 
Depressive 
Symptom- 
atology 
      1.03 (1.01-
1.06); 
p<0.01 
1.03 
(1.01-
1.06); 
p<0.01 
1.04 
(1.02-
1.07); 
p<0.001 
1.04 (1.01-
1.06); 
p<0.01 
1.04 (1.01-
1.06); 
p<0.01 
HbA1c        1.19 
(1.05-
1.35); 
p<0.01 
1.21 
(1.06-
1.37); 
p<0.01 
1.25 (1.10-
1.42); 
p<0.001 
1.26 (1.11-
1.43); 
p<0.001 
Hypertension         1.72 
(1.16-
2.53); 
p<0.01 
1.91 (1.29-
2.82); 
p<0.01 
1.97 (1.33-
2.91); 
p<0.001 
Ever Smoker          1.75 (1.20-
2.56); 
p<0.01 
1.61 (1.08-
2.39); 
p=0.01 
            
  
88 
Table 16 Continued 
WBC           1.09 (1.00-
1.19); 
p=0.04 
 
Final Model= allowed for age, sex, duration, education, calories consumed, total sports, smoking, insulin dose, testing per week, hypertension, HDL, non-HDL, lipid 
medication, WBC, fibrinogen, WHR, HbA1c, and depressive symptomatology; † per 1 SD 
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We found that the relationship between “fast eater, walker, etc.” and mortality was reduced to 
borderline significance [HR=0.85 (0.71-1.02); p=0.09].  This best model resulted in age, non-
HDL, and fibrinogen as the most influential covariates on the relationship between “fast eater, 
walker, etc.” and mortality.  We tested for an interaction between “fast eater, walker, etc.” and 
depressive symptomatology based on our previously demonstrated interaction between type A 
behavior and mortality [83] but it was non-significant (p=0.47). 
5.4 DISCUSSION 
In this current investigation, we have built on our previous research demonstrating a 
protective effect of type A behavior on mortality in those with T1D by examining the different 
scoring methods of the Bortner Scale, including the individual type A components.  Overall, we 
found that “fast eater, walker, etc.” was the most significant predictor of mortality out of all the 
scoring methods.  This association became marginal in multivariable analyses due, most 
prominently, to the additions of age, WHR, non-HDL, and fibrinogen in to the model.   
Through analysis of the different scoring methods, we were able to determine if type A 
behavior is predictive of mortality regardless of the scoring used, and if there are specific aspects 
of type A behavior that are most important in our T1D population.  We determined that there are, 
in fact, specific aspects of type A behavior that are most predictive of mortality (most 
significantly “fast eater, walker, etc.”).  As stated above, age, WHR, non-HDL, and fibrinogen 
had the greatest effect on the relationship between “fast eater, walker, etc.” and mortality.  In our 
analyses, increased inflammation and/or non-HDL in combination with age and a large waist to 
hip ratio may represent subclinical disease and poor health and therefore reduce a participants’ 
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ability to be a “fast eater, walker, etc.,” eliminating this type A behavior component’s protection 
against mortality.  Lastly, our re-evaluation (using “fast eater, walker, etc.”) of our previously 
demonstrated interaction of type A behavior with depressive symptomatology was not 
significant, suggesting different interactions for the single item versus total Bortner score in 
terms of predicting mortality.  This finding showed that the total Bortner scale likely combines 
multiple underlying traits with different characteristics some of which overlap with depressive 
symptomatology.  For example, perhaps those with higher depressive symptomatology are less 
ambitious or more likely to sit on their feelings, thus leading to an interaction with depressive 
symptomatology. 
 There are a few notable limitations to our study.  First, using the individual items of the 
Bortner Type A Behavior scale on their own has not been a previously validated measure of type 
A behavior.  However, “fast eater, walker, etc.” is one of least likely items to be misinterpreted 
on the questionnaire and thus there is not a substantial concern for bias surrounding its use.  How 
well it represents overall type A behavior on its own in a T1D population, however, is not 
studied.  Next, using this item as the main predictor was not established a priori, although the 
purpose of this research was to further explore and understand the protective effect of type A 
behavior on mortality demonstrated in our previous manuscript and thus exploration of the 
questionnaire was vital to answer our research questions [83].  Future research needs to be 
conducted to validate this item in T1D and in other populations, as well.  Lastly, a limitation of 
the study was the missing data regarding, primarily, the Bortner and BDI questionnaires, 
excluding 97 participants from analyses.  However, we described the differences in populations 
and confirmed that those excluded were not significantly different regarding their type A 
behavior scores. 
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In conclusion, we successfully evaluated the different scoring methodologies of the 
Bortner Type A Behavior Scale and determined that its separate components, specifically “fast 
eater, walker, etc.,” was the best predictor of mortality in our T1D population.  This item needs 
to be validated in other populations; however, the use of a single item to predict mortality from a 
behavioral standpoint would be very favorable and efficient in the clinical setting.  We conclude 
that there are, in fact, specific components of type A behavior that play an important role in 
mortality prevention.  We hope future research will be able to use these findings to help develop 
strategies to delay mortality in people with T1D. 
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6.0  DISCUSSION 
A thorough investigation of psychosocial factors and mortality in people with T1D was 
performed, with a particular focus on type A behavior and depressive symptomatology.  In the 
first investigation we assessed potential mediating/moderating/confounding effects on the 
relationship between type A behavior and mortality, which expanded on our previous research 
where we demonstrated a protective effect of type A behavior on mortality when high depressive 
symptoms were absent.  We determined that in men and women combined, type A behavior was 
univariately protective against mortality, but the relationship was no longer significant after the 
other risk factors were considered (most prominently, age (antecedent moderator), non-HDL and 
WBC (mediators), and fibrinogen (moderator)).  When these analyses were performed separately 
by sex, type A behavior was univariately protective against mortality in men but not in women.  
In men this relationship was lost in the multivariable modeling, most predominately after WHR 
(mediator) and age (antecedent moderator) were taken in to account in the type A behavior and 
mortality relationship.  Next, we took this research further by investigating individual 
components of the questionnaire. 
In this brief report, looking at our type A behavior and mortality findings in more depth, 
we investigated the different scoring methods of the Bortner Rating Scale to determine which 
was best for predicting mortality in our T1D population.  We found that the “fast eater, walker, 
etc.” item on the scale was the most significant predictor of mortality out of all the scoring 
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methods.  This association was lost in multivariable analyses due, most prominently, to the 
additions of age, non-HDL, and fibrinogen. There are clinical implications regarding the ease of 
using one item to screen for potential increased mortality risk.   Using one item would ensure 
time efficiency, which is important to clinicians, and may represent overall health status and/or 
wellness.  This may be important in detecting subclinical disease or a decline in functioning. 
Because psychosocial factors are usually investigated as their own, separate constructs, it 
is important to examine them with other psychosocial factors as well.  Thus, the next phase of 
our study expanded further on this research by investigating which other psychosocial factors 
interacted with our previously demonstrated relationships between type A behavior and 
depressive symptomatology and mortality.  First, we determined that depressive symptomatology 
was significant in predicting mortality regardless of which covariates were included in the 
model. In addition, we demonstrated a significant interaction between depressive 
symptomatology and anger, and this interaction term remained significant in multivariable 
modeling, such that depressive symptomatology only increased the risk for mortality in those 
with low anger scores.  Second, type A behavior did not significantly interact with any other 
psychosocial variables, and lost significance regarding its relationship with mortality in 
multivariable modeling. 
Since we demonstrated that depressive symptomatology increased the risk of mortality, it 
was thus important to us to understand factors that contribute to the demonstrated detriments of 
increased depressive symptomatology.  Based on the previous literature, we tested our 
hypotheses that an increase in stressful life events score would lead to clinically meaningful 
depression and that stressful life events would also result in a change in HbA1c (an additional 
risk factor for mortality) over the year the events occurred.  After analyses, we found that higher 
  94 
life events scores predicted clinically meaningful depressive symptomatology up to one year 
later.  This was determined despite a small proportion of participants, less than 10%, having high 
BDI scores≥16.  We did not, however, find a significant change in HbA1c after the occurrence of 
the life events. 
Our first finding, that type A behavior is protective against mortality, fits in with some 
portions of the literature and differs from others. In the earlier review by Matthews, et al., type A 
behavior was directly associated with CHD in the general population, but the findings were 
consistently inverse in chronic disease populations suggesting a protective effect [70].  T1D is a 
high-risk population, with those suffering from the disease at a higher risk of many 
complications, including CHD.  The protective effect of type A behavior demonstrated in our 
population aligns with Matthews et. al’s hypothesis [70].  In previous literature, type A behavior 
has been demonstrated to be protective against a number of complications present in those with 
T1D [171]. Our results align with this finding regarding a protective effect, as well [72]. This 
latter study performed by Lloyd et al., although cross-sectional, was one of the first papers to 
conclude that type A behavior showed a protective effect of any kind.  Our research was able to 
expand on this to assess the longitudinal relationship of type A behavior score, while taking it a 
step further beyond complications to mortality status. A study more recent than most of the type 
A behavior and T1D studies found a marginal inverse correlation between neuroticism at 
diagnosis of T1D and glycemic control 12 months later [194].  The authors conclude that this 
suggests that higher neuroticism is related to better glycemic control. While neuroticism is only a 
piece of type A behavior, these authors’ conclusions were also in the same direction as our 
findings.  
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Our previously published inverse univariate relationship between Bortner scores and all 
cause mortality remained significant during multivariable modeling.  However, the addition of 
BDI scores to the model attenuated the relationship and a significant interaction was observed, 
such that any protective effect against mortality was limited among individuals with lower BDI 
scores, while no effect was seen in those with higher BDI scores.   This was the first published 
paper to prospectively examine the relationship between type A behavior and mortality in T1D.  
Our current study expanded on this to determine which covariates may be responsible for the 
type A behavior and mortality relationship.  The multivariable relationship between type A 
behavior and mortality was lost in our current report when a greater range of factors were 
studied. Twenty individuals were not included in both papers hence are discordant. The different 
result is likely due, in part, to these 20 discordant participants who had twice the mortality 
compared to the rest of the population, hence their large effect on the results. 
Additionally, our investigation of which scoring methods of the Bortner Rating Scale best 
predicted mortality in those with T1D also expanded the type A behavior and mortality literature.  
We found that “fast eater, walker, etc.” was the best overall predictor of mortality. However, this 
item lost significance in multivariable modeling. Nonetheless, if clinicians could use one item to 
assess behavior type and therefore potential mortality risk, this would be a fast and effective 
screening tool and marker of overall health.  This item needs to be tested and validated in other 
populations as a protective factor against mortality. It should also be noted that two other items 
also showed a strong prediction and should also be evaluated in other populations. In addition, 
these items should be evaluated as to whether they protect against other negative health 
outcomes, such as CAD or nephropathy. 
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Our other primary predictor in this research project, depressive symptomatology, was 
important to study as it affects a large portion of the population with T1D. One study found that 
only about 50% of clinical depression cases were found to be receiving health care treatment 
[195].  Prevalent depression also puts individuals at a higher risk of comorbid physical 
conditions, as well [85][86][87][88].  The risk associated with depressive symptomatology in 
T1D, or any chronic disease, is expected.  One study found that those with T1D were over three 
and a half times more likely to have depression, were over two and a half times more likely to 
have a history of depression, and were two times more likely to be on an antidepressant than 
individuals free from T1D [93].   Previous research in the EDC Study has demonstrated that 
duration, hypertension, WHR, physical activity, and depressive symptomatology were all 
significant independent predictors of CAD in women.  However, depressive symptomatology did 
not increase risk for CAD in men [95]. At a later follow-up point in the study, however, both 
men and women with increased depressive symptomatology were at an increased risk of CAD 
[96].  This likely reflects that men generally score lower on the BDI thus may require longer to 
reach a critical level.  Another EDC analysis of combined men and women showed that 
increased BDI significantly predicted CHD even after controlling for hypertension, WHR, white 
blood cell count, fibrinogen, smoking status, distal symmetric polyneuropathy, and overt 
nephropathy.  However, this relationship became attenuated after the addition of all possible 
variables in the mediation analysis [96].  Depressive symptomatology has also been found to be 
cross-sectionally associated with increased WHR in both genders [97] as well as with 
macrovascular disease and a higher number of complications in those with T1D [98].   
In the EDC Study, it thus appears that depressive symptomatology plays an important 
role in the incidence and progression of diabetes-associated acute and chronic complications.  
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Our current findings align with these results.  Remarkably, although not included in the 
manuscript due to its close association with mortality, CAD was not the sole mediator in the 
depressive symptomatology and mortality relationship and did not diminish the significance 
level to a large degree.  There may be several subclinical responses to depressive 
symptomatology, and the cardiovascular system may not be the primary route, or the only route, 
in which depressive symptomatology increases mortality risk.  Depressive symptomatology may 
affect the brain, the heart, and the renal system simultaneously.  They may also cause 
participants to have poor self-care habits, as demonstrated in previous literature [91], thus 
accelerating their disease.  Lastly, perhaps depressive symptomatology increases inflammation 
throughout, causing damage to several systems. 
Regarding depressive symptomatology only being detrimental in those participants with a 
low anger score, perhaps this is due to some benefit offered by externalizing distress, in this case 
in the form of anger. We did not differentiate between constructive versus deconstructive anger, 
and this may additionally explain our results, as our participants reporting higher anger scores 
may be constructively dealing with their depressive symptomatology, offering them protection.  
This anger distinction should be examined in future research. 
Considering the other existing research on depressive symptomatology and subsequent 
risk of mortality in T1D, the FinnDiane Study Group concluded that in women only, baseline 
antidepressant agent purchase (their surrogate marker for depression) was associated with an 
increased mortality risk over nine years of follow-up [99]. These results differ from our findings, 
because we did not find a sex interaction and thus demonstrated that depressive symptomatology 
is a significant risk factor for mortality in both men and women. This difference in findings may 
be due to the differences in how the predictor was measured.  The FinnDiane group captured 
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those in treatment and with severe enough depression to be on medication.  It is known that 
women are more likely to be diagnosed with depression [99], and perhaps they are more likely to 
seek treatment and medication, thus explaining the association only being seen in women.  There 
is some evidence for this at cycle 10 in the EDC Study, because more women than men with a 
BDI score ≥16 were taking antidepressants, although this was not statistically significant most 
likely due to the small sample size. 
In the EDC Study, we have self-reported depressive symptomatology data and are thus 
able to capture those with even minimal to mild depression, which we have demonstrated is still 
detrimental to health. Screening for depression in T1D is extremely important because it has 
been demonstrated that depressive symptomatology puts patients at risk for increased 
complications and mortality.  Thus, perhaps treatment of depression may help prevent or delay 
the development of complications and early mortality, and this is discussed in greater detail 
below.   
We did not find that the other psychosocial variables interacted with type A behavior or 
depressive symptomatology.  Although hostility has been linked to CAD in other populations 
[110], [196], we did not find it was important in the two relationships on which we focused.  
Hostility may be important as an independent predictor, and although as we did not study this in 
depth it did not interact with type A behavior or depressive symptomatology.  Therefore, it does 
not seem that type A behavior’s protection differs at different levels of hostility, and the same 
can be said for depressive symptomatology’s detrimental effects.  Depressive symptomatology 
was detrimental in those with both high and low hostility.  The existing literature investigating 
the effects of hostility and its components within T1D is extremely limited. There is still a large 
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gap in the literature regarding the effects of high hostility in those with T1D and this requires 
further investigation. 
Anger, on the other hand, significantly interacted with depressive symptomatology such 
that depressive symptoms only increased mortality risk in those with low anger scores.  Anger 
has been shown to be detrimental to health in other populations, but there is a significant gap in 
the literature in those with T1D. While being an overall angry person in the general population is 
most likely detrimental, this might be different in those with a chronic disease.  It can be very 
distressing and frustrating having to live with T1D.  It is a disease that requires daily 
maintenance and rigorous care.  Based on our findings, it seems it may be helpful for those 
feeling depressed about their disease to express their anger regarding their diagnosis.  The 
concepts of anger in and anger out have been studied as separate constructs [163].  Anger-in has 
previously been described as having strong overlaps with depression [197]. Anger-out is 
expressing anger outwardly in ways that may be constructive or detrimental, including physical 
assaults and hostile verbal assault. It may be informative to study them in detail in people with 
T1D. 
Additionally, as expected, anxiety is more prevalent in the diabetes population than in the 
general population [114]  because living with a chronic disease often results in feelings of 
nervousness and stress.  Our current study, however, did not find that anxiety interacted with 
either type A behavior or depressive symptomatology in the prediction of mortality.  There is 
also a large gap in the literature surrounding anxiety in T1D, thus future research should focus on 
independently understanding how this mental state affects risk of morbidity and mortality. 
Social support is another important psychosocial construct and it refers to the network of 
family and friends surrounding a person in their external environment.  We studied the appraisal 
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component of interpersonal support, but did not find that it significantly interacted with type A 
behavior or depressive symptomatology.  The literature regarding social support in those with 
T1D is very lacking.  One study from the Veterans’ Affairs demonstrated that peer support might 
possibly be beneficial in improving glycemic control; however, future research is definitely 
needed to make any firm conclusions [161].  Social support may prove to be important to study 
in T1D, as one of the very few studies in T1D found that participants wished to converse about 
how others manage their T1D in day-to-day life, the interactions experienced with those who do 
not have T1D, and the emotions one experiences related to their T1D, and found a peer support 
group to be useful and therapeutic [127].  In addition, a recent review of the effect of peer 
support on diabetes-related outcomes found that peer support appears to benefit some people 
with T2D, but that the evidence thus far is too inconsistent to draw definite conclusions [126].   
The lack of findings in our current study may be due to our study only using the appraisal 
scale, thus future research should focus on understanding all aspects of social support in people 
with T1D. The appraisal scale is rarely looked at in the literature as its own construct.  One study 
investigating social support, stress, and functional status in patients with osteoarthritis found that 
the appraisal scale was the least predictive of functional status and was not significantly related 
[198]. Another study, however, found that increased appraisal support reduced the relationship 
between age and blood pressure in women [199].  Thus, it is difficult to determine whether our 
null findings regarding the appraisal scale fit in with current literature in either T1D or T2D.  In 
addition, there are three other constructs of support, which should be explored: belonging 
support, tangible support, and self-esteem support.  These are all functions afforded by social 
relationships. 
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Because we have demonstrated how detrimental depressive symptomatology may be in 
people with T1D, it was important to evaluate risk factors for these increased symptoms.  
Previous literature had established a strong association between stressful life events and major 
depressive episodes [116], and our findings fit in with this literature.  Specifically, a study 
investigating youth with T1D found that stressful life events were associated with greater 
psychological distress, poorer self-care behavior, and worse control in investigators’ cross-
sectional and also longitudinal analyses.  Our findings reiterate these results in adults with T1D.  
Not only is it distressing to suffer from a chronic disease, but also the addition of life events 
stress appears to cause an even further increase in depressive symptomatology.  As discussed 
above, screening for depressive symptomatology is important in this population, and in 
particular, patients with high scores of life events should be given greater focus.  Overall, the 
ADA 2014 guidelines stating that psychosocial counseling be regularly provided to those with 
T1D should be emphasized in all practices [200].  It is just as important for care as going to the 
endocrinologist and ophthalmologist.  If this population is taught how to effectively cope with 
not only their disease, but with life events that will inevitably arise sooner or later, perhaps they 
will be prepared with these coping tools to stay happy and feel in control despite the world 
around them. 
Our lack of findings regarding life events and change in glycemic control differ from the 
limited information existing in the literature, where researchers found that stressful life 
experiences were associated with maintained poor control over time or deterioration of control in 
those with T1D [122].  This difference may be, in part, due to the different methods used to 
measure stressful life-events (in-depth interviews compared to a self-complete checklist) as well 
as differences in weighting and classification.   
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While our work addresses some gaps in the literature and increases the focus on 
psychosocial health, there are many questions left unanswered. It has been previously 
demonstrated in the literature that treatment of depression in diabetes is effective for improving 
depression [201].  However, only one-third of diabetes patients with mental disorders receive 
care.  This is unfortunate, as research has shown that treating depression in those with diabetes 
not only improves depression, but glucose control, as well [202].  One study examined 
depression treatment using three arms: the chronic care model (collaborative care), 
psychotherapy, and pharmacotherapy [203]. They found that the chronic care model approach 
and psychotherapy/diabetes self-care management were effective at improving glycemic control, 
but it was difficult to tell if this improvement was because of the diabetes education, the 
reduction in depression, or both.  Investigators also found that pharmacotherapy was successful 
in reducing depressive symptomatology, but had only small effects on glycemic control.  Thus 
they concluded that a combined therapy was best in treating depression in those with diabetes, as 
the chronic care model improved glycemic control, depressive symptomatology, and quality of 
life [203].  It is important to note that the majority of depression treatment research has been 
performed in T2D, and there is very little research available in T1D. 
Depression in diabetes is further complicated by diabetes distress.  Diabetes distress is 
important to consider as it overlaps to a considerable degree, although not totally, with 
depressive symptomatology. Diabetes distress may result because caring for diabetes involves a 
large amount of self-management behavior [201].  This may leave individuals feeling 
overwhelmed, fearful of complications, and guilty about poor management.  Diabetes distress, 
below a psychiatric diagnosis of depression, has been associated with poor outcomes [201].  In 
addition, it is important to consider that the physical symptoms of depression may be difficult to 
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tease apart from symptoms of T1D.  In order to address this issue, we considered how this might 
affect our findings, and thus removed the physical symptom questions from the BDI 
questionnaire. The amended questionnaire remained predictive of mortality in our cohort [HR= 
1.22 (1.04-1.43); p=0.01] per 1 standard deviation, compared to the BDI with all items included: 
[HR=1.42 (1.22-1.66); p<0.001]. 
It is difficult to distinguish whether specific symptoms on the BDI are resulting from 
depression or diabetes distress. Perhaps people who are feeling sad are sad because they are 
experiencing depressive symptomatology, or because of distress from their diabetes.  In addition, 
sleep may be affected because of either of the above, as may fatigue.  However, regardless of the 
origin of the symptoms detected via the BDI, treatment of depressive symptomatology reduces 
diabetes distress, and has the potential to reduce the physical symptoms (e.g. fatigue, loss of 
appetite, loss of interest in sex) if they result from depressive symptomatology.  Research 
presented at the American Diabetes Association’s annual scientific meetings (2014) by Larry 
Fisher showed that symptoms of depression in people with T2D can be significantly reduced 
through interventions for “diabetes distress [204].”  Thus, from a treatment standpoint, it may not 
initially be imperative to distinguish where the symptoms are originating, as the initial treatment 
maybe to address distress. However if depressive symptomatology remains specific 
antidepressant therapy would be appropriate. Thus, the most important next step might be 
designing and conducting a clinical trial to treat depressive symptomatology in people with T1D 
using the chronic care model versus usual care, while gathering in depth psychosocial 
information both before and after the intervention.  The clinical trial (randomized by practice) 
would screen T1D participants for depressive symptomatology and clinical depression and then 
refer them for care (chronic care model versus usual care (control group)).  The chronic care 
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model is a multifaceted framework for enhancing health care delivery.  This method is focused 
on treating long-term conditions as opposed to acute care, and aims to improve care at the 
patient, provider, community, and health system levels [205].  The chronic care model is 
comprised of 5 elements: the community, the health system, self-management support, delivery 
system design, decision support and clinical information systems.  The trial I am recommending 
should also treat those with minimal and mild symptoms with the chronic care model versus 
usual care, as well, to determine if reducing even low depressive symptomatology improves 
outcomes.  The outcomes I recommend to be initially measured are glycemic control and 
psychosocial factors, specifically diabetes distress, as these associations have been demonstrated 
in other diabetes populations [206] After an appropriate amount of time passed, I recommend 
assessing the number of incident complications as well as assessing them separately 
(nephropathy and CAD in particular, as they were demonstrated to be partial mediators [100]) 
and investigating mortality if possible. 
Previous research investigated whether the use of chronic care model elements was 
associated with higher-quality care for diabetes.  Investigators found that greater physician use of 
the chronic care model in their clinics was associated with higher behavioral care, but not clinical 
care in this T2D population [207]. These investigators also looked at physiological outcomes, 
and found that clinician score for use of a chronic care model (the higher the clinician score, the 
more they utilized the chronic care model and its elements) was associated with lower HbA1c 
and lower non-HDL. An additional study investigating the chronic care model in T2D found that 
after the first 12 months of follow up there were clinical, behavioral, psychosocial, and process 
improvements in subjects who received a chronic care model-based, multifaceted intervention 
compared to the usual care group [208].  These investigators used the WHO Quality of Well 
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Being Index-10 (QWB10), which measures perceived current well-being and provides an overall 
indicator of mental health over the past 2 weeks (i.e. depression, anxiety, energy, sleep, and 
positive well-being).  After three years of follow-up, investigators found sustained improvements 
for HbA1c level, blood pressure levels, and self-monitoring for all groups.  However, they found 
that QWB10 scores improved in the chronic care model group only.  Authors note that it is 
difficult to determine why QWB10 scores did not improve in the provider education only group 
because of the very low sample sizes.  Perhaps they were underpowered or there may not have 
been any actual improvements in QWB10.  Thus, quality of life would be an additional 
important construct to measure in the future trial I am recommending.  The authors conclude that 
other sustained improvements may be due to improvements in diabetes care in general.  Again, it 
is important to note that there is a lack of research regarding the chronic care model in T1D, so 
my proposed trial would add a great deal to the literature.  
Intervention studies have been designed to screen for and treat depression to prevent poor 
outcomes in other populations.  For example, Dr. Bruce Rollman was funded to conduct the 
Hopeful Heart Trial.  He and his team screened hospitalized heart failure patients with the Patient 
Health Questionnaire-2 (PHQ-2) and then also determined vital status at up to 12-months of 
follow-up. He found that among hospitalized heart failure patients, a positive PHQ-2 depression 
screen was associated with an elevated 12-month mortality risk, thus demonstrating the 
importance for an intervention.   
It is important to note, however, that in the ENRICHD trial of myocardial infarction 
patients, they did not find that depression treatment increased event-free survival [125].  Authors 
found that the intervention improved depression and feelings of social isolation, but the 
improvement in the psychosocial intervention group compared with the usual care group was 
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less than expected.  This was most likely due to important improvements in usual care patients 
[125].  In addition, with secondary analyses, investigators found that the risk of death or 
recurrent MI was significantly lower in patients taking selective serotonin reuptake inhibitors 
(SSRIs) compared with patients who were not on these medications [209]. Thus, the literature is 
conflicting as to whether depression treatment can improve mortality.  How this treatment would 
affect increased mortality risk from depressive symptomatology in T1D is unknown, thus further 
emphasizing the need for a clinical trial of depression treatment in T1D with long term follow-
up. 
Intervention studies are being conducted in other high-risk populations, thus it seems 
timely and relevant to conduct similar research in those with T1D.  In addition, psychosocial 
factors in diabetes are currently receiving a great deal of attention [201], perhaps providing a 
funding opportunity.  Previous research regarding depression interventions in T1D were lacking 
in terms of additional psychosocial factors (e.g. anxiety, coping skills, social support) [210], 
[211], thus this study would additionally build on previous literature by assessing these factors in 
addition to depressive symptomatology.  Furthermore, only one study assessed health behaviors 
such as smoking and physical activity, thus the collection of these and other important covariates 
would be part of the study design.  Lastly, long-term follow-up after the intervention is crucial to 
assessing complication development and mortality in T1D. 
As stated above, I would also aim to collect detailed information on these psychosocial 
factors: anger, anxiety, coping, social support, behavior type, quality of life, and diabetes distress 
using valid questionnaires in order to assess whether one or more of these contributes to the 
effectiveness of a depression intervention via the chronic care model.  These items could be 
investigated as potential mediators/moderators or as outcome variables.  I hypothesize that those 
  107 
experiencing increased social support may assist in reducing depressive symptomatology along 
with the screening/treatment, although this is based on other literature using the full scale [126] 
as we did not demonstrate a relationship between appraisal support and our outcome variables.  
In addition, I hypothesize that treatment of depressive symptomatology via the chronic care 
model will improve quality of life, depressive symptomatology, and glycemic control based on 
the literature discussed above.  Based on my current research, I also hypothesize that those with 
higher anger scores will have better outcomes then those with low anger scores due to a 
therapeutic expression regarding the difficulties of living with a chronic disease.  In order to 
assess this appropriately based on my theory regarding the benefits of expressing anger, I would 
administer both the State-Trait Anger Scale and the Anger Expression (AX) Scale to try and 
understand the depressive symptomatology and anger interaction in more depth. 
 In addition to recommending the above clinical trial, I would also recommend 
redistributing all of the same questionnaires captured at the EDC Study baseline exam again at 
the 30-year clinic visit, along with additional psychosocial questionnaires that are currently 
popular for use.  This would allow researchers to assess whether any of the psychosocial 
constructs stayed constant over time, as well as how well a specific psychosocial factor at 
baseline predicts the others 30 years later.  In addition our study would be able to investigate the 
comparability of older questionnaires to the newer questionnaires (all completed at the 30 year 
visit).  For example, investigators could assess whether the Bortner Rating Scale, which is no 
longer commonly used, gives similar personality findings as the Eysenck Personality 
Questionnaire.  Furthermore, they could assess whether the two different scales are associated 
with outcomes (e.g. glycemic control) the same way.  For example, the EDC Study could 
investigate whether state anger, trait anger, anger in, and anger out have similar relationships and 
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associations with glycemic control and other diabetes care measures.  Administering this packet 
of psychosocial questionnaires would be an inexpensive additional to the 30 year clinic visit 
exam, and the only negative aspect would be the additional participant burden created by having 
them complete supplementary paperwork.  Having these data at baseline and again at 30 years of 
follow-up would be a very unique addition to the psychosocial literature as a whole, as well as 
the T1D literature, as there is little known about long term repeatability of some of these 
measures. 
 In order to tie these current research findings together, there are important concepts to 
take into consideration (Figure 6).   
 
  
Figure 6: Combining the Locus of Control Theory and Important Psychosocial Risk Factors for 
Outcome Prediction in T1D. 
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 The locus of control theory refers to the degree to which individuals believe they can control 
events in their lives [212].  According to this theory, people deal with this control in one of two 
ways: internally, that is a person believes he/she has control over his/her life, or externally, 
where a person believes the environment, or fate, has the control and that it cannot be influence 
[212].  For example, those with internal control believe their hard work will pay off while those 
with external control believe events are a result of luck or other peoples’ influence. Because 
those with external control believe they have no control over their lives, they tend to become 
more stressed or depressed compared to internals [213].  On the other hand, those with internal 
control believe that they can exhibit control over their lives, and if they set things up in such a 
way that success seems imminent, happiness may be more likely.  
A relationship between the health locus of control and diabetes management might exist. 
Being diagnosed with a chronic disease requiring meticulous care with T1D offering no breaks in 
care and no days off.  Even taking one day off from testing blood glucose or administering 
insulin can have deadly consequences.  It is thus easy to imagine that individuals with an internal 
locus of control might take responsibility for the care of their T1D, resulting in better glycemic 
control and health care behaviors, than someone with an external locus who might blame fate or 
bad luck and become depressed and distressed.  It is plausible that someone with type A behavior 
(described as hard-driving) may also be more likely to have an internal control and believe their 
actions can influence their health outcomes (e.g. complications), therefore motivating them to 
adopt the appropriate diabetes care behaviors.  This regimented care has the potential to protect 
them from mortality, as we demonstrated in our results.  In addition, being a “fast eater, walker, 
  110 
etc.” would seem to represent this idea of striving for control, not allowing a chronic disease to 
slow them down. 
 The health belief model ties into this, as well, with a particular focus on a few of its 
components: perceived susceptibility, perceived benefits, perceived barriers, and self-efficacy.  
Perceived susceptibility maintains that those who believe they are susceptible to a particular 
health problem will take part in behaviors to reduce their risk [214].  Perceived benefits refer to 
the belief that taking action will reduce this susceptibility [214].  If those with higher type A 
behavior are more internal with their control, it is plausible that they believe their actions will 
reduce their susceptibility to T1D complications thus they are more likely to care for themselves 
appropriately.  Perceived barriers are an individual’s assessment of the obstacles to health care 
behaviors [215].  These barriers may prevent their undertaking of positive health behaviors.  
Because those with type A behavior may feel they have control over their diagnosis, they might 
believe there are fewer barriers to care compared to people with external control.  Lastly, self-
efficacy refers to how well someone believes they can successfully perform a behavior [215].  
People who exhibit internal control, perhaps our people with higher type A behavior, may be 
more likely to have previously worked to obtain positive outcomes and thus have better self-
efficacy due to past successes. 
On the other hand, however, it is also easy to see people falling in to the second group 
already feeling burdened by the idea that they have no control of their lives and on being 
diagnosed with diabetes having this reinforced. It is understandable that this might result in 
increased depressive symptomatology [213].  The combination of the toll T1D takes on the body, 
as well as on the mind through disease burden, and the potential feeling of a lack of control over 
their situation, may increase the risk of poor health outcomes.  If one believes that their poor 
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health is due to bad luck or insufficient care by their providers, they are most likely not 
motivated to take action, as their outcomes are out of their control.   
It is plausible that this lack of control may cause people to also feel angry.  Based on our 
work, perhaps it is this anger that helps to protect them.  For those with external control who 
believe they were dealt a difficult hand in life, perhaps getting angry about feeling physically and 
mentally stressed, may offer some protection through anger expression, as described above. 
Feeling a lack of control over ones’ life combined with the physical and mental burdens of the 
disease does not appear, according to our findings, to produce the best outcomes when 
internalized.  In addition, if people are vocal about their disease distress or depressive 
symptomatology this may alert those around them to be a support network in their time of 
difficulty.  While we did not find a relationship with social support, again this may be due to us 
only having the appraisal scale section of the questionnaire.  Social support overall may still 
prove to be important in future research. 
In this external control group, they most likely believe that their actions will not reduce 
their susceptibility to T1D complications. Therefore, regardless of their perceived susceptibility, 
they do not take action.  They also may believe that if they are lucky, in combination with 
receiving excellent care from their provider, they will see positive results.  This success does not 
require action on their part. The perceived barriers of the health belief model may also prevent 
them from undertaking positive health behaviors [215].  Because these individuals with external 
control may be more likely to become stressed or depressed with a T1D diagnosis, these mental 
health comorbidities may also act as barriers to diabetes care, influencing risk of poor health 
outcomes.  Lastly, people who are externals, and may be more likely to have higher depressive 
symptomatology, may suffer from low-esteem among other depressive effects, and thus have 
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lower self-efficacy.  This low self-efficacy may result in the belief that one will fail at 
performing a health care behavior, thus there is no sense in performing it, thereby increasing the 
risk of poor T1D outcomes. 
Furthermore with regard to the locus of control, life events stress would only intensify 
these feelings of losing control, which in those with external control may increase depressive 
symptomatology beyond the depressive symptomatology potentially resulting from a T1D 
diagnosis.  With increased life events, the control has extended from internally (i.e. a chronic 
disease) to the outside environment, as well.  It may be that even those with external control who 
were able avoid stress and depressive symptomatology through living with T1D become stressed 
or depressed when unanticipated life events occur.  Based on our findings, this theory is 
plausible.  People who experienced higher life event scores were at an increased risk of clinically 
important depressive symptomatology.  It should be noted that this was based on their prior 
depressive symptomatology, as well, so that previous feelings of depression were taken in to 
account when assessing this relationship.  Specifically, if participants reached a median life 
events score, they were at an almost 50% increased risk of clinically relevant depression.  
Perhaps our results, which demonstrate the effect of life events on high depressive 
symptomatology, provide further evidence for the idea that feeling out of control is difficult for 
some people to tolerate.  While this theory seems dismal, we also demonstrated that in our 
population there were ways people managed to reduce some of their increased risk of mortality 
brought on by physical and mental burdens.  The theorizing of combining type A behavior and 
depressive symptomatology, based on our results, with the locus of control and health belief 
models to potentially explain health outcomes in people with T1D is an important avenue of 
research to pursue in the future. 
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Through this research project, we have demonstrated that in additional to traditional T1D 
risk factors, psychosocial factors are also important in outcome prediction.  However, there are 
several limitations to consider.  First, we were limited to our psychosocial data assessed only at 
the baseline visit.  Thus, it is difficult to determine causality between the exposures and the 
outcomes due to the long follow-up between when the exposures and outcomes were assessed.  
We did our best to account for this using Cox proportional hazards modeling, however this does 
not definitely determine causality.  Next, because of the long follow-up, it is important to 
consider whether type A behavior changes over time.  There are two different outlooks, one is 
that personality stays constant over the lifetime and the other is that personality changes with 
age.  It is difficult to determine whether our type A behavior measure stays constant over time 
because we are confined to baseline data only.  Thus, the relationship between type A behavior 
and mortality may change over the course of the study, as people get older.  In regards to 
depressive symptomatology, however, we have it measured over time.   I investigated depressive 
symptomatology as a time-varying predictor in a separate analysis, and found that it predicts 
mortality not only at baseline, but over 20-years of follow-up, as well.  Thus, we are confident 
that our findings regarding depressive symptomatology and mortality are consistent over the 
course of the study.  Lastly, it is possible that the psychosocial factors impact one another during 
completion of the questionnaires.  For example, perhaps someone with higher depressive 
symptomatology is more likely to rate themselves as angry.  Because we have baseline data only 
on anger, we cannot assess the temporal relationship between the psychosocial variables.  We 
attempted to study their interactions, however, in Chapter 3.0. 
The above recommended screening and treatment regimen may have the potential to have 
a significant public health impact in not only those with T1D, but with chronic diseases in 
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general.  Implementing mental burden screenings into all clinical settings has the potential to 
capture many people suffering from depressive symptomatology and diabetes distress.  If the 
appropriate referral networks are put into place, these people can receive treatment to alleviate 
mental disease and greatly improve their quality of life and potentially even their risk of 
mortality. There is some evidence that these interventions improve depression, and intervening 
with the chronic care model may prove to be very important in the eventual treatment of 
depression in T1D. Because mental diseases like depression are not as tangible as physical 
diseases does not mean they should not be given secondary attention.  Psychosocial factors can 
be felt just as intensely as physical factors, with depressive symptomatology resulting in a large 
degree of disease burden.  Understanding these feelings and psychosocial cognitions creates a 
more enriched and complete care model and should be given serious attention in the literature 
and in the clinical setting. 
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APPENDIX A: PSYCHOSOCIAL QUESTIONNAIRES: STRENGTHS AND 
WEAKNESSES 
 
Table 17: Psychosocial Questionnaires: Strengths and Weaknesses 
Measure Questionnaire Strengths Weaknesses 
Type A Behavior Bortner Rating Scale Previously used in T1D 
populations; high re-test 
reliability and inter-rater 
reliability; sufficiently 
correlated with other 
type A measures 
Self report; scoring 
discrepancies; no 
longer used as often 
as other personality 
questionnaires. 
Depressive 
symptomatology 
Beck Depression 
Inventory 
Validated in both 
healthy and ill 
populations; used 
extensively in the 
literature; associated 
with clinically 
meaningful depression; 
used in previous T1D 
research 
Self report; does not 
diagnose clinical 
depression 
Hostility Cook-Medley 
Hostility Scale 
Predictive of health 
outcomes; can be broken 
down into valid 
subscales that may be 
more informative then 
the overall measure in 
some populations and 
when examining some 
outcomes. 
Self report; some of 
the subscales appear 
to measure other 
constructs besides 
hostility; not 
commonly used in 
T1D research. 
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Table 17 Continued 
Anger Spielberger Trait 
Anger/Anxiety Scale 
Only requires a sixth 
grade reading level; 
Used across 
socioeconomic groups; 
valid for identifying 
state anger 
Self report; does not 
measure state anger 
or anger expression. 
Anxiety Spielberger Trait 
Anger/Anxiety Scale 
Only requires a sixth 
grade reading level; 
Used across 
socioeconomic groups; 
Can be used to diagnose 
anxiety in combination 
with the state portion of 
the scale; Useful in 
research to differentiate 
between anxiety and 
depression. 
Self report; does not 
measure state 
anxiety. 
Interpersonal 
Support 
The Interpersonal 
Support Evaluation 
List: Appraisal Scale 
Measures the functional 
components of social 
support; validated and 
used since the 1980s. 
Self report; only 
includes one of the 
interpersonal support 
scales.  One of our 
questions on the scale 
was slightly 
modified. 
Stressful Life 
Events 
Life Events Checklist Comprised of 50 life 
event items covering a 
wide variety of events 
from positive to 
negative, severe and less 
severe.  The checklist 
was very similar to the 
one by Holmes and Rahe 
and thus we were able to 
calculate 
scoring/weighting. 
Self-report; differs 
from the standard, 
validated life events 
checklist. 
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APPENDIX B: TYPE A BEHAVIOR AND RISK OF ALL CAUSE MORTALITY, CAD, 
AND CAD-RELATED MORTALITY IN A TYPE 1 DIABETIC POPULATION: 22 
YEARS OF FOLLOW UP IN THE PITTSBURGH EPIDEMIOLOGY OF DIABETES 
COMPLICATIONS STUDY 
B.1 INTRODUCTION 
The incidence of T1D, which remains incurable, has continued to rise annually by 
approximately 3% [1]. Unfortunately, prevention is not currently feasible.  Therefore, the 
exploration of T1D complications, untimely mortality and the associated risk factors must 
continue. Type A behavior has been described as an action-emotion complex, meaning that the 
behavior is elicited by the outside environment [70].  People characterized as having type A 
behavior tend to focus toward achieving and accomplishing more in less time than others.  
Because of these tendencies, these people tend to be competitive, aggressive, time urgent, work-
oriented, and can become annoyed if things are not achieved in a time frame they find sufficient 
[70]. Therefore, it seems that type A behaviors are not a set of personality characteristics that 
come about due to the environment; rather, the behavior is a result of predispositions within a 
person that are exhibited due to specific situations [70]. In an earlier review, Matthews et al. 
noted that although type A behavior was linked to increased CHD risk in the general population, 
findings were consistently negative in high-risk populations [70].  For example, the prospective 
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Western Collaborative Group Study (WCGS) found that those with type A behavior experienced 
an increased rate of CHD compared to type B behavior (p=0.001) [153]. However, in their high-
risk population who had already undergone a CHD event, type A behavior had a lower CHD-
associated mortality rate in those surviving 24 hours or more than those characterized as having 
type B behavior (p=0.03) [154]. Therefore, it appears that type A behavior may have different 
effects on health depending on underlying chronic disease status.   
Little is known about the psychosocial contribution to the increased CAD risk seen in 
people with T1D beyond depression [96], [171], in particular, whether T1D is an additional high 
risk group in which the inverse association between type A behavior and CAD/mortality exists. 
Cross-sectional data from the EDC study have shown (using the Bortner Rating Scale) that 
participants with multiple complications, including CAD, retinopathy, neuropathy, and/or 
nephropathy, reported less type A behaviors than those without complications (p<0.05) [171]. 
The long length of follow-up now available in the EDC allowed a prospective analysis of the role 
of type A behavior in mortality and CAD and we are unaware of other investigations of this 
relationship. We also investigated the association between type A behavior and CAD-related 
mortality in those already diagnosed with CAD, and whether the established effect of depressive 
symptomatology on CAD incidence interacted with or explained any effect of type A behavior.   
Thus, the aims of the current study were to investigate the relationships between type A 
behavior and mortality, type A behavior and incident CAD, and type A behavior and mortality 
among those with CAD during 22 years of follow-up. 
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B.2 METHODS 
The EDC study is comprised of participants diagnosed with T1D between 1950 and 1980 
at age <17 years, seen within one year of diagnosis at Children’s Hospital of Pittsburgh.  
Biennial follow-up has occurred since baseline in 1986-1988, which included questionnaires 
with physician examinations, and laboratory analyses of urine and blood for the first 10 years 
and again at 18 years.  Data up to the 22-year follow-up are now available. Participants ≥18 
years of age at study entry completed the Bortner Type A Questionnaire which measures aspects 
of type A behavior [132] and has been shown to have good test-retest reliability [70]. 
Participants were asked to circle the dot on the line that represents where they believed they fell 
between two different sentences.  Some examples of the sentences included “never late” versus 
“casual about appointments,” “always rushed” versus “never rushed, even under pressure,” and 
“take things one at a time” versus “try to do many things at once, thinking about what I am going 
to do next.”  CAD was defined as myocardial infarction confirmed by hospital records or Q 
waves on ECG (Minnesota codes 1.1 or 1.2); coronary artery stenosis, defined as ≥50% 
blockage, or revascularization; ischemic ECG, defined using Minnesota Code 1.3, 4.1–4.3, 5.1–
5.3, 7.1; angina, diagnosed by an EDC physician; or CAD death (determined by a mortality 
classification committee).  
Overall mortality, including CAD-associated mortality and complication status, was 
determined as of February 25, 2011. Searches were performed in both the Social Security Death 
Index and the National Death Index. In order to confirm each death, death certificates were 
obtained, plus as appropriate: 1) hospital records; 2) autopsy/coroner’s reports; and 3) interview 
with next of kin regarding the death. The underlying causes of death, and the hierarchal order for 
all contributing causes of death, were determined by a Mortality Classification Committee 
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consisting of two or more physician epidemiologists.  This method is based on standardized 
procedures [216].  
The following covariates were chosen as potential predictors for our final model: age, 
sex, duration, education, physical activity, smoking, BMI, insulin dosage, HbA1c, and 
depressive symptomatology. These covariates were chosen because they are previously 
demonstrated risk factors for CAD and/or early mortality in T1D [133].  Education was assessed 
using a 5-point scale, i.e.: some high school, high school graduate, some college, bachelor’s 
degree, graduate education beyond bachelor’s.  Physical activity was assessed using questions 
about current levels of leisure activities [168], as well as by estimating the energy expenditure 
over the past week (kcals/week) through use of questions asking about the daily number of 
flights of stairs climbed, the number of blocks walked daily, and all sports participation that had 
occurred over the past week.  Ever smoked was defined as having had more than 100 cigarettes 
over their lifetime.  Insulin dosage was expressed as the number of units of insulin used per day 
divided by the participants’ weight in kilograms.  BMI was calculated as participants’ weight in 
kilograms divided by the square of their height in meters. Fasting blood samples were analyzed 
for HbA1 (microcolumn cation exchange; Isolab, Akron, OH, USA), and these original HbA1 
values were converted to DCCT-aligned HbA1c for all analyses using a regression equation 
derived from duplicate assays (DCCT HbA1c=0.14+0.83[EDC HbA1]).  Finally, depressive 
symptomatology was measured using the Beck Depression Inventory (BDI) [217].  The BDI is a 
21-item self-report scale that is widely used in both healthy and ill populations.  A score of 0–9 
indicates minimal depression, 10–18 indicates mild depression, 19–29 indicates moderate 
depression, and 30–63 indicates severe depression [217]. BDI scores have been shown to 
approximate clinically significant symptoms of depression [217]. 
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 Cox proportional hazards models were utilized to examine the univariate and 
multivariable relationship between baseline Bortner scores and overall mortality, CAD incidence 
over 22 years of follow-up, and CAD-related mortality among those with CAD.  To assess 
univariate associations between baseline Bortner score and potential covariates (i.e. age, sex, 
duration, education, physical activity, smoking, BMI, insulin dosage, HbA1c, and depressive 
symptomatology), Student’s t-test or Wilcoxon rank-sign test was used as appropriate.  Cox 
proportional hazards modeling was used to examine the independent association between 
Bortner score and each outcome (overall mortality, CAD incidence, and incident CAD death 
among those with CAD) adjusting for significant baseline covariates.  All statistics were 
performed using SAS 9.3 (SAS Institute, Cary, NC). 
B.3 RESULTS 
At the EDC baseline exam, 658 participants were seen.  One hundred and fifty two 
participants were excluded from this analysis for having missing covariate measures; however, 
60 of these participants were <18 years and therefore not eligible to complete the Bortner or the 
BDI, and an additional 92 participants were excluded, most commonly, for missing data on the 
BDI, Bortner, or physical activity measures.   
As of February 25, 2011, of EDC participants who completed both the Bortner and the 
BDI at baseline, and who had complete covariate data (N=506, 250 males and 256 females), 
there were 128 deaths (25.3%).  Those excluded were less likely to have a high school education 
(p=0.01), and were more likely to be smokers (p<0.01), but did not differ significantly for age, 
duration, sex, HbA1c, physical activity, BMI, or depressive symptomatology. 
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Significant covariate differences existed between those with and without incident CAD 
for age, duration, physical activity, smoking, BDI, and insulin dosage (Table 18).  
 
Table 18: Baseline Characteristics by CAD Incidence, 1986-1988 
 No Incident CAD 
(n=331)  
Incident CAD (n=176)  p-value  
Age 26.7 (6.3) 32.1 (6.5) <0.0001 
Sex, %(n), Males 47.1 (156) 54.0 (95) 0.14 
Duration 17.9 (6.6) 23.6 (6.9) <0.0001 
Education, %(n), Above High 
School 
 
65.8 (212) 60.7 (105) 0.25 
Total energy 
expenditure/week (kcals)  
1583.0 (646.0, 2961.0)† 1149.0 (448.0, 2238.0)† <0. 01 
Total sports expenditure/week 450.0 (0.0, 1500.0)† 0.0 (0.0, 630.0)† <0.0001  
Smoke Ever, % (n), Yes 
 
32.5 (107)  50.8 (89)  <0.0001  
BMI 23.4 (21.6, 25.4)† 23.7 (21.9, 26.1)† 0.25 
HbA1c % (mmol/mol) 8.6 (1.5) (70(16.4)) 8.7 (1.4) (72(15.3)) 0.72  
Insulin dosage (Total 
units/weight) 
0.79 (0.24) 0.73 (0.23) 0.01 
Bortner Rating Scale 190.1 (25.2) 186.2 (24.6) 0.09 
Beck Depression Inventory 
(BDI)  
5.0 (2.0, 10.0)† 6.0 (3.0, 11.0)† 0.01  
† Median (Interquartile Range) 
 
A significant trend was demonstrated for both Bortner score (p=0.05) and BDI score (p=0.01) at 
baseline and CAD incidence (Figure 7).   
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 Figure 7: A: Bortner Quintiles and CAD Rate; B: Bortner Quintiles and Mortality Rate; C: BDI 
Quintiles and CAD Rate; D: BDI Quintiles and Mortality Rate 
 
A borderline univariate relationship was seen between baseline Bortner scores and CAD 
incidence (p=0.09). No significant interaction was observed between Bortner and BDI in relation 
to CAD incidence. 
Differences existed by subsequent mortality for most baseline covariates.  Deceased 
participants tended to be older, with longer diabetes duration, male, less physically active, ever 
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smokers, had a higher HbA1c and BDI score, and a lower Bortner score compared to survivors 
(Table 20).  
 
Table 19: Baseline Characteristics (1986-1988) by Subsequent Mortality 
 Living (n=378)  Deceased (n=128)  p-value  
Age 27.6 (6.5) 33.6 (6.3) <0.0001 
Sex %(n), Males 
 
47.1 (178) 56.2 (72) 0.07 
Duration 18.8 (6.8) 24.6 (6.5) <0.0001 
Education, %(n), Above High 
School 
 
65.6 (248) 60.1 (77) 0.26 
Total energy expenditure/week 
(kcals)  
1531.0 (646.0, 2860.0)† 1064.0(336.0,2059.0)† <0.001 
Total sports expenditure/week  400.0 (0.0, 1425.0)† 0.0(0.0, 512.5)† <0.0001  
Smoke Ever, %(n), Yes 33.3 (126)  57.0 (73)  <0.0001  
BMI 23.5 (21.9, 25.5)† 23.6 (21.0, 26.3)† 0.91 
HbA1c % (mmol/mol) 8.6 (1.4) (70(15.3)) 9.0 (1.6) (75(17.5)) <0.01  
Insulin dosage (Total units/kg 
body weight) 
0.77 (0.22) 0.73 (0.29) 0.11 
Bortner Rating Scale 190.0 (24.2) 182.5 (25.8) <0.01 
Beck Depression Inventory 
(BDI)  
5.0 (2.0, 10.0)† 8.0 (4.0, 14.0)† <0.0001  
† Median (Interquartile Range) 
 
 
The univariate association between Bortner scores and all-cause mortality is shown in 
more detail by quintiles (p=0.01) (Figure 1B). Those with higher type A behavior tended to be at 
a reduced risk for mortality with a significant trend (p=0.01). Multivariable analyses (Table 20) 
of the association between type A behavior and all-cause mortality were performed with four 
models, progressively controlling for covariates.  
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Table 20: Associate between type A behavior and all-cause mortality in type 1 diabetes- Cox regression 
(n=506; 128 events) 
                                                                 HR (95% CI) for all-cause mortality  
          per 1 unit change in Bortner score 
 Covariate Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits  
 
p-value AIC 
Model 1a Bortner 0.99 (0.98, 0.99) 0.01 1464.84 
 Age 1.10 (1.08, 1.13) <0.0001  
 Sex 0.65 (0.46, 0.93) 0.01  
      
Model 2b Bortner 0.99 (0.98, 0.99) 0.04 1434.22 
 Age 1.10 (1.08, 1.13) <0.0001  
 Sex 0.70 (0.49, 0.99) 0.05  
 Ever smoker 2.05 (1.43, 2.92) <0.0001  
 HbA1c 1.32 (1.17, 1.48) <0.0001  
      
Model 3c Bortner 0.99 (0.98, 1.00) 0.11 1424.40 
 BDI 1.04 (1.02, 1.07) <0.001  
 Age 1.10 (1.07, 1.13) <0.0001  
 Sex 0.65 (0.45, 0.93) 0.01  
 Ever Smoker 2.00 (1.40, 2.85) <0.001  
 HbA1c 1.29 (1.15, 1.45) <0.0001  
      
Model 4d Bortner 0.98 (0.97, 0.99) <0.01 1421.84 
 BDI 0.85 (0.70, 1.03) 0.10  
 Age 1.11 (1.08, 1.13) <0.0001  
 Sex 0.64 (0.44, 0.92) 0.01  
 Ever Smoker 1.93 (1.35, 2.76) <0.001  
 HbA1c 1.28 (1.15, 1.43) <0.0001  
 Bortner*BDI 1.001 (1.000, 1.002) 0.03  
aModel 1= allowed for age, sex, and duration 
bModel 2= allowed for Model 1 + HbA1c, education, smoking, and physical activity 
cModel 3= allowed for Model 2 + BDI as a continuous variable 
dModel 4= allowed for Model 3 + Bortner and BDI interaction term 
 
Model 1 adjusted for age and sex, with Bortner score remaining significant (p=0.01).  
Model 2 included age, sex, duration, HbA1c, education, smoking, BMI, and physical activity as 
covariates and demonstrated that Bortner score continued to significantly predict mortality 
[HR=0.99; 95% confidence interval (CI): (0.98-1.00); p=0.03]. For every one-point increase on 
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the Bortner scale, there was a 1% lower mortality risk (Bortner rating scale range: 97-258). 
However, further adjustment for BDI (model 3), reduced the association between Bortner and 
mortality (p=0.11).   
Model 4 tested for an interaction between the Bortner Rating Scale and BDI for mortality 
(Table 20) as a significant inverse correlation was found between the two (r=-0.18, p<0.001).  
This interaction was significant (p=0.03), meaning type A behavior is only operative in those 
with lower BDI scores.  Further BDI stratified analyses were then performed.  Based on the 
quintiles determined in our study population (BDI scores: 0-1, 2-3, 4-6, 7-12, and 13-32) (Figure 
7, Panel D), we compared the first three quintiles with the upper two quintiles resulting in two 
categories, a BDI score ≤6 versus a BDI score ≥7.  A borderline significant protective effect 
against mortality was seen with higher type A behavior score in the lower BDI quintiles 
(p=0.07), but not with a BDI score >7 (p=0.97).  
Performing analyses by sex (mean Bortner score in men: 191.1 vs. women: 185.2; 
p<0.01), a significant univariate relationship between Bortner and mortality [0.98, (0.97, 0.99); 
p<0.001] was seen in men but not in women [0.99, (0.98, 1.00); p=0.12].  However, a greater 
proportion of men than women were type A within our population (p=0.03).  The significant 
relationship among men remained after multivariable adjustment [0.99, (0.98, 0.99); p=0.03], but 
was attenuated after further adjusting for BDI [0.99, (0.98, 1.00); p=0.10].  A significant 
interaction between Bortner and BDI (p=0.03) was noted though stratification by the same cut 
points of BDI as above did not yield any significant differences. Stratifying by minimal to mild 
versus moderate to severe depressive symptoms, however, demonstrated men with minimal to 
mild BDI [0.98, (0.97, 0.99); p=0.02] were protected against mortality compared to those with 
moderate to severe BDI [1.00, (0.97, 1.04); p=0.63] in multivariable analyses. 
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Out of 506 participants, there were 64 CAD-related deaths (12.6%).  We found that 
Bortner significantly predicted CAD mortality [0.99, (0.98, 1.00); p=0.04].  The analyses were 
subsequently repeated excluding non-CAD deaths from the control group (essentially comparing 
survivors to CAD death (14.3%)), and a significant relationship between Bortner and CAD death 
was found, as well [0.98, (0.97, 0.99); p=0.03]. 
  We then examined the predictive value of Bortner Rating Scale for CAD mortality in 
those with prevalent CAD.  No univariate association was found with death among those with 
CAD within 22 years of follow-up (p=0.35). 
B.4 DISCUSSION 
 We observed a significant relationship between Bortner scores and all-cause mortality, 
which was attenuated after adjustment for BDI.  We also noted the presence of significant effect 
modification of the relationship between the Bortner and mortality by BDI score. Thus, a 
borderline significant inverse association between type A behavior and mortality was only 
apparent among those in the bottom three BDI quintiles, while this relationship was lost in the 
top two quintiles.  Analyses stratifying by gender suggested that only men were protected against 
mortality with higher type A behavior score, even after adjustment for BDI.  However, 
stratifying by BDI revealed a protective effect of type A behavior only in those with minimal to 
mild, but not moderate to severe, depressive symptoms. We found a borderline significant 
relationship between Bortner scores and incident CAD, which was attenuated after adjustment 
for duration.  
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 To our knowledge, this is the first study to investigate the relationship between type A 
behavior and all-cause mortality in a T1D population.  Strengths of our study are the long 
follow-up and the completeness of data obtained for our population.  In addition to 
demonstrating the importance of type A behavior and depressive symptomatology, our results 
affirm the role traditional, important covariates play on CAD development and early mortality in 
T1D. Those with the highest type A behavior scores were at the lowest mortality risk, which is 
consistent with most of the literature demonstrating that high-risk populations are protected with 
greater type A behavior [70], [153], [171].  However, with the addition of BDI to our model, this 
relationship was attenuated.  After determining that the Bortner scale and BDI were inversely 
correlated, we tested for an interaction between them to determine if the protective effect we 
observed from high type A behavior was really due to the low depressive symptomatology score 
in this group.  The interaction term was significant, suggesting that type A behavior may be 
protective against mortality in the absence of depressive symptomatology (although this was 
only borderline significant).  Any protection from type A behavior appears to be lost once the 
higher quintiles of depressive symptomatology are reached.  This suggests that depressive 
symptomatology is a stronger predictor of mortality than type A behavior in T1D.  Indeed, the 
death rate was 17.8% in the bottom three quintiles, approximately two times higher than in the 
top two quintiles, at 34.5%.   
The importance of depressive symptomatology in T1D is expected, as it has been 
frequently demonstrated that those with high depressive symptomatology are at an increased 
mortality [91] and morbidity risk (including diabetes complications) [92]. Co-morbid depression 
and T1D is also associated with poorer diabetes self-management and metabolic control, 
decreased quality of life, and higher healthcare usage [91].  Our previous research showed that 
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BDI significantly predicted CHD even after controlling for hypertension, waist to hip ratio 
(WHR), white blood cell count, fibrinogen, smoking status, distal symmetric polyneuropathy, 
and overt nephropathy.  However, this relationship became attenuated after the addition of all 
possible variables in the mediation analysis [96].  Depressive symptomatology has also been 
found to increase WHR in both genders [97] and appears to play an important role in the 
incidence and progression of T1D associated complications, as confirmed in our study. 
We hypothesized that Bortner scores would continue to be predictive of mortality, even after 
controlling for BDI, particularly because individuals with diabetes have to adopt regimented 
control along with other characteristic type A behaviors, such as having to do many things at 
once, thinking of what they might need to do next, becoming less casual about things, and 
feeling ambitious [132].  Type A behaviors may increase the efficiency in which an individual 
cares for their T1D, therefore preventing complications and early mortality. However, depressive 
symptoms may out-weigh the significance of type A behavior, as demonstrated in our analysis.  
Adopting type A behaviors in order to better care for a chronic disease like T1D may also 
partially explain why type A behavior is protective in high-risk, as opposed to the general, 
populations.  Those with greater type A behavior in the presence of a chronic disease may treat 
symptoms and suspected complications more seriously and intensively than those characterized 
as having less type A behavior.   
Little research exists on depressive symptomatotology and subsequent risk of mortality in 
T1D. The FinnDiane Study Group concluded that in women, baseline antidepressant agent 
purchase (their surrogate marker for depression) was associated with an increased mortality risk 
over nine years of follow-up [2.15 (1.34, 3.45)] [99].  Though this association was only seen in 
women, our results demonstrate a similar relationship.  Those with increased depressive 
  130 
symptomatotology were not only at increased mortality risk, but the protection offered by type A 
behavior disappeared with increased BDI.  Depressive symptoms, therefore, appear to play a 
very important role in predicting mortality in T1D. 
Investigating the association between type A behavior and mortality by sex showed that 
the protective effects of type A behavior are only significant in men.  However, these findings 
may be partially attributable to a lack of power to detect the relationship in women as fewer 
women had a high type A score. The relationship among men remained until BDI adjustment.  
We compared those with minimal to mild versus moderate to severe depressive symptoms, and 
found only those with high type A behavior and less than moderate depressive symptoms were 
protected against mortality. 
It has been previously noted that because type A behavior questionnaires can be 
interpreted as geared toward work or competitive behaviors, men may respond differently than 
women [70].  In other words, men may feel it’s more socially acceptable, expected, and fitting of 
their traditional role to declare themselves as “very competitive, “hard driving,” and “ambitious” 
while women may not feel the pressure to fulfill that stereotype.  Therefore, our male 
participants’ responses on the Bortner scale may differ compared to women due to social norms, 
especially in 1980s when the questionnaire was completed.  At that time, if women were 
homemakers, perhaps they felt they were not facing the daily demands of a career and therefore 
had less type A responses.  This is consistent with our data as we saw a statistically higher mean 
type A behavior score in men compared to women (191.1 vs. 185.2; p<0.01).  A study which 
also administered the Bortner scale in the 1980s found that participants with no or minimal 
obstructive CAD had higher type A scores compared to those with obstructive disease.  After 
further analysis by sex, the effect was only significant in men, consistent with our findings [218]. 
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We also examined the relationship between Bortner scores and CAD as it is a major 
contributor to death.  In those free of CAD at baseline, type A behavior predicted CAD during 
22-years of follow-up, although this was of borderline statistical significance, and this 
relationship was attenuated after adjustment for duration.  Thus, we did not find that in our 
population, increased type A behavior was protective against CAD or indeed CAD death among 
those with CAD.  Other factors not measured in our study may play a role and further research is 
needed to determine which other covariates may offer protection against CAD.  Our results were 
not as hypothesized, however it should be noted that type A behavior was also not detrimental to 
the development of CAD, which supports previous research in other high-risk groups [70], [153].  
Because type A behavior was not related to CAD development, we evaluated whether mortality 
was predicted by Bortner scores based on whether the primary cause of death was CAD or non-
CAD related.  We found a significant difference between these two groups, with type A behavior 
protecting against CAD-related death, and again when comparing CAD-death to survivors only.   
A previous study by Lloyd, et al. concluded that lower type A behavior scores were associated 
with an increased macrovascular disease risk [171], however the present study is the first we are 
aware of to demonstrate that type A behavior in T1D is protective against CAD-death, 
specifically.  In a 10-year follow-up study of middle-aged, employed men, specific personality 
traits that would be considered type A did not predict CAD-death [219].  The literature 
examining the relationship between type A personality and CAD-death is limited.  Our 
remarkable finding that type A behavior is specifically protective against CAD-death merits 
further investigation. 
 Thus far, study findings examining type A behavior in T1D are conflicting and often 
focused on surrogate outcomes (such as glycemic control and complications) due to short length 
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of follow-up time.  The results of studies examining type A behavior and glycemic control were 
mixed, with some suggesting no association [75], [77], [220], others a detrimental association 
[75], [221], and another a protective association of specific type A behaviors (i.e. neuroticism) 
[82].  However, the majority of these studies were conducted three decades ago with large 
amounts of bias, which may explain why mixed results were demonstrated.  The majority of the 
previously published studies were conducted cross-sectionally, using very small sample sizes, 
and used univariate methods of analysis only. Those that utilized multivariable analyses only 
controlled for a few relevant covariates.  Lloyd et al. found that those T1D participants with 
multiple complications reported less type A behavior than those without any complications 
(p<0.05) [171].  In a separate study, it was also determined that in men, lower type A behavior 
score was predictive of an increased WHR [97].  Because type A behavior was not shown to be 
detrimental in T1D, and protective against complications as a whole and WHR, our hypothesis 
was generated that with longer follow-up, higher type A behavior may be protective against 
mortality.  Future research needs to take place to examine this relationship in other high-risk 
populations. 
Based on the literature that high-risk groups are protected by their type A behavior, we 
investigated the relationship between the Bortner Rating Scale and CAD case-fatality rate.  We 
hypothesized that in this very high-risk group of people with both T1D and CAD, type A 
behavior would be even more protective, but a relationship was not found.  This may be due to 
several reasons, one being that we may have had an insufficient sample size to find a statistically 
significant result (28 deaths/125 with CAD).   Another reason may be that these participants 
were too unhealthy to benefit from type A behavior at all, being that they have both T1D and a 
serious complication.   Another explanation may be that the type A behaviors were initiated at 
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too late a time in life, and that T1D and CAD had already done too much physical damage for 
any protective effect to take place against mortality.  Perhaps behavior type is a trait and not a 
state, and can therefore be modified.  If so, this has great implications for care as we can support 
behavior change to improve self management, improving the health of those living with diabetes. 
There were several strengths and limitations of our study.  As mentioned previously, our long 
follow-up time allowed for us to use mortality as our outcome, as opposed to a surrogate 
endpoint such as complication status.   Additionally, this was the first study to investigate the 
relationship between type A behavior and mortality in T1D, providing data where there currently 
are none.  Limitations of our study include our small sample size for detecting incident CAD 
death among those with CAD, which may have lead to null results.  Another limitation is the 
possibility of residual confounding; however, we feel we included predictors that are essential 
for investigating mortality in T1D.  Furthermore, there were up to 22 years of follow-up time 
between measuring type A behavior and mortality and/or the onset of CAD; however, we 
attempted to control for this in the analysis through use of Cox proportional hazards models. 
In conclusion, future research is needed to investigate the interaction between BDI and 
type A behavior, as the latter was only protective in those with low depressive symptomatology. 
Further research is also needed to explore the protective relationship between type A behavior 
and CAD-death. Understanding these relationships are important next steps in exploring the 
effects of psychosocial factors on mortality in T1D. 
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APPENDIX C: ADDITIONAL BACKGROUND 
C.1 MAJOR OUTCOMES OF DIABETES/NATURAL HISTORY 
The majority of this excess CVD risk seen in those with T1D is due to atherosclerosis, 
which is strongly linked to vascular health [222], [223]. Several factors may also influence 
vascular health and aging, including age, glycemic control, and autonomic neuropathy (AN).  
AN predicts both cardiovascular events and mortality in those with T1D [224]. Cardiovascular 
AN is also associated with subclinical CVD such as increased coronary artery calcium score, 
subclinical left ventricular dysfunction, and increased pulse pressure in normoalbuminuric T1D 
participants[225], as well as decreased estimated myocardial perfusion [226]. Along with AN, 
nephropathy has also been shown to be an important predictor of CAD [227]–[230].  A study by 
Zgibor et al. aimed to create a CHD risk prediction model for T1D.  They found that for males, 
predictors were higher white blood cell count, micro- or macroalbuminuira, lower HDL, and 
longer diabetes duration. For females, larger waist/hip ratio, higher non-HDL, higher SBP, use of 
blood pressure medication, and longer diabetes duration were important predictors [231].   
Research has shown that adverse changes in CVD function, arterial compliance, and 
atherosclerosis exist even in adolescence in those with T1D [232]. Carotid intima-media 
thickness (cIMT) was studied in adolescents approximately 14 years old and cIMT was found to 
be related to sex and diabetes duration but not age. cIMT was higher in males than in females, 
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and pulse pressure and duration in males and low-density lipoprotein (LDL) cholesterol, HbA1c, 
and duration in females showed a significant association with cIMT.  Therefore the T1D itself 
and other cardiovascular risk factors were determined to be important determinants of cIMT 
[233]. 
Another determinant of CVD in T1D is diet.  One study reported that dietary saturated 
fatty acid is not associated with CVD or all-cause mortality, while higher fiber consumption, 
particularly soluble fiber, may assist in the prevention of CVD and all-cause mortality [234].  
This is an important avenue for CVD prevention because diet is highly modifiable.  Other 
modifiable risk factors that may help to minimize CVD risk are rigorous management of 
glycemic control, lipids, and blood pressure [235]. 
As stated above, nephropathy is an important predictor of CVD and also mortality.  
Previous research published in 1983 showed that 83% of participants with T1D who developed 
persistent proteinuria died throughout follow-up compared with 25% of those without [236]. 
Uremia was responsible for 66% of deaths, with ischaemic heart disease and stroke accounting 
for 19% of deaths. Forty-nine percent of participants had died within 7 years of the onset of 
persistent proteinuria [236].  Another early study of people diagnosed between 1933 and 1952 
found that in participants free from proteinuria, the relative risk of mortality was approximately 
2.0 compared to a relative risk as high as 100.0 in those with persistent proteinuria.  In addition, 
life expectancy was 50% longer in those diagnosed with proteinuria in 1950 compared to 
participants diagnosed in 1935.  This was mainly due to the decreasing incidence of persistent 
proteinuria overall.  In this European population, uremia was responsible for 66% of deaths in 
those with proteinuria, with CVD being the cause of death for 23% of participants. Mortality 
from CVD was approximately tenfold higher in participants with proteinuria compared to those 
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without [237].  It is important to keep in mind, however, that both of these studies were 
conducted before the 1980s and therefore nephropathy was diagnosed late, only after the 
appearance of dipstick-positive proteinuria.  At this point, kidney damage was already severe and 
most likely irreversible [238]. 
Urine albumin excretion (UAE) began to be measured in the 1980s [239], [240], with the 
first study post-radioimmunoassay demonstrating cross-sectionally that in participants with a 
UAE rate >20 μg/min, both systolic and diastolic blood pressures were higher compared with 
those with lower levels of albuminuria/normal albumin excretion. These participants were also 
more likely to have proliferative retinopathy; however, glomular filtration rate (GFR) was 
similar and all participants demonstrated hyperfiltration. Glycemic control also did not 
significantly differ across the different UAE categories [241].   The majority of newer studies 
have demonstrated that the cumulative incidences of both persistent proteinuria and of end stage 
renal disease (ESRD) in those with a diabetes duration of 25–30 years have declined since the 
studies conducted in the 1980s [9], [242]–[246]. In slight contrast, the European Dialysis and 
Transplant Association Registry showed that there has been an increase in renal replacement 
therapy in those with T1D, however this is most likely due to the increasing prevalence of the 
disease [247].  This may be also be explained such that instead of preventing proteinuria, its 
onset is delayed through improved diabetes care [238].  However, the incidence of ESRD 
appears to be lower than that reported in the 1980s, although the difference between 
investigating centers is considerable [242], [243], [246] and the time from proteinuria diagnosis 
to ESRD or mortality has greatly improved [248], [249].  After a T1D duration of 30 years, the 
cumulative incidences of nephropathy was 25% in the DCCT conventional treatment group, 17% 
in the EDC cohort, and 9% in the DCCT intensive therapy group [129].  Therefore, it may be 
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that incidence is not increasing, however life expectancy is and therefore the prevalence of those 
with diabetes living with ESRD is higher.  The delay and prevention of microalbuminuria has 
also improved over time with the use of intensive glucose management. The regression from 
microalbuminuria back to normal albumin excretion is much higher than in previous decades and 
the progression to proteinuria has decreased, as well [250], [251].  There is also evidence that 
proteinuria may regress to microalbuminuria most likely following improvements in blood 
pressure control and LDL-c [252], [253]. The EDC study also demonstrated that lipid 
abnormalities and hypertension accelerate nephropathy [254], and the FinnDiane study group 
also found that lipid abnormalities predicted renal progression [255].  In addition, the 
progression to nephropathy may also be due in part to genetics [256].  In diabetic mice, it has 
been shown that the reduced local production of glomerular vascular endothelial growth factor A 
(VEGFA) promotes endothelial injury, which in turn prompts the progression of glomerular 
injury. Therefore, perhaps the upregulation of VEGFA in the kidneys of those with T1D protects 
the microvasculature from injury. It is reasonable to conclude that a reduction of VEGFA  may 
be detrimental in those with T1D [257]. 
Evidence is conflicting on whether or not the development of hyperfiltration and 
microalbuminuria necessarily lead to ESRD in those with T1D.  A meta-analysis of 10 small 
studies demonstrated that the presence of hyperfiltration increased the risk of developing micro- 
or macroalbuminuria by two-fold [258], while a study involving follow-up at the Joslin Clinic 
demonstrated no increased risk of progression to microalbuminuria with the presence of 
hyperfiltration [259]. The FinnDiane study has recently shown that participants with 
hyperfiltration were not more likely to progress to microalbuminuria than those with normal 
GFRs [260].  One explanation for this may be that currently, only a small number of patients 
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have chronic hyperglycemia and all patients in their Finnish population have access to insulin 
and glucose monitors.  Perhaps the clinical situations that previously demonstrated 
hyperfiltration in those with diabetes are no longer prevalent [260]. Therefore it may be more 
important to monitor and control HbA1c and lipid levels, rather than hyperfiltration, in order to 
prevent the progression of kidney disease [260]. 
Neuropathy, defined as “the presence of symptoms and/or signs of peripheral nerve 
dysfunction in people with diabetes after the exclusion of other causes” [261], is one of the most 
frequent, major complications of diabetes and is the main cause of foot ulceration, Charcot 
neuroarthropathy, and lower-extremity amputation (LEA) [262]. In a study by Cusick et al., 
amputation was determined to be the strongest predictor for mortality out of all complications, 
and there was also an increased risk of mortality as each individual neuropathy-related 
complication worsened [263]. In another study, a 23-fold increased risk of LEA was found in 
those with T1D and T2D compared to the general population, with 49% of all LEAs having 
occurred in those with diabetes [264], [265]. Three large studies done in Europe found that the 
prevalence of diabetic polyneuropathy was between 23 to 29% in their populations including 
both T1D and T2D [266]–[268]. In the Bypass Angioplasty Revascularization Investigation in 
Type 2 Diabetes (BARI 2D) study of patients with T2D and heart disease, the prevalence of 
peripheral neuropathy was found to be 51% [269]. Diabetes-related amputation rates appear to 
differ by region, as demonstrated by a US study performed, adjusting for age, sex, and race 
[270], and these results were confirmed a decade later in a separate US study [271].  Two 
English studies of LEA found regional variations, as well, which is an important addition to the 
literature as their health care coverage is universal unlike the US [265], [272].  
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Many factors, including disease severity, co-morbidities, social and individual patient 
factors, access to and quality of primary care, referral delays, and availability of specialist 
resources, influence the decision of whether or not to amputate as well as the risk of amputation 
[273].  Another risk factor for amputation in addition to diabetes itself is peripheral artery disease 
(PAD).  In those with PAD, infection was a specific predictor of non-healing, which differed 
from those without PAD [274]. Another study found that primary healing of a foot ulcer was 
related to co-morbidity, diabetes duration, extent of peripheral vascular disease (PVD), and the 
type of ulcer present. In those participants with neuropathic ulcers, deep foot infection, site of 
ulcer, and co-morbidity were related to risk of amputation. In those with neuroischemic ulcers, 
co-morbidity, PVD, and type of ulcer present were related to the risk of amputation. This study 
demonstrated that co-morbidities including the prevalence of multiple diseased organs led to an 
increased risk of amputation in those with diabetes [275]. 
The International Consensus on the Diabetic Foot (ICDF) was implemented in order to 
improve the care of patients with foot ulcers and other complications [276].  A study investigated 
the rates of LEAs over a five year period of time and found that while non-diabetes related LEA 
rates increased, major diabetes related LEA rates had fallen. This also demonstrates an 
improvement in care of foot disease in those with diabetes due to improved care [277]. The 
ICDF also implemented a group to investigate the effectiveness of revascularization, and found 
that studies demonstrated improved rates of limb salvage associated with revascularization 
compared with those without revascularization. However, the number of studies and information 
provided thus far in the literature is lacking such that they were unable to recommend a best 
method of revascularization [278]. Another improvement in care has resulted from the creation 
of the foot risk classification of the International Working Group on the Diabetic Foot [279].   
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The highest prevalence of neuropathy is in those with poor blood glucose control, 
measured by HbA1c, offering another area for its potential prevention [280].  Both T1D and T2D 
neuropathy were investigated in a review and were found to differ in regards to prevention 
efforts. In T1D, glucose control was successful in preventing neuropathy; however, in T2D, 
glucose control had a small effect on neuropathy prevention [281]. In 2011, the Experimental 
Diabetes Research journal featured articles related to autonomic neuropathy in hopes of drawing 
attention to this important and frequently-occurring complication and to encourage its screening 
by physicians [282]. 
Painful diabetic neuropathy (PDN) is responsible for substantial morbidity and, through 
the American Academy of Neurology, evidence-based guidelines have been made available for 
its management [283]. A large, observational study of patients with diabetes in northwest 
England were assessed for PDN using both the neuropathy symptom score (NSS) and the 
neuropathy disability score (NDS) [284]. The study found a prevalence of painful symptoms 
(NSS ≥5) and PDN (NSS ≥5 and NDS ≥3) was 34% and 21%. In 26% of patients without 
neuropathy (NDS ≤2), painful symptoms occurred, and these symptoms occurred in 60% of 
patients with severe neuropathy (NDS >8). The authors adjusted for severity of neuropathy, foot 
deformities, smoking, alcohol, and insulin use and found that the risk of painful neuropathic 
symptoms in T2D was double that compared to those with T1D.  They also found a 50% 
increased adjusted risk of painful symptoms in women compared with men [284]. 
New methods for detecting neuropathy have been developed over the years, one of the 
most popular being the Michigan Neuropathy Screening Instrument (MNSI) for measuring distal 
symmetrical peripheral neuropathy (DSP).  The DCCT/EDIC confirmed that the MNSI is a non-
invasive, valid, and effective measure of DSP in those with T1D. They also noted the benefit of 
  141 
altering the cut point to define an abnormal test from ≥ 7 abnormal to ≥ 4 abnormal items on the 
questionnaire portion completed by participants.  This appears to improve the effectiveness of 
the MNSI questionnaire [285]. In contrast, not all recommend the use of the MNSI for diagnosis 
of diabetic neuropathies [286].  Other methods for detecting neuropathy, specifically DSP, 
include the Vibratron II, NC-stat(®), and Neurometer(®), and two clinical protocols: the 
monofilament, and as discussed above, the MSNI.  These methods are useful in identifying those 
with DSP, as well as those at risk for amputation, ulcer, and neuropathic pain. The EDC study-
Pittsburgh found that the Vibratron II and MNSI demonstrated the highest sensitivity for DSP 
and pain related to neuropathy, whereas the monofilament had the highest specificity for both as 
well as the highest positive predictive value.  However, it also had the lowest sensitivity. The 
MNSI demonstrated the highest negative predictive value and Youden's Index and therefore 
currently demonstrates the best combination of sensitivity and specificity of DSP in those with 
T1D [287].  The NC-stat is a point-of-care device and performs standard, noninvasive nerve 
conduction studies.  These studies do not require technical personnel.  Nerve conduction velocity 
has proven to be the best predictor of polyneuropathy in those with diabetes, particularly the 
sural sensory study component of the test [288]. 
Retinopathy in those with T1D is a prevalent cause of visual impairment and eventual 
blindness,[289] with it remaining a leading cause of blindness in many countries [290].  Among 
those living with diabetes worldwide, over one-third are living with retinopathy [291], with 
proliferative retinopathy being the most common visually impairing lesion in T1D [292].  In a 
recent meta-analysis using population-based studies from 35 separate countries, it was found that 
77% of those with T1D have some form of retinopathy, while 32% have proliferative retinopathy 
and 14% have diabetic macular edema [291]. At the 25-year follow-up of the Wisconsin 
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Epidemiologic Study of Diabetic Retinopathy (WESDR), the T1D cohort demonstrated that 97% 
of participants had developed retinopathy, 42% developed proliferative retinopathy, 29% 
developed diabetic macular edema, and 17% developed a more serious case of macular edema 
[293], [294].  There is some evidence, however, that the prevalence and incidence of severe 
retinopathy is decreasing in the more recently diagnosed T1D cohorts [295]. 
  Screening has become a very important avenue for prevention and treatment [296]–
[299], as retinopathy can progress with few visual symptoms [295]. It is also well known in the 
literature that regular dilated eye exams are important for not only detecting retinopathy, but in 
treating it as well [290].  The regularity of these exams should be individualized, with those at 
higher risk (e.g. with a longer duration of T1D) seen more frequently.  This should occur even in 
those without prevalent retinopathy [300]. Fractal analysis has already been utilized in many 
branches of medicine to characterize the geometric complexity of blood vessels, and “[t]he 
geometric complexity of the retinal vasculature can be quantified through calculation of fractal 
dimension from digital retinal images” [301]. A recent advancement in fractal analysis has been 
displayed by a study in Australia, showing that retinal fractal dimension (measured using the 
fractal analysis via a computer-based program) is independently associated with early 
retinopathy signs in those with T1D and therefore performing fractal analysis on fundus 
photographs appears to show early microvascular damage of the eyes [301].  A study used focus 
groups to attempt to better understand the barriers to undergoing these retinopathy screenings, 
and found that patients not attending screenings differed from those that did in that they had 
lower levels of education, a more recent diagnosis of diabetes, and they less frequently used 
insulin. Patients that attended screenings more often reported 'knowledge of detrimental effects 
of retinopathy on visual acuity', 'sense of duty' and 'fear of impaired vision' as their main 
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incentives to attend [302]. The main barrier determined was the absence of a recommendation by 
a health-care provider [302], which is a very modifiable barrier and should be addressed by those 
working in the clinical setting. 
A recent study investigating specific risk factors for development and progression of 
retinopathy using a risk model found that along with duration of T1D, high HbA1c was a 
significant independent predictor for reaching a treatment end-point [303]. Therefore, this further 
demonstrates that the lowering of blood glucose can slow the progression of retinopathy[304] 
and confirms the results found in the UKPDS and DCCT [305].  The DCCT found that for each 
percent reduction in HbA1c, there was a reduced risk of retinopathy of 30-40% [306].  Another 
important risk factor for retinopathy in those with T1D is increased blood pressure [300].  A 
European study investigating the effect of lisinopril on retinopathy in those with T1D found that 
treatment with a blood pressure lowering agent decreased retinopathy progression, however this 
only occurred in those where nephropathy was limited [307].   
Inflammatory factors may also play a role in the progression and severity of retinopathy 
[308].  Multiple studies have demonstrated raised levels of inflammatory proteins in the vitreous 
and the serum of T1D patients with retinopathy [309]. Treating this inflammation has been 
explored in clinical trials, with one study using intravitreal administration of corticosteroids and 
finding a reduced progression of diabetic macular edema and the improvement or at least 
stabilization of visual acuity.  Unfortunately, these positive results are usually accompanied by 
the steroid-related adverse events [295].  In a very recent study, the DCCT found that increased 
levels of both AGE-LDL and oxidized LDL in immunocomplexes are associated with increased 
progression to advanced retinopathy in T1D [310]. Another, although unmodifiable, risk factor 
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appears to be puberty, specifically the length of the prepubertal duration [311]. However, the 
literature is inconclusive thus far on the subject and further research is needed. 
Not only does retinopathy cause visual impairment and blindness, but it is also a marker 
of other complications [295], including nephropathy [312]. In the EURODIAB IDDM 
Complications Study, they found that the prevalence of macroalbuminuria for patients with no 
retinopathy was 1.6%, non-proliferative retinopathy was 9.0%, and proliferative retinopathy was 
34.0% [313].  A separate study found that nephropathy occurred almost 3 times more often for 
patients with proliferative retinopathy at baseline, compared to those free of the complication 
[314]. The presence of retinopathy is also a marker for increased risk of systemic vascular 
complications [315]. A double to triple risk of stroke, CHD, and heart failure are also seen in 
conjunction with retinopathy [316]–[318].  Although many complications are associated with the 
presence of retinopathy, it is not as likely that retinopathy is the cause, but rather that it is a sign 
of existing damage in the microcirculatory system and organs. 
Damage in the circulatory system causes an increased risk of another serious 
complication, as well: CBVD, which has long been established for people with diabetes [319]–
[322].  This risk of stroke has been associated with changes in the cerebral vessels of people with 
diabetes [323].  The Nurses’ Health Study found that participants with T1D had a six-fold risk of 
stroke compared to participants free of diabetes.  Specifically, risk of thrombotic stroke was eight 
times higher and 4.5 times higher for hemorrhagic stroke in those with T1D [324]. The 
pathophysiology of CBVD in those with diabetes is not fully understood, but all blood vessels 
appear to be affected by the disease. Possible causal mechanisms may involve “excess glycation, 
endothelial dysfunction, increased platelet aggregation, impaired fibrinolysis, and insulin 
resistance” [324].  A study done in the UK also found an increased risk of fatal and non-fatal 
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stroke for those with T1D, with men having an almost fourfold risk compared to participants free 
of diabetes, and women having an almost fivefold risk [325].  A Swedish study wished to focus 
specifically on individuals between 15-49 years of age (a somewhat younger age group) admitted 
to the hospital due to their T1D.  They investigated whether or not this had an impact on 
premature non-fatal or fatal stroke.  They also investigated whether the premature stroke risk was 
due to being admitted for diabetes complications [326].  Investigators found that those in the 15–
49 age group at first hospital admission for T1D had a higher risk of premature stroke than those 
not admitted to the hospital. Both men and women with nephropathy had the highest SIRs of 
premature stroke. 
A large mortality study in the UK [65] confirmed the findings from the World Health 
Organization multinational study of vascular disease in diabetes, which demonstrated a raised 
CBVD mortality in those with T1D (however, the WHO had seen considerable variation between 
the different countries) [327].  The UK study found that CBVD mortality was raised not only in 
older T1D patients, but within all age groups in their population [65].  Younger age groups have 
been a focus of CBVD research in those with T1D, and pediatric case-reports have been studied, 
as well.  Pediatric incidents of stroke largely go undiagnosed, however there is evidence that 
ketoacidosis in T1D may be a risk factor for pediatric stroke, as well as stroke later in life [328].  
More research utilizing population-based study designs is needed to make any firm conclusions. 
Many risk factors for CBVD are now known for those with T1D.  A meta-analysis of the 
literature regarding glycemic control and risk of CBVD found that that improved glycemic 
control resulted in substantial reductions in CBVD risk in those with T1D [329].  This meta-
analysis therefore further demonstrates the importance of tight glycemic control in those with 
T1D in order to assist in preventing macrovascular events.  A study performed on a population in 
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Australia did not find a difference in HbA1c levels, however they had a small number of events 
and this was likely responsible for the null result.  Even with their small sample size, however, 
they found a strong association between low serum HDL-c and ischaemic stroke in their patients 
without a CBVD background [330].  A larger study found that there is an important risk profile 
that exists for those with T1D compared to those without, specifically that those with T1D were 
more likely to have hypertension and small-vessel disease [331]. Also, those with T1D had 
increased CAD and PAD compared to those free of T1D.  Lastly, the study authors found that 
the cumulative recurrent ischemic stroke rate after 10 years of follow-up was 40.9% [331].   
A recently published study investigating the predictors of stroke, as well as the survival 
afterwards in those with T1D, found that non-HDLc, diabetes duration, and kidney damage and 
disease were very strong predictors of stroke overall [13]. For ischemic stroke, duration, non-
HDLc, WBC count, pulse, and overt nephropathy were all significant predictors, and for the few 
participants with haemorrhagic stroke, duration, HbA1c, and DBP were important predictors 
[13].  Study authors also found that the only significant predictor of fatal stroke was HbA1c, and 
that the overall median survival time after a participant had undergone an incident stroke was 3.8 
years.   Along with glycemic control, research has demonstrated that control of lipids, 
hypertension, and prevention of renal damage are especially important in stroke prevention, as is 
the monitoring of CVD on both a large-vessel and small-vessel level as those with T1D have a 
much shorter median survival after stroke compared to the general population [332].  cIMT may 
be a useful tool for predicting stroke in those with T1D [333], however these data are currently 
limited and future studies would be especially useful.   
In conclusion, those with T1D suffer from a number of temporary and chronic 
complications.  The importance of treating prevalent complications as intensely as possible in 
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order to prevent other complications from occurring should be emphasized in the clinical setting.  
Also, many modifiable covariates are precursors to many of the major complications, including 
HbA1c, blood pressure, lipid levels, and inflammation as discussed above.  Tight control of 
blood glucose levels appears to be beneficial in the majority of situations and HbA1c targets 
should continue to be encouraged by physicians and met by patients.  Also, the presence of renal 
damage appears to be an important risk factor for several of the T1D related complications and 
testing of patients’ urine should be done frequently by physicians and hospitals.  Screening and 
treatment for the risk factors of these complications, as well as for the complications themselves, 
will continue to improve the early mortality that is potentially associated with living with T1D. 
C.2 PHYSIOLOGICAL RISK FACTORS 
Until the DCCT, there was a lack of conclusive evidence from clinical trials that lowering 
HbA1c would in turn lower the development of chronic T1D complications [334]–[336]. The 
DCCT randomized participants to either intensive blood glucose therapy or conventional 
therapy. The intensive therapy group used three or more daily insulin injections or treatment with 
an insulin pump in order to achieve normal values while the conventional therapy group utilized 
one or two insulin injections per day [68]. The intensive therapy group aimed to fall within the 
normal range of HbA1c, which was defined as less than 6.05%.  Those in the intensive group had 
an average HbA1c of approximately 7.0% over the course of the study, while the conventional 
treatment group had an average HbA1c of approximately 9.0%.   
While there were many positives to being intensively treated, there were statistically 
significant differences in adverse events between the two groups based on the treatment regimen.  
  148 
There was a higher risk of severe hypoglycemia with intensive therapy, but this group did not 
experience differences in neuropsychological functioning or quality-of-life. Weight gain was 
also an issue within the intensive therapy group. At five years, patients receiving intensive 
therapy had gained a mean of 4.6 kg more than patients receiving conventional therapy [68].  
Very importantly, however, the intensive therapy group delayed the onset as well as slowed the 
progression of retinopathy, nephropathy, and neuropathy between 35-70% compared to the 
conventionally treated group.  Early worsening of retinopathy was seen in the DCCT as well, 
however they demonstrated that this worsening is temporary and intensive treatment is protective 
after longer follow-up.  The DCCT was not able to offer a specific target HbA1c value, but 
advised getting patients as close to the normal range as possible while ensuring their safety and 
protection against frequent hypoglycemic events [68]. 
Glycemic control is extremely important, and in turn so is the self-monitoring of blood 
glucose levels.  Previous research has demonstrated that self-monitoring of blood glucose is 
associated with improved glycemic control [337]. An additional important issue in monitoring 
and controlling HbA1c involves the use of continuous glucose monitoring.  Continuous glucose 
monitoring offers detailed information regarding the direction, magnitude, duration, frequency, 
and causes of fluctuations in blood glucose levels in those with T1D. An additional asset of the 
continuous glucose monitor is the frequent readings, which supply trend information.  These 
trends can help identify and therefore prevent periods of hypoglycemia and hyperglycemia [338]. 
A recent meta-analysis aimed to establish the how effective real time continuous glucose 
monitoring was compared with self monitoring in those with T1D [339].  The investigators 
found that the key determinants of HbA1c level included baseline HbA1c, age, self monitoring, 
and frequency of sensor usage.  Importantly, they also determined that there was an overall 
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reduction in HbA1c of 0.30% among those utilizing continuous glucose monitoring compared to 
self monitoring [339]. Those with the highest HbA1c at baseline and who used the sensor the 
most frequently benefitted the most.  There was however, no difference in the rates of 
hypoglycemia between the two monitoring groups.  Continuous glucose monitoring was 
therefore effective in reducing HbA1c compared to self-monitoring.  The clinical implications of 
this analysis are significant, because the cost effectiveness of continuous glucose monitoring is 
now available for calculation for several patient groups based on their HbA1c, sensor usage, and 
age [339]. A very recent article highlights the improvements made to the continuous glucose 
monitor using real-time algorithms, and demonstrated that these algorithms enhance the monitors 
and show clinical importance for hypoglycemic and hyperglycemic alert generation [340]. 
HbA1c is a very important risk factor for complications and early mortality in those with 
T1D.  Elevated HbA1c levels, particularly those maintained over time, predict an increase, 
sometimes drastically, of chronic T1D complications [121]. Key clinical trials have 
demonstrated the importance of tight regulation of HbA1c in the reduction of these 
complications, and advances in technology have allowed for close monitoring of daily blood 
glucose levels.   
Another essential physiological risk factor for those with T1D are lipid levels [341].  
Abnormal lipid levels have been shown to be very important in predicting CAD, specifically in 
those with T1D [342], [343].  Those with T1D experience glycemia, and in turn oxidative stress 
which ages the vessels, and therefore the effects of abnormal lipids become apparent at younger 
ages in this group.  When those with T1D do have higher lipid levels, they appear to be at a 
greater risk of atherosclerosis and eventual CAD than the general population with the same lipid 
levels [344].  Also importantly, young T1D patients who have not yet developed complications 
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are the least likely to be treated for their high cholesterol [345], which may put them at risk of 
complication development/more rapid complication progression.  HbA1c plays an important role 
in the development of abnormal lipid levels.  One study found that among their patients not on 
dyslipidemia medication, a higher HbA1c was significantly related to worse lipid levels except 
for HDL-c. The associations between HbA1c and any lipid levels among those on dyslipidemia 
medication were in the same direction, but became insignificant when the investigators 
compared these patients with those on no dyslipidemia medication [346]. 
As discussed above, tight glycemic control is beneficial in preventing T1D 
complications, however, with tighter glycemic control often comes with weight gain.  Whether 
this weight gain associated with glycemic control in the DCCT is related to an increase in lipid 
levels was investigated [347]. The study demonstrated that intensive blood glucose therapy 
resulted in similar control in each of the weight gain quartiles. Improvements resulting from the 
intensive therapy were counterbalanced by the weight gain, and they found that the first quartile 
of weight gain did not significantly experience a change in weight during the study and therefore 
had improvements in triglyceride, total cholesterol, and LDL-c levels compared with their 
baseline values. Therefore, without weight gain, improved HbA1c control resulted in improved 
lipid levels. However, those in the fourth quartile (the only quartile in the obese BMI range) 
experienced a significant worsening of lipid levels compared with their baseline measures [347].  
Therefore, it appears that intensive glycemic control is beneficial for lipid levels when 
participants are not gaining excessive amounts of weight due to the therapy.  Once an excessive 
amount of weight is gained, however, it seems it is important to re-evaluate tight glycemic 
control as the weight of the person alone can increase their risk for complications, rendering the 
intensive treatment unbeneficial or even harmful.  A similar subject yielded the same results: 
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when predicting insulin resistance, WHR is of particular importance along with lipid levels, 
hypertension, glycemic control, and family history of T2D [348].  Thus, these results reiterate the 
relationship between weight and lipids in predicting health outcomes. 
In SEARCH, investigators studied the effects of lipid levels in youth with T1D and 
compared them to the mean lipid levels among control subjects, youth with T1D with optimal 
HbA1c (<7.5%), and youth with less than optimal HbA1c (≥7.5%) after adjusting for age, sex, 
race and ethnicity, and BMI [349].  The investigators found that in those with T1D and relatively 
short disease duration of about 4 years, mean lipid levels and prevalence of specific lipid 
abnormalities were significantly influenced by HbA1c level. Those with T1D and optimal 
HbA1c had similar lipid profiles and sometimes even better profiles than the control participants. 
However, youth with T1D and less than optimal glycemic control had higher lipid levels and a 
greater prevalence of lipid abnormalities than the controls. Overall, the study demonstrated that 
youth with T1D have significantly elevated apoB levels and more small, dense LDL particles 
than the control group, regardless of their HbA1c level [349]. Further evidence has demonstrated 
that increased lipid levels, specifically total cholesterol and non-HDL cholesterol, may be 
associated with an increased albumin-to-creatinine ratio (ACR) [350]. Another interesting 
finding is that parental lipid levels are associated with increased lipid levels in youth with T1D, 
however whether this is the result of genetics, a shared environment, or most likely, a 
combination of both has not been teased out [351].  This has significant clinical implications, and 
perhaps monitoring lipids in T1D youth with parents who have high lipid levels may be 
important in reducing complications later in life. 
Lipid levels play an important role in the development of complications [344] and risk 
factors [350] in those with T1D not only in adult patients, but in youth, as well.  Close 
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monitoring and control of lipid levels [352] along with HbA1c serves to further prevent the 
development or worsening of T1D related complications.  This is especially important as those 
with T1D may have the same lipid levels as the general population, yet experience an increase in 
detrimental effects. 
Hypertension has detrimental effects on those with T1D, as well.  The EDC study found 
at their 10-year follow-up that a systolic blood pressure (SBP) of 110 mmHg was predictive of 
CAD and a diastolic blood pressure (DBP) ≥80 mmHg was predictive of total mortality, lower-
extremity arterial disease (LEAD), and proliferative retinopathy (PR) [352].  Recent work 
published from the EDC study demonstrated that participants who subsequently developed 
hypertension after being free of it at baseline were older and had elevated baseline blood 
pressure (BP), non-HDL-c, AER, and WBC count compared to those who remained 
hypertension free. Similar results were also found in the DCCT/EDIC study where they 
demonstrated that higher HbA1c increased the risk for incident hypertension. Also, older age, 
male sex, family history of hypertension, greater baseline BMI, weight gain during the course of 
the study, and increased AER were all independently associated with an elevated risk of 
hypertension in this population [353]. 
The prevalence of hypertension is related to the development of numerous complications 
in those with T1D.  Ambulatory blood pressure measurements (ABPM) were found to be 
significantly related to ACR both cross-sectionally and longitudinally [354].  Specifically, DBP 
during the day was independently associated with the progression to microalbuminuria.  As 
discussed above in the complications section, microalbuminuria precedes many chronic T1D 
complications, and monitoring BP may be an important way to screen for those at greatest risk of 
developing microalbuminuria.  A separate cross-sectional study found that in those with T1D, 
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SBP and DBP during sleep were higher in microalbuminuric than in normoalbuminuric 
participants or in the control group [355]. This demonstrates that not only is daytime BP 
important, but a rise or steady state during the night (known as non-dippers) is associated with 
microalbuminuria, as well.  Non-dipping was also shown to be independently associated with 
proteinuria in the EDC study, involving associations with LDL-c and hypertension [356]. The 
relationship between BP and nephropathy has been confirmed in a prospective study from the 
DCCT/EDIC group in which study investigators demonstrated that both SBP and DBP are 
associated with the development of nephropathy [357].  A clinical trial, published in the New 
England Journal of Medicine, demonstrated that the antihypertensive used, captopril, in their 
treatment group significantly reduced the rate of renal function decline in those with T1D and 
nephropathy. In the antihypertensive group, there was an almost one half reduction in the risk of 
a doubling of the serum creatinine concentration. This was also seen regarding the combined risk 
of death, dialysis, or transplantation [358].  The investigators concluded that the decrease in 
proteinuria can be explained by a favorable effect of the antihypertensive on glomerular 
hemodynamics and glomerular pathology [358].  Unfortunately, the effects of blood pressure on 
the development of microalbuminuria have been prospectively demonstrated in youth with T1D, 
as well [359]. 
Closely tied in with hypertension is another risk factor, smoking.  Cigarette smoking has 
been shown to be associated with arterial stiffness indexes, specifically in those with 
hypertension [360]. The EDC study found that along with cardiovascular autonomic neuropathy, 
low HDL cholesterol and cigarette smoking were predictive of increased arterial stiffness 
indexes [361]. A review of the literature regarding smoking and diabetes found that smoking 
predicts the onset and progression of nephropathy in those with T1D [362].  T1D smokers were 
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also shown to have increased frequency of microalbuminuria and poorer kidney function.  They 
also had worse glycemic control and an increased frequency of retinopathy [362].  Since 
smoking is a modifiable risk factor, clinicians should be sure to discuss smoking cessation with 
their T1D patients.  
Hypertension and smoking are other important physiological risk factor that put those 
with T1D at an increased risk for the development of complications and even early mortality.  It 
appears that they play a very important role in the development of CAD, both fatal and non-fatal, 
as well as a decline in renal function.  Both CAD and nephropathy are serious T1D 
complications that increase the risk of death and can also negatively affect the quality of life.  
Hypertension and smoking in those with T1D should be screened for regularly and treated in 
order to reduce its impact on complication development and early death. 
Briefly mentioned above, inflammation is another unfortunate consequence of living with 
T1D, and its presence puts patients at an increased risk of complications and early death.  A 
group of participants with T1D, free from macrovascular disease and other major complications, 
were compared to age and sex-matched controls in order to investigate whether inflammation 
was higher due to having T1D itself and not due to having accompanying complications.  
Investigators found that high-sensitivity C-reactive protein (hsCRP), soluble CD40 ligand 
(sCD40L), soluble intracellular adhesion molecule (sICAM), soluble E-selectin (sE-selectin), 
soluble P-selectin (sP-selectin), nitrotyrosine, and interleukin-6 (IL-6)  levels (all markers of 
inflammation, oxidative stress, and monocyte function) were significantly increased in subjects 
with T1D compared with that of control subjects [146].  None of these inflammatory markers 
were significantly correlated with glycemic control or BMI.  This study provided important 
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information, because inflammation and oxidative stress appear to be elevated even in those T1D 
participants free from macrovascular disease. 
Not only does inflammation occur as a result of having T1D, but it seems to be present 
even before onset of disease [363].  The combination of islet cell antibodies and inflammation 
can predict who becomes a patient with T1D, thus inflammation plays a very important role in 
the disease.  Inflammation also can be triggered and cause further vascular damage through 
hypoglycemia.  In both people with and without T1D, hypoglycemia results in elevated levels of 
inflammatory markers [364].  Inflammation may therefore be an important mechanism in which 
hypoglycemia causes damage to the vascular system.  Other components of T1D, besides the 
T1D itself, influence inflammation levels, as well.  Because endothelial dysfunction and 
inflammation are some of the first steps in the process of atherogenesis, which is largely 
responsible for the development of ischemic heart disease and thrombotic strokes, it is 
imperative to understand what causes them to occur/ accelerates them.  YKL-40, a marker of 
inflammation and endothelial dysfunction, has been measured in those with T1D versus those 
without.  Investigators found that YKL-40 was higher in those with T1D than in those without 
[365].  Interestingly, after multivariable analysis YKL-40 levels were significantly associated 
with level of albuminuria. Investigators demonstrated a significant association between YKL-40 
levels and increasing levels of albuminuria to the level of microalbuminuria, however no 
difference was found between those with microalbuminuria versus those with macroalbuminuria 
[365]. In a Finnish study, both CRP and IL-6 increased as level of albuminuria increased, as 
well.  In this study however, there was also a difference in the marker levels between the 
microalbuminuria and macroalbuminuria groups [366].  A separate study also found a significant 
increase in CRP, nitrotyrosine, vascular cell adhesion molecule, monocyte superoxide anion 
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release, and interleukin-1 release in participants with both T1D and microvascular disease 
compared with those with T1D [367]. Based on the results of these studies, low-grade 
inflammation and endothelial dysfunction appear to be very closely linked, with each affecting 
one another, and therefore each should be treated as a risk factor for both micro- and 
macrovascular disease. 
The DCCT/EDIC group also wished to investigate the role inflammation plays in the 
development of complications, and therefore studied C-reactive protein and fibrinogen, soluble 
vascular cell adhesion molecule-1, intracellular adhesion molecule-1, and E-selectin, and 
fibrinolytic markers mainly cross-sectionally [150].  They found that fibrinogen was the marker 
most strongly associated with the progression of both internal and common carotid IMT, and that 
sE-selectin was the marker most strongly associated with nephropathy.  The authors stress the 
clinical implications of their findings, in that they are predictors of future complications and 
hopefully therefore interventions can take place.  sE-selectin has been demonstrated to be 
predictive for soft CAD in the EDC study [368], demonstrating its possible relationship with 
other complications, as well. 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been recently studied regarding 
inflammation as well, and functions as “an enzyme produced by macrophages in advanced, 
rupture prone, atherosclerotic plaques. It circulates bound primarily to lipoproteins in the plasma 
and hydrolyses oxidized LDL generating two proinflammatory mediators, oxidized free fatty 
acids and lysophosphatidylcholine” [369]. Because of the interaction with LDL particles, it is 
plausible that Lp-PLA2 may be directly involved in producing atherosclerotic lesions [370].  The 
EDC study investigators found that those T1D participants with proteinuria, with the highest Lp-
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PLA2 activity and the highest levels of CRP, were almost three times more likely to develop 
CAD than those participants with the lowest levels in each group [369].  
In conclusion, elevated levels of HbA1c, lipids, BP, and inflammation all detrimentally 
affect those with T1D both on their own and in conjunction with one another.  The literature has 
demonstrated that all of these physiological risk factors put individuals at a high risk of 
developing complications, as well as further progressing existing complications.  The one 
positive, however, is that each of these risk factors can serve as a measure of current or future 
organ damage and are therefore clinically important.  Elevated levels of all the risk factors 
should be treated seriously and monitored closely in order to prevent the further progression of 
complications, or even their incidence all together. 
C.3 DIABETES CARE 
T1D care, including glucose monitoring and new methods of drug administration such as 
the insulin pump, have improved over time [371].  Major advances in the care of T1D include 
the development of quick-acting and long-acting insulins, as well as improved methods for 
monitoring blood glucose and improved methods for checking blood glucose levels [372].  
Before the discovery of insulin in 1921, T1D patients died within just a few years beyond their 
diagnosis [372]. Although insulin is not considered a cure, its discovery was the first major 
breakthrough in diabetes treatment. The DCCT was the first study to exhibit the importance of 
A1c control.  They demonstrated that keeping blood glucose levels as close to normal as can be 
achieved delays the onset as well as the progression of retinopathy, nephropathy, and neuropathy 
caused by T1D [373]. Investigators also demonstrated that any sustained lowering of blood 
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glucose is beneficial even with a history of poor control [373].  Previous research has also 
demonstrated that self-monitoring of blood glucose is associated with improved glycemic control 
[337]. In more recent diabetes care news, a study demonstrated that continuous subcutaneous 
insulin infusion resulted in higher quality of life in children and adolescents with T1D [374]. 
However, further improvements in the prevention of acute and chronic comorbidities through 
increased education and involvement of patients as well as providers is needed.  The EDC study 
found that awareness of hypertension and hypercholesterolemia increased as their study 
progressed, but that there was little improvement in their treatment or control [345].  This was 
particularly noted in the younger age-groups. Clear guidelines are lacking for treating lipid 
problems in young adults with T1D, and this is likely partially responsible for the findings. 
Based on the increased risk of chronic complications resulting from hypertension and 
hyperlipidemia, the investigators note the magnitude of importance (e.g., only 32.1% of those 
with hypertension in 1986-1988 were controlled and only 28% in 1996-1998, while the rates 
were 0% for those with hypercholesterolemia in 1986-1988 and 5.5% in 1996-1988) that should 
be placed on interventions to treat these conditions in all age groups [345].  It also appears that 
those T1D patients who are diagnosed and being treated for hypertension and hyperlipidemia are 
also being treated for a chronic complication, meaning that because of care provided for their 
complication, screening and treatment for these two disorders was done more frequently than in 
those complications free.  The focus should be on screening for and treating these conditions 
earlier, before these complications develop. 
 A variety of barriers to care has been thoroughly discussed, and can be 
summarized in the following diagram (Figure 8 [375]). 
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 Figure 8: External barriers to care, health care utilization, and outcomes 
In this T1D population, there are several aspects of care that play important roles, and 
combined, can lead to the occurrence of both short-term and long-term complications when 
prevention and/or adherence to treatment guidelines are lacking. 
Caring for a chronic disease such as T1D is not only a physical burden, but is an 
economic burden as well.  The literature has demonstrated that pediatric patients with T1D and 
good glycemic control have lower costs related to diabetes care spending than those with poor 
glycemic control [376], [377]. This is due to fewer hospitalizations because of ketoacidosis and 
other acute T1D complications, therefore decreasing costs.  A US study of pediatric patients, 
with reimbursed costs obtained from January 2004 to December 2005, found that the total 
diabetes-related costs averaged approximately $4,730 a person. Ten percent of total costs went 
towards diabetes education and ambulatory care, while diabetic supplies and medications 
accounted for a combined 71%. Hospitalizations were 15% of the cost while medication costs 
were the highest for patients on multiple injections while supply costs were highest for those on 
an insulin pump [376].  The investigators found that total costs were significantly higher for 
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those with an HbA1c >8.5%, a more intensive insulin regimen (regardless of distribution 
method), a single-parent household, female gender, and older age [376]. 
Because glycemic control has been shown to be an important factor in caring for T1D, it 
is important to implement interventions to improve control.  Nutrition and diet have been 
demonstrated to be particularly important in caring for T1D.  The DCCT study found that 
participants’ adherence to the provided meal plan and their adjustment of food and/or insulin 
dose due to hyperglycemia, meal size, and content had significantly lower HbA1c levels [378]. 
Overly treating their hypoglycemia and the consumption of extra snacks not included in the 
prescribed meal plan had significantly higher HbA1c levels [378]. Along with diet, physical 
activity has also been shown to be significant in caring for T1D.  A meta-analysis demonstrated 
that aerobic exercise, resistance exercise, mixed exercise (aerobic and resistance training) and 
exercise of high-intensity significantly decreased blood glucose levels [379]. In order to keep 
late-onset hypoglycemic episodes from occurring, investigators found that the incorporation of 
single bouts of sprints into participants’ aerobic exercise routine can be recommended. They also 
demonstrated that regular exercise has a significant effect on acute and chronic glycemic control, 
specifically aerobic training [379]. There were not enough studies to have adequate power to 
assess the effects of the other exercises.  Both diet and exercise are modifiable methods to 
improve glycemic control, which in turn reduces complication development and progression. 
One area that cannot be overlooked and is becoming increasingly utilized in public health 
in general is the use of technology.  One trial, which investigated this, had one group of 
adolescents report their blood glucose levels weekly over the Internet to a diabetes care team.  
The control group received usual care.  Unfortunately, their intervention group was non-
compliant and they did not have power to detect a significant difference, however they did find 
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that in those that were compliant, HbA1c was reduced at the end of six months, whereas in the 
usual care group HbA1c increased [380].  A small pilot study introduced adolescent T1D 
patients to two different mobile phone applications.  One application was in depth and visually 
stimulating, with pictures to assist in logging physical activity, as well as allowing participants to 
take pictures of their food for monitoring purposes as well as log their glucose levels.  The other 
group was given the capability of directly contacting diabetes care specialists as well as other 
adolescents with T1D in order to facilitate communication and support.  Although they found no 
significant decreases in HbA1c in either group from baseline to the end of follow-up (most likely 
due to a lack of power regarding the 12 participants), they received important feedback regarding 
the adolescents’ preference for the visual application, as well as the increased access to diabetes 
care professionals. The study investigators are using this information moving forward in 
designing a clinical trial [381].  Lastly, in regards to the use of technology in attempts to improve 
care, a review reported that the majority of studies in both T1D and T2D that utilized 
videoconferencing, mobile phones, telephone calls, and/or  feedback letters, showed significant 
metabolic improvement in 44% of the studies [382].  The use of telemedicine in conjunction with 
convention care is still a new area of research, but appears to be promising and worth discussing. 
A review published in the Lancet investigated the effectiveness of quality improvement 
(QI) strategies on the management of diabetes (both T1D and T2D) and reported that these 
strategies were associated with increases in retinopathy, kidney-related, and foot screenings on 
behalf of the participants over approximately a year of follow-up [383].  In the studies that 
enrolled patients with low baseline achievement of quality indicators (i.e.: HbA1c, LDL 
cholesterol, SBP, and DBP), the strategies were associated with larger effects on participants’ 
HbA1c, SBP, DBP, and LDL-c.  Each QI strategy’s effectiveness was dependent on baseline 
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HbA1c. Decreases of 0.5% or more in HbA1c were seen for four of the QI strategies, including 
team changes, case management, patients' education, and promotion of self-management in the 
trials of patients with 8.0% or greater starting HbA1c.  Education of clinicians proved to be 
important in reducing HbA1c, as well in these particular patients, by about 0.33%.    The authors 
note the importance of future clinical trials studying QI strategies and encourage investigators to 
describe their interventions in precise detail so that, if successful, they can be effectively 
repeated and implemented [383].  On a side note, the authors of another literature review 
concluded that the majority of QI trials contain moderate to high levels of bias [384].  The 
feedback from the reviews and future well-designed clinical trials will assist in determining 
which QI strategies and combinations of strategies are the most useful and to encourage 
implementation in the real world. 
Investigators in Italy have also attempted to improve their diabetes care, and developed 
and validated an educational model, which shifts the emphasis from the traditional one-to-one 
patient–provider relationship to interactive educational techniques applied in a group setting.  
They ran a clinical trial to investigate this in participants with either T1D or T2D [385].  The 
group care participants received group education sessions instead of the usual individual visit, 
and these took place every 2 to 3 months for those with T1D and 3 to 4 months for those with 
T2D. One or two healthcare professionals such as doctors, nurses, dieticians, educators, or 
psychological educators would lead the sessions. The complete program is designed for 2 years 
of sessions (but continues on after that), each lasting 40-50 minutes, and involves motivational 
aspects, acceptance of diabetes, psychosocial problems, and coping strategies. At the end of the 
session, brief individual consultations with the doctor take place to discuss laboratory results, 
details of the group session, or their yearly diabetes-related check-up [385]. 
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After approximately 6.6 years of follow-up, those with T1D and the group sessions 
experienced a lower HbA1c (7.4%) compared to the control subjects (8.5%).  They evaluated 
patients’ feelings (using propositional analysis) towards either the group care or the usual care, 
and found those in group care used mostly positive concepts to describe their experiences; 
however, those in usual care expressed negative concepts. Participants with T1D described the 
usual visit with the following words or phrases: “What a drag!”, “Too much to wait,” or 
“Tension.” Those with T2D described the visit as: “Let’s hope the results are OK,” “Too much to 
wait,” “Anxiety,” and “Fear.” On the other hand, the group visit T1D patients described the 
sessions as: “Comparing,” “Knowledge,” “Educational,” and “Friendship.” T2D patients in the 
group setting described their experience as: “Friendship,” “I feel good,” “I like this,” “I learn,” 
and “Interesting” [385].  It appears that this model suggests that collaborative diabetes care 
should involve a transformation of the relationship between the health care professional and the 
patient. Those attending the group sessions also experienced an increased sense of personal 
empowerment in caring for and managing their chronic disease.  Perhaps the most important 
finding of this study was that in those receiving the group care the focus was on health instead of 
disease, prevention and education as opposed to cure, and successfully made people aware of 
their choices in relation to their health whereas they may otherwise feel helpless against their 
disease [385]. The significance of this focus on support in caring for those with diabetes has been 
discussed in the literature previously [386]. 
Another European study recruited both professionals and patients and conducted focus 
groups wishing to identify perceived gaps in current diabetes care, as well as the associated 
feelings [387].  Investigators found that patients felt they were provided with insufficient 
diabetes information, and a lack of collaboration between themselves and their provider. 
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Participants also expressed difficulties in self-management.  Both the professionals and patients 
expressed financial concerns relating to diabetes. The proposed solutions that came up in the 
focus groups involved reinforcing existing structures, developing educational tools for self-
management, and focusing on more coordinated care, communication between the patient and 
provider, and a feeling of teamwork [387]. 
One specific area of diabetes care that has been of much focus lately is the transitional 
period between the pediatric care doctor and the adult endocrinologist.  Adolescents experience a 
gap in their care, in combination with other life changes associated with this age-group, that 
negatively affect their diabetes care as well as their physical health.  A good deal of research is 
currently focusing on addressing and improving this important problem.  In 2011, the American 
Diabetes Association (ADA) put out recommendations for the transition from pediatric to adult 
diabetes care [388].  The ADA discusses how these specific patients are at a time in their lives 
where they are assuming responsibility for their own care and gaining independence from their 
families.  This results in patients under-utilizing available healthcare, having poorer glycemic 
control, and experiencing an increase in acute and chronic complications.  Within research, there 
is a real lack of well-defined criteria to determine when a patient is ready to transition from their 
pediatric doctor to an adult doctor.  Another large issue is that many patients in emerging 
adulthood face gaps in their health insurance [388]. The introduction of high-risk behaviors, such 
as smoking, alcohol, and drug abuse, is also common.  In research, there is a complete lack of 
controlled trials to test validated transition programs, thus the only collected data are through 
observational studies or uncontrolled data.   
Children’s Hospital of Boston also addressed the issues involved with transitioning from 
pediatric to adult care.  They mailed emerging adults, between the ages of 22 and 30, a survey to 
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evaluate the transition process [389].  All participants were being seen by an adult care clinic.  
The mean age of their responding population was 19.5 years and 34% of these respondents 
reported a gap >6 months in transitioning to adult care. Common reasons patients transitioned to 
an adult clinician included feeling too old for their pediatric doctor, following a pediatric 
provider suggestion, and going to college. Less than half of those respondents received an adult 
provider recommendation from their pediatric clinician and <15% reported having a transition 
preparation visit or receiving any type of written transition materials [389].  Although the 
investigators believe that transition guidelines are important to follow and may bridge the gap 
between pediatric and adult care, they did not find a significant difference in HbA1c between 
those patients who felt the most prepared for their transition versus those that did not feel 
prepared [389]. 
Caring for T1D is a lifelong commitment that can be both challenging and fear-inducing 
in patients.  In addition to the insulin pump and improved monitoring devices, other novel 
interventions for furthering the improvement of care are currently being developed, and the use 
of mobile applications will most likely be a primary focus particularly in children and 
adolescents.  Having teens learn to monitor themselves via a mobile app or other means would 
potentially smooth the process from pediatric care to adult care during their emerging adult 
years.  Already knowing how to monitor their disease on their own, while with oversight by 
parents, would be an important first step in gaining independence.  The guidelines and 
recommendations for providers regarding the transition of their patients to adult care should be 
heavily considered and implemented.  A hefty problem, however, is the lack of existing clinical 
trials determining which methods of transition assistance are best and which are worth funding 
and implementing in the clinical care setting.  Future research should be dedicated to addressing 
  166 
these shortcomings in the literature, as well as to developing improved techniques for caring for 
T1D both on the patient’s behalf and the provider’s. 
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